Safety and Tolerability of Initiating Aripiprazole  Lauroxil  in 
Subject s with Schizophrenia who are Inadequately Treated 
with Paliperidone Palmitate or Risperidone Long Acting 
Injection  
 
 
Unique Protocol ID:  ALK9072 -A401  
Study ID: [REMOVED]  
Date of Protocol:   07 September  2016 
 
TITLE PAGE  
 
CLINICAL STUDY PROTO COL  
ALK9072-A401  
Study Title  Safety and Tolerability of Initiating Aripiprazole Lauroxil in 
Subjects with Schizophrenia who are Inadequately Treated 
with Paliperidone Palmitate or Risperidone Long Acting 
Injection  
Document Status  Final  
Document Date  Original Protocol: 18 Sep 2015 
v1.0 (incorporates Amendment 1 ): 07 Sep  2016 
Sponsor Alkermes, Inc.  
852 Winter Street 
Waltham, MA  02451 
USA 
 
 
 
  
 
  
 
CONFIDENTIAL  
Information and data in this protocol contain trade secrets and privileged or confidential information, 
which is the property of Alkermes, Inc. No person is authorized to make it public without the written 
permission of Alkermes, Inc. These restrictions or disclosures will apply equally to all future information suppli ed to you that is indicated as privileged or confidential.  

 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 2 CONTACT INFORMATION 
Role in Study  Name  Address and Telephone  
Alkermes Medical Monitor   Alkermes, Inc.  
852 Winter Street 
Waltham, MA 02451 USA 
Office t elephone:  
 Medical Monitor   
 
Ral
eigh, North Carolina 27604 
Office  telephone:  
Mobile telephone:  
 
Alkermes Drug Safety 
Specialist   Alkermes, Inc.  
852 Winter Street 
Waltham, MA 02451 USA Office t elephone:  
 
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 3 1. SYNOPSIS  
Name of Sponsor/Company:  Alkermes, Inc.  
Name of Product:  Aripiprazole lauroxil  
Name of Active Ingredient: Aripiprazole  
Title of study:  Safety and Tolerabil ity of Initiating Aripiprazole Lauroxil in Subjects with Schizophrenia 
who are Inadequately Treated with Paliperidone Palmitate  or Risperidone Long Acting Injection  
Study Center  Multicenter study (United States [US]) 
Study Period:  
Estimated date of first subject’s consent:  Q4 2015 
Estimated date of last subject’s last visit:  Q3 2017 Phase of Study:  
4 
Objectives:  
Primary:  
• To evaluate the safety, tolerability, and efficacy of aripiprazole lauroxil in subjects with 
schizophrenia who are inadequately treated  with paliperidone palmitate  or risperidone long 
acting injection  
Secondary:  
• To evaluate quality of life, including daily and social functioning, after treatment with aripiprazole lauroxil
 
• To characterize the caregiver and healthcare burden  
Methodology: 
This is an open- label  study in subjects who are switched to aripiprazole lauroxil from paliperidone 
palmitate  or risperidone long acting injection . Subjects will participate for approximately 7 months, 
including a screening period of up to 30 days, and will be administered 4 to 6 doses of  intramuscular (IM ) 
aripiprazole lauroxil. Dosing may occur in monthly (441 mg, 662 mg, or 882 mg) or 6-week (882 mg 
only) intervals. The dose and frequency of dosing will be at the discretion of the investigator, based on t he 
dose selected, and on dosing instructions. 
Potential subjects will be evaluated for eligibility according to the inclusion and exclusion criteria at a 
screening visit and again on Day 1. The first dose of aripiprazole lauroxil will be administered on Day 1. 
Subjects will receive their first dose of aripiprazole lauroxil no earlier than one week and not later than 
6 weeks following their previous injection  of paliperidone palmitate  or risperidone long acting injection. 
For subjects who have never taken aripiprazole, two test doses of oral aripiprazole 5 mg will be administered during the screening period. Only subjects who exhibit tolerability to oral aripiprazole 
(either following test doses or by past experience) are eligible to enroll in the study. 
On Day 1, qualified subjects will be administered a single IM injection of aripiprazole lauroxil into the 
gluteal (441 mg, 662 mg, or 882 mg) or deltoid (441 mg only) muscle, according to the dosing 
instructions. Following the first injection, subjects will re turn to the study site monthly or every 6 weeks 
for IM aripiprazole lauroxil administration and outpatient assessments. Additional outpatient assessments may be scheduled at the discretion of the investigator.  
If a subject must withdraw from the study earl y, an early termination (ET) visit should be completed 
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 4 using the assessments scheduled for Day 169.  
Number of Subjects Planned:  
This study will enroll approximately 50 subjects. 
Main Criteria for Inclusion:  
Men and women 18 through 65 years of age (inclusive) with a diagnosis of schizophrenia at screening 
and who have been taking paliperidone palmitate or risperidone long acting injection with inadequate 
results for at least 3 doses prior to screening may be eligible for this study. 
Product, Dosage, Dura tion and Mode of Administration:  
Aripiprazole lauroxil in doses of 441 mg (via deltoid or gluteal muscle) , 662 mg (via gluteal muscle) , or 
882 mg IM (via gluteal muscle) will be administered monthly or every 6 weeks (882 mg only) . The dose 
and frequency of dosing will be at the discretion of the investigator, based on the dose selected, and on 
dosing instructions (as depicted in the table below).  
Dose  Dosing Frequency  Site of Intramuscular Injection  
441 mg Monthly Deltoid or Gluteal  
662 mg Monthly Gluteal  
882 mg Monthly or every 6 weeks Gluteal  
 
Reference Therapy, Dosage, Duration and Mode of administration: 
Not applicable.  
Duration of Study:  
Approximately 7 months. 
Criteria for Evaluation:  
Efficacy:  
The following scales will be used to assess efficacy: 
• CGI-S and BPRS  
Safety and Tolerability:  
The following safety and tolerability measures will be assessed:  
• AEs 
• Injection site reactions  
• Vital signs (blood pressure, heart rate, respiratory rate, and body temperature), weight, and 
waist circumference  
• Clinical laboratory parameters (chemistry [including prolacti n], hematology, and urinalysis) 
• C-SSRS responses  
• ESRS -A scores  
Quality of Life, Daily and Social Functioning 
The following assessments will be conducted to characterize any change in quality of life, including daily 
and social functioning: 
− Quality of Life Scale (QLS) 
− Negative Symptom Assessment -16 (NSA -16) 
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 5 − Sexual functioning subscale from UKU Side Effect Rating Scale and CSFQ -14 scores  
− Personal and Social Performance scale (PSP)  
− Total and individual items scores of the Modified - MSQ  
Other Assessments  
The following assessments will be collected to explore potential changes in healthcare burden, cognition, 
insight, and psychosocial care needs: 
• Health economics 
− Total healthcare costs as measured by Treatme nt Services Review  (TSR-6) (Modified for 
Mental Health)  
• Functional Assessment  
− Birchwood Insight Scale ( BIS) 
• Family Measures  
− Caregiver Quality of Life – Burden Dimensions ( CarerQOL –7D) and VAS  
− Burden Assessment Scale  
• Investigator - and Caregiver -Rated Cognition 
− Respective New York Assessment of Adverse Cognitive Effects of Neuropsychiatric 
Treatment (NY-AA CENT ) subscales  
• Substance Use  
− Mini International Neuropsychiatric Interview (M.I.N.I.) Module I (alcohol use disorder) 
− Mini International Neuropsychiatric I nterview (M.I.N.I.) Module J (substance use 
disorder)  
Statistical Methods:  
The safety population will include all subjects who received at least one dose of aripiprazole lauroxil 
injection. All analyses will be carried out using the safety population. 
Efficacy:  
The change from baseline in CGI- S and BPRS scores at each post -baseline visit will be summarized.  
Safety and Tolerability: 
The number and percentage of treatment emergent adverse events ( TEAEs ) will be summarized by 
treatment group and overall by sy stem organ class, and preferred terms within each system organ class. 
Serious adverse events (SAEs) and AEs resulting in treatment discontin uation will also be summarized. 
Observed values and change from baseline in vital signs, clinical laboratory data, and ESRS scores will be 
summarized  
Shift tables and potential clinical significance tables, along with supporting listings, will be provided for 
selected parameters.  
Analyses of Other Assessments  
Data on quality of life and functional domains including pers onal, social, and family measures will be 
summarized using the safety population. 
 
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 6 Sample Size Considerations:  
No formal sample size calculations have been performed. The sample size is based on clinical 
considerations. 
Alkermes, I nc. 
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL  
Page 7 2. TABLE OF CONTENTS
TITLE PAGE  ...................................................................................................................................1  
CONTACT INFORMATION  ..........................................................................................................2  
1. SYNOPSIS  ...................................................................................................................3  
2. TABLE OF CONTENTS .............................................................................................7 
3. LIST OF ABBREVIATION S.....................................................................................12  
4. INTRODUCTION  ......................................................................................................14  
5. OBJECTIVES  .............................................................................................................15  
5.1. Primary Objective  .......................................................................................................15  
5.2. Secondary Objectives  .................................................................................................15  
6. SELECTION AND WITHDRAWAL OF SUBJECTS  ..............................................16  
6.1. Subject Inclusion Criteria  ...........................................................................................16  
6.2. Subject Exclusion Criteria  ..........................................................................................17  
6.3. Subject Withdrawal  ....................................................................................................18  
6.4. Replacement of Subjects  .............................................................................................19  
7. STUDY DESIGN  .......................................................................................................20  
7.1. Overall Study Design and Plan  ...................................................................................20  
7.2. Schedule of Visits and Assessments ...........................................................................21  
7.3. Study Procedures Descriptions ...................................................................................26  
7.3.1.  Informed Consent .......................................................................................................26  
7.3.2.  Eligibility Review  .......................................................................................................26  
7.3.3.  Demographics and Medical History ...........................................................................26  
7.3.4.  Concomitant Medication Review ...............................................................................26  
7.3.5.  Vital Signs, Weight, and Waist Circumference  ..........................................................26  
7.3.6.  Physical Examination  .................................................................................................26  
7.3.7.  12-Lead Electrocardiogram  ........................................................................................26  
7.3.8.  Columbia Suicide Severity Rating Scale  ....................................................................27  
7.3.9.  Extrapyramidal Symptom Rating Scale – Ab breviated  ..............................................27  
7.3.10.  Laboratory Assessments  .............................................................................................27  
7.3.10.1.  Drug Testing  ...............................................................................................................27  
7.3.10.2.  Hematology, Biochemistry, and Urinalysis  ................................................................27  
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 8 7.3.10.3.  Pregnancy Testing  ......................................................................................................28  
7.3.11.  Drug Dispensation and Reconciliation  .......................................................................28  
7.3.12.  Adverse Event Monitoring .........................................................................................28  
7.3.13.  Efficacy Assessments  .................................................................................................29  
7.3.13.1.  Clinical Global Impressions -Severity  .........................................................................29  
7.3.13.2.  Brief Psychiatric Rating Scale  ....................................................................................29  
7.3.14.  Quality of Life, Daily, and Social Functioning Assessments .....................................29  
7.3.14.1.  Sexual Functioning Subscale from Udvalg for Kliniske Undersøgelser Side 
Effect Rating Scale  .....................................................................................................29  
7.3.14.2.  Changes in Sexual Functioning Questionnaire Short Form .......................................29  
7.3.14.3.  Personal and Social Performance Scale  ......................................................................29  
7.3.14.4.  Heinrichs -Carpenter Quality of Life Scale  .................................................................29  
7.3.14.5.  Negative Symptom Assessment-16 ............................................................................30  
7.3.14.6.  Modified Medication Satisfaction Questionnaire .......................................................30  
7.3.15.  Other Assessments  ......................................................................................................30  
7.3.15.1.  Sixth edition of the Treatment Servi ces Review (TSR -6)-Modified for 
Mental Health  .............................................................................................................30  
7.3.15.2.  Caregiver Quality of Life – Burden Dimensions (7D) and Visual Analog 
Scale  ............................................................................................................................30  
7.3.15.3.  Burden Assessment Scale ...........................................................................................30  
7.3.15.4.  Birchwood Insight Scale (BIS) ...................................................................................31  
7.3.15.5.  New York Assessment of Advers e Cognitive Effects of Neuropsychiatric 
Treatment subscales  ....................................................................................................31  
7.3.15.6.  MINI International Neuropsychiatric Interview – Modules I and J  ...........................31  
7.4. Study Requirements and Restrictions .........................................................................31  
7.4.1.  Prohibited Medications ...............................................................................................31  
7.4.2.  Contraception and Pregnancy .....................................................................................31  
8. TREATMENT OF SUBJECTS ..................................................................................33  
8.1. Study Drug Dose and Administration  .........................................................................33  
8.2. Missed Doses ..............................................................................................................34  
8.3. Early Dosing  ...............................................................................................................34  
8.4. Dose Adjustments for CYP450 Considerations .........................................................35  
8.5. Oral Aripiprazole Test Doses  .....................................................................................36  
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 9 8.6. Treatment Adherence  ..................................................................................................36  
8.7. Blinding ......................................................................................................................36  
9. STUDY DRUG MATERIALS  AND MANAGEMENT  ...........................................37  
9.1. Study Drugs  ................................................................................................................37  
9.2. Accounta bility  .............................................................................................................37  
9.3. Handling and Disposal ................................................................................................37  
10. ASSESSMENT OF EFFICA CY ................................................................................38  
11. QUALITY OF LIFE, DAI LY AND SOCIAL FUNCTI ONING ...............................39  
12. OTHER ASSESSMENTS  ..........................................................................................40  
13. ASSESSMENT OF SAFETY  AND TOLERABILITY  .............................................41  
13.1.  Definition of Adverse Event .......................................................................................41  
13.2.  Definition of Serious Adverse Event ..........................................................................41  
13.3.  Relationship to Study Drug ........................................................................................42  
13.4.  Monitoring and Recording of Adverse Events ...........................................................43  
13.5.  Reporting of Serious Adverse Events .........................................................................44  
14. STATISTICS  ..............................................................................................................45  
14.1.  Sample Size Considerations .......................................................................................45  
14.2.  General Statistical Methodology  ................................................................................45  
14.2.1.  Study Population .........................................................................................................45  
14.3.  Demographics and Baseline Data  ...............................................................................45  
14.4.  Efficacy Analyses  .......................................................................................................45  
14.5.  Safety and Tolerability Analysis  ................................................................................45  
14.6.  Analyses of Other Assessments  ..................................................................................46  
15. DIRECT ACCESS TO SOU RCE DATA/DOCUMENTS .........................................47  
15.1.  Study Monitoring ........................................................................................................47  
15.2.  Audits and Inspections ................................................................................................47  
15.3.  Institutional Review Board/ Independent Ethics Committee  .....................................47  
16. QUALITY CONTROL AND QUALITY ASSURANCE  .........................................48  
16.1.  Case Report Forms  .....................................................................................................48  
16.2.  Confidentiality of Data ...............................................................................................48  
17. ETHICAL CONSIDERATIONS ................................................................................49  
17.1.  Ethics Review  .............................................................................................................49  
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 10 17.2.  Ethical Con duct of the Study ......................................................................................49  
17.3.  Written Informed Consent ..........................................................................................49  
18. DATA HANDLING AND RECORDKEEPING  .......................................................51  
18.1.  Data Capture  ...............................................................................................................51  
18.2.  Inspection of Records .................................................................................................51  
18.3.  Retention of Records ..................................................................................................51  
18.4.  Use of Information and Publication Policy ................................................................52  
19. REFERENCES  ...........................................................................................................53  
 
 
LIST OF TABLES  
Table 1:  Schedule of Visits and Assessments ...........................................................................22  
Table 2:  Clinical Laboratory Assessments  ...............................................................................28  
Table 3:  Aripiprazole Lauroxil Dosing Frequency and Site of Injection .................................33  
Table 4:  Aripiprazole Lauroxil Doses Based on Oral Aripiprazole Total Daily Dose .............34  
Table 5:  Recommendation for Concomitant Oral Aripiprazole Supplementation 
Following Missed Dosesa ...........................................................................................34  
Table 6:  Aripiprazole Lauroxil Dose Adjustments with Concomitant CYP450 Modulator Use ............................................................................................................35
 
Table 7:  Adverse Event Causality Guidelines  ..........................................................................43  
 
 
LIST OF FIGURES  
Figure  1: Study Design (ALK9072-A401).................................................................................20  
 
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 11 LIST OF APPENDICES  
Appendix A. Columbia Suicide Severity Rating Scale (Sample)  
Appendix B. Extrapyramidal Symptom Rating Scale – Abbreviated (ESRS -A) (Sample)  
Appendix C. Clinical Global Impressions -Severity (CGI -S) (Sample)  
Appendix D. Brief Psychiatric Rating Scale (BPRS) (Sample)  
Appendix E. Sexual Functioning Subscale from Udvalg for Kliniske Undersøgelser (UKU) Side Effect 
Rating Scale  (Sample)  
Appendix F. Changes in Sexual Functioning Questionnaire  (Sample)  
Appendix G. Personal and Social Performance Scale (PSP) (Sample)  
Appendix H. Heinrichs- Carpenter Quality of Life Scale (QLS) (Sample)  
Appendix I. Negative Symptom Assessment -16 (NSA-16) (Sample)  
Appendix J.  Modified Medication Satis faction Questionnaire (Modified MSQ) (Sample)  
Appendix K. Sixth Edition of the Treatment Services Review (TSR -6) (Sample)  
Appendix L. Caregiver Quality of Life (CarerQOL) – Burden Dimensions (7D) [Brouwer WBF, 2006]  
and Visual Analog Scale (VAS) (Sample)  
Appendix M. Burden Assessment Scale (Sample)  
Appendix N. Birchwood Insight Scale (BIS) (Sample)  
Appendix O. New York Assessment of Adverse Cognitive Effects of Neuropsychiatric Treatment  
(NY- AACENT) Subscales (Sample)  
Appendix P. Mini International Ne uropsychiatric Interview (M.I.N.I.) – Modules I and J (Sample)  
Appendix Q. List of Potent Cytochrome P450 3A4 (CYP3A4) Inducers and Moderate- to-Strong 
Inhibitors of 3A4 or 2D6 
 
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 12 3. LIST OF ABBREVIATION S 
The following abbreviations are used in this study protocol. 
Abbreviation or Term  Explanation or Definition  
AE adverse event  
ALK -P alkaline phosphatase  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
ATC  Anatomical Therapeutic Chemical [classification system ] 
BIS Birchwood Insight Scale 
BPRS  Brief Psychiatric Rating Scale  
CarerQOL -7D Caregiver Quality of Life – Burden Dimensions 
CGI-S Clinical Global Impressions -Severity  
CPK creatine phosphokinase 
CSA Clinical Study Agreement 
CSFQ -14 Changes in Sexual Functioning Questionnaire Short Form 
CRO  contract research organization 
C-SSRS  Columbia Suicide Severity Rating Scale  
DSM -5 Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition  
EC Ethics Committee  
ECG  electrocardiogram  
eCRF  electronic case report form  
EPS Extrapyramidal symptoms  
ESRS -A Extrapyramidal Symptom Rating Scale  - Abbreviated 
ET early termination  
FDA Food and Drug Administration 
GCP  Good Clinical Practice  
GGP  gamma -glutamyl transferase 
HIV human immunodeficiency virus 
HR heart rate  
IB Investigator’s Br ochure  
ICF informed consent form  
ICH International Conference on Harmonisation  of Technical Requirements 
for Registration of Pharmaceuticals for Human Use  
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 13 Abbreviation or Term  Explanation or Definition  
IRB Institutional Review Board  
ISR injection site reaction  
LAI long acting injectable antipsycho tic 
LDH lactic dehydrogenase 
MedDRA  Medical Dictionary for Regulatory Activities  
M.I.N.I. Mini International Neuropsychiatric Interview  
NSA -16 Negative Symptom Assessment -16 
NY-AACENT  New York Assessment of Adverse Cognitive Effects of Neuropsychiatri c 
Treatment  
PANSS  Positive and Negative Syndrome Scale  
PK pharmacokinetics  
QLS  Quality of Life Scale  
RR respiratory rate  
SAE  serious adverse event  
SAP statistical analysis plan  
SD standard deviation  
TEAE  treatment -emergent adverse event  
TSR-6 Sixth edition of the Treatment Services Review  
UKU Udvalg for Kliniske Undersøgelser  
ULN upper limit of normal 
VAS  Visual Analog Scale 
WHO World Health Organization 
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 14 4. INTRODUCTION 
Aripiprazole lauroxil is a covalently bonded, non- ester modification of aripiprazole, a second 
generation atypical antipsychotic agent, to form N-lauroyloxymethyl aripiprazole. It is 
formulated as an extended -release suspension to be administered via intramuscular (IM) 
injection into the gluteal or deltoid muscle. Conversion of ari piprazole lauroxil to aripiprazole is 
governed by dissolution of the aripiprazole lauroxil drug crystal from the injection site and 
subsequent enzyme- mediated cleavage, generating lauric acid and N-hydroxymethyl 
aripiprazole; the covalently bonded hydroxymethyl group N -hydroxymethyl aripiprazole 
dissociates, releasing aripiprazole and form aldehyde.  
In clinical trials, treatment with aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at 
Week 12, compared with placebo. Aripiprazole lauroxil was generally well tolerated for patients 
with schizophrenia at monthly IM dosing of 441 mg and 882 mg with the most common adverse events being insomnia, akathisia, and headache. This study is designed to demonstrate that 1) the 
transition from treatment with other long acting injectable antipsychotics (LAIs) to aripiprazole lauroxil is clinically feasible, and that 2) comparative assessments of the safety and tolerability profil es of the respective treatments is clinically important.  
Paliperidone palmitate (Invega
® Sustenna®) or risperidone long acting injection ( Risperdal® 
Consta®) are commonly prescribed long- acting injectable antipsychotic s. Paliperidone palmitate 
is a prodrug of paliperidone (9-hydroxy risperidone), the active metabolite of risperidone. As 
potent D2 antagonists, risperidone and paliperidone are pharmacologically distinct from 
aripiprazole’s hypothesized principal mechanism of antipsychotic action, one of high affinity, partial dopamine agonism. 
This study is an open label, 7-month prospective evaluation of the safety, tolerability, and 
efficacy of aripiprazole lauroxil in subjects with schizophrenia inadequately treated with risperidone long acting injection  or paliperidone palmitate.  
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 15 5. OBJECTIVES 
5.1. Primary Objective  
The primary objective of this study is to evaluate the safety, tolerability, and efficacy of 
aripiprazole lauroxil in subjects with schizophrenia who are inadequately treated with 
paliperidone palmitate  or risperidone long acting injection . 
5.2. Secondary Objectives  
The secondary objectives of this study are to: 
• Evaluate quality of life, including daily and social functioning, after treatment with 
aripiprazole lauroxil 
• Characterize the caregiver and healthcar e burden 
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 16 6. SELECTION AND WITHDR AWAL OF SUBJECTS  
Each subject must meet all of the eligibility criteria to be qualified to participate in this study.  
6.1. Subject Inclusion Criteria 
Each subject must meet all of the following inclusion criteria to be qualified to participate in this 
study.  
1. Is willing and able to provide informed consent 
2. Is between 18 and 65 years of age, inclusive, at screening 
3. Meets either of the following aripiprazole tolerability criteria:  
• Has demonstrated tolerability to test doses of oral arip iprazole during screening; OR 
• Has a history of tolerated use of aripiprazole 
4. Has a diagnosis of schizophrenia  as defined by Diagnostic and Statistical Manual of 
Mental Disorders, 5th Edition [ DSM -5] (American Psychiatric Association 2013 ) criteria 
at screening  
5. Is clinically stable as evidenced by no hospitalizations for acute psychiatric exacerbations 
within the 2 months prior to screening and prior to initiation on Day 1. Social 
hospitalizations are not applicable and should not disqualify subjects 
6. Has a BPRS score of ≥30 and ≤45 at screening 
7. Has received at least 3 doses of risperidone long acting injection ( Risperdal Consta®) or 
paliperidone palmitate  (Invega Sustenna®) prior to screening (may include the ‘loading’ 
dose). Has no antipsychotic medication regimen change for 4 weeks prior to Day 1 
(medication or dose level, unless due to tolerability). 
8. In the judgment of the investigator, is inadequately responding to or not tolerating long acting injectable (risperidone or paliperidone), and is likely to benefit from a transition to aripiprazole lauroxil 
9. Agrees to abide by the contraceptive requirements of the protocol (as defined in Section  7.4.2)  
10. Has an identified reliable informant (caregiver), in the opin ion of the investigator 
11. Resides in a stable living situation, in the opinion of the investigator 
12. Is fluent (oral and written) in the language in which standardized tests will be administered, and can be reliably rated  
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 17 6.2. Subject Exclusion Criteria  
Each subject must not have any of the following conditions to be qualified to participate in this 
study.  
1. Is currently pregnant or breastfeeding, or is planning to become pregnant during the study 
2. Has received Invega Trinza® (3-month formulation of paliperidone palmit ate), 
aripiprazole lauroxil or IM depot aripiprazole within 6 months of screening 
3. Has a history of poor or inadequate response to oral or injectable aripiprazole 
4. Has participated in a clinical trial involving any investigational product (ie, drug, device, biologic) within the past 3 months, or is currently participating in a clinical trial involving 
an investigational product 
5. Has a history of psychopathology other than schizophrenia as indicated by any of the 
following: 
• Has a DSM -5 (American Psychiatric Association 2013 ) diagnosis of moderate to 
severe substance use disorder (except tobacco use disorder), within the 12 months 
prior to screening 
• Has any primary DSM -5 diagnosis other than schizophrenia within the 12 months 
prior to screening or upon admission (depression, schizoaffective disorder, bipolar 
disorder, or neurocognitive disorder) 
6. In the opinion of the investigator, the subject is a danger to himself/herself or others at 
screening or upon admission or meets one of the following criteria for elevated suicidal 
ideation or behavior: 
• At screening (using “Baseline” version of the C -SSRS):  
− Answers “Yes” to items 4 or 5 of the C-S SRS “Suicidal Ideation” section with the 
most recent episode occurring within the 6 months prior to screening 
− Answers “Yes” to any of the 5 items C -SSRS “Suicidal Behavior” with an 
episode occurring within the 1 year prior to screening 
• Upon entry (on Day 1) (using “Since Last Visit” version of the C -SSRS):  
− Answers “Yes” to items 4 or 5 of the C- SSRS “Suicidal Ideation”  
− Answers “Yes” to any of the 5 items of the C -SSRS “Suicidal Behavior”  
7. Has a history or current evidence of a clinically significant conditio n or abnormality 
(including clinical laboratory test results or ECG findings) that in the investigator’s 
opinion could preclude safe participation in this study, or prevent, limit, or confound 
protocol specified assessments  
8. Has any of the following conditions or abnormalities at screening: 
• In the opinion of the investigator or sponsor has uncontrolled diabetes , heart disease 
or stroke 
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 18 • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels ≥ 3 times 
the upper limit of the laboratory reference range at screening  
• An absolute neutrophil count ≤1.5 × 103 μL (or for black patients with history of 
“benign neutropenia” , a sustained count of ≤1 × 103 μL) 
• A platelet count ≤100 × 103 μL 
• Has a QT interval (corrected using the Fridericia formula; QTcF) >450 milliseconds 
for men or >470 milliseconds for women at screening 
9. Has a history of neuroleptic malignant syndrome or clinically  significant tardive 
dyskinesia 
10. Is taking both strong CYP2D6 and strong CYP3A4 inhibitors. In addition, patients who 
are known CYP2D6 poor metabolizers taking strong CYP3A4 inhibitors are excluded 
11. Has a positive urine drug test for illicit use of amphetamines, barbiturates, cocaine, 
methadone, opiates, phencyclidine, at screening. Repeat testing may be performed if 
positive results cannot be confirmed by a history of presumed active substance use, or use of prescribed medications which may account for the positive urine drug test results  
12. Is employed by Alkermes,  the investigator, the study center (includes 
permanent or temporary contract workers and designees responsible for the conduct of the study), or a third-party agent of this study or is immediate family of an employee of 
Alkermes,  the investigator, the study center, or other third- party agent  
• Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted. 
6.3. Subject Withdrawal  
A subject may be discontinued from the study at any time if the subject, investigator, or sponsor 
determines that it is not in the best interest of the subject to continue participation. Reasons for 
discontinuation include: 
• AE 
• Lost to follow-up 
• Lack of Efficacy  
• Withdrawal by subject 
• Non-compliance with study drug 
• Other  
• Pregnancy  
• Protocol deviation 
• Study terminated by sponsor 
Subjects completing all visits up to and including Day 169 will be considered completers. 
PPD
PPD
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 19 If a subject withdraws from the study for any reason , any ongoing AEs will be followed until 
resolution, until deemed stable by the investigator , or until the subject is deemed by the 
investigator  to be lost to follow-up. If, in the opinion of the investigator, it is necessary to 
monitor a subject beyond the final study visit, the study period may be extended as necessary. In 
such instances, the sponsor and the investigator will agree to an acceptable schedule. 
In the event that a subject chooses to withdraw from the study, the investigator should make a 
reasonable effort to ascertain the reason(s) for withdrawal, while fully respecting the subject’s 
rights. Subjects are to be asked to return to the clinic for an ET visit. If the subject fails or refuses to return to the study center, an attempt must be made to contact the subject by telephone in 
order to assess as many safety and efficacy parameters as possible. All data collected over the telephone must be documented and kept in the subject’s record. 
The investigator must maintain a record of all subjects wh o fail to complete the study. The 
reason for study discontinuation will be made on the appropriate electronic case report form 
(eCRF). If a subject is lost to follow -up, a reasonable attempt to contact the subject must be 
made and documented. 
6.4. Replacement o f Subjects  
Subjects who withdraw before completion of the study will not be replaced . 
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 20 7. STUDY DESIGN 
7.1. Overall Study Design and Plan  
This is an open- label study in approximately 50 subjects who are switched to aripiprazole 
lauroxil from long acting injectable risperidone or paliperidone palmitate. In total, subjects will 
participate for approximately 7  months, including a screening period of up to 30 days, and will 
be administered 4 to 6 doses of IM aripiprazole lauroxil ( Figure  1). Dosing may occur in 
monthly (441 mg, 662 mg, or 882 mg) or 6-week (882 mg only) intervals. The dose and 
frequency of dosing will be at the discretion of the investigator, based on the subject’s history, dose selected, and on dosing instructions ( Section  8.1). 
Figure  1: Study Design (ALK9072-A401) 
 
Potential subjects will be evaluated for eligibility according to the inclusion and exclusion criteria at a screeni ng visit and again on Day 1. The first dose of aripiprazole lauroxil will be 
administered on Day 1. Subjects will receive their first dose of aripiprazole lauroxil no earlier than one week and not later than six weeks following their previous injection of paliperidone 
palmitate  or risperidone. The cross -tapering from risperidone or paliperidone to aripiprazole 
lauroxil is facilitated by the gradual disappearance of plasma risperidone/paliperidone while 
aripiprazole is concomitantly released from the initial IM aripiprazole lauroxil injection.  
For subjects who have never taken aripiprazole, two test doses of oral aripiprazole 5 mg will be 
administered during the screening period. Only subjects who exhibit tolerability to oral 
aripiprazole (either following te st doses or by past experience) are eligible to enroll in the study.  
On Day 1, qualified subjects will be administered a single IM injection of aripiprazole lauroxil 
into the gluteal (441, 662 or 882 mg) or deltoid muscle  (441 mg), according to the dosing 
instructions ( Section  8.1). Following the first injection, subjects will return to the study site 
monthly or every 6 weeks (882 mg, gluteal IM only) for IM aripiprazole lauroxil administration 
and outpatient asse ssments. Additional outpatient assessments may be scheduled at the discretion 
of the investigator. 
Efficacy will be evaluated based on Clinical Global Impressions -Severity (CGI -S) and Brief 
Psychiatric Rating Scale (BPRS) responses.  
Day 
 (127) 
Monthly AL injection  
Q 6 weeks AL injection  
 
(882 mg)  
Screening  
1 
 29 
 57 
 85 
 113 
 141 
 169 
EOT/ET  
Treatment Period  
- 
30 to  
 
- 
1 
 ( 
43) 
 
 
AL =  
 
aripiprazole  
lauroxil  
EOT = end of treatment; ET = early terminatio n 
 Alkermes, Inc.  
Clinical Protocol Amendment 1.0 (Amendment 1.0) CONFIDENTIAL   
 
Page 21 Safety and tolerability  will be evaluated based on adverse events (AEs), injection site reactions 
(ISRs), clinical laboratory data, vital sign data, Columbia Suicide Severity Rating Scale 
(C-SSRS) responses, and Abbreviated Extrapyramidal Symptom Rating Scale (ESRS -A) scores. 
Potential changes in informant- rated cognition, insight, treatment satisfaction, quality of life, 
daily and social functioning, caregiver and healthcare burden, and psychosocial care needs following a transition to aripiprazole lauroxil will be examined. Total healthcare costs as 
measured by TSR -6-(Modified for Mental Health)  survey will also be evaluated.  
7.2. Schedule of Visits and Assessments  
The schedules of visits and assessments are shown in Table 1. 
For a missed visi t, the site should attempt to contact the subject to reschedule.  
Premature discontinuation procedures are provided in Section  6.3. 
Clinical Protocol  Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0)  CONFIDENTIAL  
 
Page 22 Table 1: Schedule of Visits and Assessments  
 
Screening  Treatment Period1) 
Day 1  Month 1  Month 2  Month 32) Month 4  Month 5  Month 6 
EOT/ET  
V1 V2 V3 V4 V5 V6 V7 V8 
Visit windows  
(days)   Day 1  22-36 37-64 65-92 93-120 121-148 149-183 
4 week dosing target day  1 29 57 85 113 141 169 
6 week dos ing target day  1 May skip  
Visit3) 43 85 May skip  
Visit3) 127 169 
Study Drug Administration   Injections are to be given monthly (6 total injections) or every 6 weeks (4 total injections) based on 
the dosing regimen selected; After Day 1, subsequent injections will occur 28 or 42 days following 
the previous injection   
Informed Consent  X        
Eligibility Criteria 
Review4) X X       
Oral Aripiprazole Test Dose Administration
5) X        
Drug Screen6) X        
12-Lead ECG  X        
Demographics and Med ical 
History  X        
Reason for switching 
paliperidone /risperidone  X        
MINI (Modules I & J)  X       X 
Height  X        
Pregnancy Testing7) X X       
Clinical Protocol  Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0)  CONFIDENTIAL  
 
Page 23 Table 1: Schedule of Visits and Assessments (Continued)  
 
Screening  Trea tment Period1) 
Day 1  Month 1  Month 2  Month 32) Month 4  Month 5  Month 6 
EOT/ET  
V1 V2 V3 V4 V5 V6 V7 V8 
Visit windows  
(days)   Day 1  22-36 37-64 65-92 93-120 121-148 149-183 
Physical Exam8) X X       
Adverse Event Monitoring  X X X X X X X X 
Concomita nt Medication 
Review  X X X X X X X X 
Vital Signs, Weight, Waist 
Circumference9) X X X X X X X X 
ESRS -A  X   X   X 
Clinical Lab Tests10) X X X11) X11) X11)   X 
Modified MSQ  X12)       X12) 
Modified UKU  X X      X 
CSFQ -14 X X      X 
Injection Site Ev aluation13)  X X X X X X X 
C-SSRS14) X X X X X X X X 
TSR-6-Modified  X X X X X X X X 
CGI-S X X X X X X X X 
BPRS  X X X X X X X X 
QLS  X    X   X 
NSA -16 X    X   X 
NY-AACENT  X       X 
Clinical Protocol  Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0)  CONFIDENTIAL  
 
Page 24 Table 1: Schedule of Visits and Assessments  (Continued)  
 
Screening  Treatment Period1) 
Day 1  Month 1  Month 2  Month 32) Month 4  Month 5  Month 6 
EOT/ET  
V1 V2 V3 V4 V5 V6 V7 V8 
Visit windows  
(days)   Day 1  22-36 37-64 65-92 93-120 121-148 149-183 
PSP X    X   X 
BIS X       X 
Burden Assessment S cale X       X 
CarerQOL -7D+VAS  X       X 
EOT= end of treatment; ET= early termination; ECG= electrocardiogram; MINI = Mini International Neuropsychiatric Interview; E SRS- A=Abbreviated 
Extrapyramidal Symptom Rating Scale; MSQ= Medication Satisfaction Questionnaire; UKU= Udvalg for Kliniske Undersøgelser Side Effect Rating Scale; 
CSFQ -14=Changes in Sexual Functioning Questionnaire Short Form; C -SSRS= Columbia Suicide Severity Rating Scale; TSR -6= Sixth edition of the 
Treatment Services Review; CGI -S= Clinical Global Impressions -Severity; BPRS= Brief Psychiatric Rating Scale; QLS = Quality of Life Scale; NSA -16 = 
Negative Symptom Assessment -16; NY -AACENT= New York Assessment of Adverse Cognitive Effects of Neuropsychiatric Treatment; PSP= Personal and 
Social Performance scale; BIS= Birchwood Insight Scale; CarerQOL- 7D+VAS= Caregiver Quality of Life – burden dimensions and visual analog scale  
1) For all visits other than Screening and Day 1, the visit will be anchored to the previous visit (based on dosing regi men schedule)  
2) In the event the Month 3 visit is missed or skipped, the additional assessments required at the Month 3 visit (ESRS -A, prolactin, QLS, NSA -16, PSP)  should be 
conducted (via unscheduled assessment) at the subject’s next visit  
3) Visits may be skipped for subjects on a 6 week dosing regimen 
4) Eligibility Review Form must be reviewed by  Clinical Surveillance Team (CST) prior to enrolling a subject on Day 1  
5) Only for prospective subjects who have never received aripiprazole. The oral ari piprazole test doses will consist of 5  mg/day for 2 consecutive days during  the 
screening period. The first test dose should be administered at the clinic.  
6) Urine drug screen via dipstick at screening. The urine drug screen includes amphetamines, barbiturates, cocaine, methadone, opiates, and phencyclidine. Rescreening may be performed if positive results cannot be confirmed by a history of presumed active substance use or use of prescribed medications, which 
may account for the positive urine drug test r esults.  
7) Urine pregnancy testing will be completed for ALL women. At screening, pregnancy test should be completed prior to the administration of the first oral aripiprazole test dose, where applicable. On Day 1, testing will be performed before dosing.  
8) Full physical examination at screening; brief physical examination on Day 1; symptom directed physical exams may be performed as needed at the 
Investigator’s discretion.  
9) Vital signs include blood pressure, heart rate, respiratory rate, and body tempe rature, 
10)Includes biochemistry (including prolactin), hematology, and urinalysis.  
11)Prolactin only will be measured at Month 1, Month 2  and Month 3 . 
PPD
Clinical Protocol  Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0)  CONFIDENTIAL  
 
Page 25 12)Modified MSQ question #1 only at screening ; the entire modified  MSQ will be completed at Visit 8 (EOT ) 
13)The injection site and surrounding area will be evaluated following each injection and monitored so long as there are reactions to be monitored; if there are no 
observed reactions, continuing evaluation is not necessary  
14)“Baseline” version used at s creening; “since last visit” used at all subsequent visits  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 26 7.3. Study Procedures Descriptions  
Details of the study procedures are described below. The overall schedules of assessments are 
provided in Table 1. 
7.3.1. Informed C onsent  
The nature of the study and its risks and benefits will be explained to the subject and caregiver 
by the principal investigator or designated study personnel as outlined in Section  17.3. 
Prior to the administration of any study -specific procedures, authorized study personnel will 
obtain written informed consent from each potential subject and caregiver. 
7.3.2. Eligibility Review  
An eligibility review will be conducted by the investigator at the visits specified in  Table 1 using 
the subject inclusion criteria in Section  6.1 and  exclusion criteria in  Section  6.2. 
7.3.3. Demographics and Medical History  
Subject’s  demographic data and medical history will be reviewed and documented at the time 
point(s) specified in Table 1. 
7.3.4. Concomitant Medication Review  
At the time point(s) specified in  Table 1, prospective subjects will be asked about the 
medications they have taken since the last visit and are currently taking, including prescription 
and nonprescription medications, vitamins, and supplements. 
The investigator will record the followin g data on all medications used by the subject:  name, 
dose, regimen, route of administration, start and stop dates, and the indication for use. 
7.3.5. Vital Signs , Weight, and Waist Circumference 
Vital signs (blood pressure, heart rate, respiratory rate, and  body temperature), waist 
circumference, and weight will be assessed at the time point(s) specified in  Table 1. Blood 
pressure, heart rate, and respiratory rate will be measured after the subject has been resting in a 
seated or supine position for at least 5 minutes.  
7.3.6. Physical Examination 
A full physical examination will be performed at screening and a brief physical exam  performed 
on Day 1. Symptom- directed  physical exams may be performed as needed at the Investigator’s 
discretion . 
7.3.7. 12-Lead Electrocardiogram  
A 12 -lead electrocardiogram (ECG) will be conducted at screening only.  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 27 7.3.8. Columbia Suicide Severity Rating Scale  
The PI or designee will administer the C -SSRS ( Appendix A ) according to the schedule in 
Table 1. At screening, the “Baseline” version will be admi
ni
stered (Posner, Brent et al.  2009), 
and at all other visits, the “Since Last Visit” version will be administered (Posner, Brent et al. 
2009). For “Since Last Visit” versions, subjects should be asked to report on ideation and 
behavior since the last scheduled C- SSRS assessment. The C -SSRS should be administered by a 
clinician trained to assess and man age suicidal ideation and behavior. 
7.3.9. Extrapyramidal Symptom Rating Scale – Abbreviated  
The ESRS -A is a questionnaire that assesses the severity and/or frequency of drug induced 
movement disorders (eg. Parkinsonism, dystonia, dyskinesia, and akathisia)  (Chouinard and 
Margolese 2005) . The investigator or designee will administer the ESRS -A scale at time points 
specified in  Table 1. A sample of the ESRS-A can be found in Appendix B . 
7.3.10. Laboratory Assessments 
7.3.10.1. Drug Testing  
Subjects will complete a urine drug test for illicit amphetamines, barbiturates, cocaine, methadone, opiates, phencyclidine, at screening. A positive drug test will exclude the subject 
from the study. Repeat testing may be performed if positive results cannot be confirmed by a 
history of presumed active substance use or use of prescribed medications which account for the 
positive urine drug test results. 
7.3.10.2. Hematolo gy, Biochemistry, and Urinalysis 
Blood and urine samples will be collected at the time points specified in  Table  1 for specific 
hematology, biochemistry, and urinalysis assessments that are listed in  Table 2. Samples will be 
analyzed by a central laboratory. Laboratory assessments may be repeated at the investigator’s 
discretion. 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 28 Table 2: Clinical Laboratory Assessments 
Hematology  Bioche mistry  Urinalysis  
• Hematocrit  
• Hemoglobin 
• Platelets  
• Red blood cell count 
• Total and differential 
(absolute) white blood 
cell count  • Albumin 
• Creatine phosphokinase(CPK) 
• Glucose 
• Lactic dehydrogenase (LDH) 
• Potassium 
• Sodium 
• Total protein  
• Alanine aminotransferase(ALT) 
• Alkaline phosphatase(ALK -P) 
• Aspartate 
aminotransferase(AST)  
• Gamma -glutamyl transferase 
(GGT)  
• Total bilirubin  
• Prolactin  
• Blood urea nitrogen 
• Creatinine  
• HbA1c  
• Total cholesterol  
• LDL  
• HDL  
• Triglycerides  
• TSH , at screening only  • Bilirubin  
• Color and appearance  
• Glucose 
• Nitrite  
• Occult blood 
• pH 
• Protein  
• Specific gravity  
• Urobilinogen 
7.3.10.3. Pregnancy Testing  
Urine pregnancy testing will be completed for all women at the time points specified in  Table 1. 
Pregnancy testing will be per formed before administration of the first 5  mg aripiprazole test dose 
(where required) at Screening and before dosing on Day 1. 
Results must be negative for initial study eligibility and continued participation.  
7.3.11. Drug Dispensation and Reconciliation 
Section  8 provides information related to drug dispensing procedures. Study drug will be 
administered at the time point(s) specified in  Table 1 and reviewed with the subject. 
7.3.12. Adverse Event Monitoring  
AEs will be monitored continuously from the time a subject signs the informed consent 
document until the completion of the final study visit (see  Table 1) . AEs and serious adverse 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 29 events (SAEs)  are defined in Section  13.1 and 13.2, respectively. Section  13.4 provides guidance 
on the monitoring and reporting requirem ents for AEs. Section  13.5 provides guidance on the 
reporting requirements for SAEs.  
7.3.13. Efficacy Assessments  
7.3.13.1. Clinical Global Impressions -Severity  
The investigator or designee will complete the Clinical Global Impres sion – Severity (CGI -S) 
(Appendix C ) scale (Guy 2000)  at screening and at every time point as identified in  Table 1.  
7.3.13.2. Brief Psychiatric Rating Scale 
The investigator or designee will complete the Brief Psychiatric Rating Scale (BPRS) 
(Appendix D ) at screening and at every time point as identified in  Table 1.  
7.3.14. Quality of Life, Daily, and Social Functioning Assessments
 
7.3.14.1. Sexual Functioning Subs
cale from Udvalg for Kliniske Undersøgelser Side Effect 
Rating Scale 
The sexual functioning subscale from the UKU Side Effect Rating Scale (Appendix E ) contains 
7 items for males and 9 items for females  (Lingjaerde, Ahlfors et al. 1987, Lindstrom, Lewander  
et al. 2001) . Each item is rated on a 4 -point scale (0 = none or doubtful, 1 = present to a mild 
degree,  2 = present to a moderate degree, and 3 = present to a severe degree). This scale will be 
completed by the patient at the time points specified in  Table 1.  
7.3.14.2.
 Changes in Sexual Functioning Questionna
ire Short Form 
The CSFQ -14 ( Appendix F ) is a 14-item rating scale that evaluates sexual functioning in each 
domain of the sexual response cycle ( Keller, McGarvey et al. 2006). The  subjects rate their 
sexual functioning on a 5-point Likert scale. Higher scores indica
te mor
e sexual dysfunction. 
The CSFQ will be completed by the patient  at the 
time points specified in  Table 1.  
7.3.14.3. Person
al and Soci al Performance Scale  
The investigator or designee will complete the 5-point Personal and Social Performance (PSP) 
(Appendix G ) scale (Patrick, Burns et al. 2009) at the time points identified in  Table 1. 
7.3.14.4. Heinrichs -Carpenter Quality of Life Scale 
The QLS is a clinician -rated scale that is used to assess health -related quality of life and 
functioning in patients with schizophrenia during the preceding 4 weeks ( Heinri chs, Hanlon et al. 
1984)  (Appendix H ). The QLS consists of 21 items in 4 major domains (Intrapsychic 
Foundations, Interpersonal Relations, Instrumental Role, and Common Objects and Act
ivities). 
Following a semi- structured interview, each item is rated on  a 7-point scale, from 0 (severe 
impairment) to 6 (normal or unimpaired functioning). The QLS will be completed at the time 
points specified in Table 1. 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 30 7.3.14.5. Negative Symptom Assessment -16  
The Negative Symptom Assessment is a clinician -rated scale that is used to evaluate the 
presence, severity, and range of the negative symptoms that often impact the quality of life of 
those with schizophrenia ( Axelrod, Goldman et al. 1993) ( Appendix I ). The NSA-16 consists of 
16 items with 5  domains (Communication, Emotion/Affect, Social Involvement, Motivation, and 
Retardation). Each item 
is rated on a 6 -point scale that ranges from 1 to 6 w ith higher scores 
indicating more severe pathology. The NSA- 16 will be completed at the time points specified in 
Table 1.  
7.3.14.6. Modified Medication Satisfaction Questionnaire  
The Modified MSQ  (Appendix J ) is a 3 -item self -report pat
ient satisfaction questionnaire which 
assesses the level of patient satisfaction with me
dication . Subjects rate their satisfaction with 
their current medication, their preference for their current medication versus the one taken prior to the stu dy, and their opinion on the side effects of their current medication versus the one taken 
prior to the study. Ratings are on a 5 -point Likert scale. The Modified MSQ will be collected at 
the time points identified in  Table 1. 
7.3.15. Other Assessments  
7.3.15.1. Sixth edition of the Treatment Services Review (TSR -6)-Modified  for Men
tal 
Health  
The modified TSR-6 ( Appendix K ) is a brief structured interview to  assess specific services 
provided to patients; this version was modified for use in a patient popula
tion for chronic mental 
illness. The modified TSR-6 focuses on services for five potential problem areas: medical condition, employment and support, legal status, family/social relations, and psychiatric function. Patients are asked about the services that they received in the past 28-42 days. The 
modified TSR- 6 consists of 22 items; it will be administered at the time points identified in 
Table 1.  
7.3.15.2. Caregiver Quality of Life – Burden Dimensions (7D) and Visual Analog Scale 
The Ca
rerQOL -7D and VAS  (Brouwer, van Exel et al. 2006) ( Appendix L ) measures  care-
related quality of life in informal caregivers. The burden component utilizes
 7 items to assess 
burden, and the valuation component uses a VAS to ascertain level of happiness. The burden items require caregivers to indicate whether they have ‘no’, ‘some’ or ‘a lot’ of problems or 
fulfillment/ support regarding the given dimension. For problem-related items, ‘no, ‘some’ and 
‘a lot’ are scored 3, 2, and 1, respectively. For fulfillment/support items, reverse scoring applies, so a high score indicates a high level of burden. The valuation component allows for the 
calculation of a score from 0  (completely unhappy) to 10 (completely happy). The CarerQOL -7D 
and VAS will be completed by the designated caregiver at the time points identified in  Table 1.  
7.3.15.3. Burden Assessment Scale 
The Burden Assessment Scale ( Appendix M ) is a 19-item scale complet
ed by the caregiver that 
focuses on specific subject
ive and objective consequences of families caring for individuals with 
severe mental disorders  (Reinhard, Gubman et al. 1994). Responde
nts are required to indicate 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 31 whether they have experienced each of the types of burden - ‘Not at all’, ‘A little’, ‘Some’ or ‘A 
lot’ - in the past four weeks. These are scored 1, 2, 3, and 4 respectively. A higher score indicates 
more perceived burden. The Burden Assessment Scale will be completed by the designated 
caregiver at the time points identified in  Table 1. 
7.3.15.4. Birchwood Insight Scale (BIS)  
The BIS ( Appendix N ) is an 8-item self -report measure addressing the three components of 
insight: awareness of il
lness, relabeling of symptoms (ie, attribution of one's symptoms as part of 
one's disorder), and need for treatment ( Birchwood, Smith et al. 1994). Possible responses of 
"agree," "unsure," or "disagree"
 are scored on a Likert -type scale ranging from 0 to 2. The total 
score will be summed for a BIS total score (range = 0 -16), with higher scores indicating greater 
insight. The BIS will be completed b y the subject at  the time points identified in  Table 1.  
7.3.15.5. New York Assessment of Adverse Cognitive Effects of Neuropsychiatric 
Treatment subscales  
The NY -AAC ENT subscales ( Appendix O ) are used to detect changes in cognitive function 
subs
equent to pharmacolog
ical or similar treatments for neurological or
 psychiatric problems 
(Opler, Antonius et al. 2015). It is comprised of seven items for the patient , s
even items for the 
caregiver, and seven items for the clinician derived from these seven domains: speed of 
processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and 
problem solving, and social cognition. The NY -AAC ENT will be administered at the time points 
identified in  Table 1.  
7.3.15.6. MINI International Neuropsychiatric Interview  – Modules I and J  
The MINI is a short, clinician -administered, structured diagnostic interview for making D SM-5 
diagnoses ( Appendix P ). The MINI has been validated against the much longer St
ructured 
Clinical Interview for DSM diagnoses (SCID -5). Modules I (Al
cohol Use Disorder) and J 
(Substance Use Disorder) from the MINI will be administered as shown in Table 1.  
7.4. Study Requirements and Restrictions  
7.4.1. Prohibited Medications  
Concomitant use of potent oral CYP3A4 inhibitors and  CYP2D6 inhibitors is to be a voided. In 
addition, subjects with known CYP2D6 poor metabolism should not receive strong oral CYP3A4 
inhibitors during the study. During the study, dose adjustment may be necessary in the event of potent oral CYP2D6 inhibitor, or a CYP3A4 inhibitor or inducer, use. For example, the use of 
CYP3A4 inducers may require dose escalation. Investigators should consult the Medical Monitor 
for questions regarding any such dose adjustments. A list of common CYP3A4 inducers or inhibitors and CYP2D6 inhibitors is provided in Appendix Q . 
7.4.2. Contraception 
and Pregnancy  
All male and female subjects must agree to use an acceptable method of contraception for the duration of the study unless they are surgically sterile or post-menopausal (see below). The following are considered acceptable methods of contraception: 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 32 1. Double-barrier protection (eg, a condom with spermicide or a diaphragm with 
spermicide)  
2. Intrauterine device (IUD)  
3. Oral contraceptive pills or other hormonal methods (eg, a vaginal ring, contraceptive patch, contraceptive implant) 
Subjects who are abstinent are eligible, provided they agree to use an acceptable contraceptive 
method should they become sexually active. 
Subjects who are surgically sterile are exempt from the requ irement to use contraception. 
Women who have undergone a hysterectomy, bilateral tubal ligation, or bilateral salpingo-
oophorectomy are considered surgically sterile. Men who have undergone a vasectomy or 
bilateral orchiectomy are considered surgically ste rile. Partner vasectomy is not considered an 
approved acceptable method of contraception for a female subject. 
Women who are postmenopausal are also exempt from the requirement to use contraception. For 
the purpose of this study, postmenopausal is defined as the permanent cessation of menstruation for at least 12 months prior to screening in women who are 45 years of age or older. 
If a subject becomes pregnant while participating in the study, she will be discontinued from 
study drug immediately. Pregnancy is not considered an AE, however pregnancy, whether a 
female study subject or the partner of a male study subject, must be immediately documented on 
a Pregnancy Form and faxed to  at the SAE reporting fax number ( Section  13.5) 
within 24 hours of the investigator becoming aware of the pregnancy. Additional follow-up may 
be required. 
PPD
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 33 8. TREATMENT OF SUBJECTS 
8.1. Study Drug Dose and Administration  
The initial dose of aripiprazole lauroxil will be selected accord ing to the investigator's judgment 
and will be prepared and administered in accordance with the Directions for Use.  
Depending on individual patient’s needs, treatment with aripiprazole lauroxil can be initiated at a 
dose of 441 mg, 662 mg or 882 mg adminis tered monthly , which corresponds to 300 mg, 450 mg 
and 600 mg of aripiprazole, respectively. Treatment may also be initiated with the 882  mg dose 
every 6 weeks . 
Subjects will receive their first dose of aripiprazole lauroxil no earlier than one week and not 
later than 6 weeks following their previous dose of injectable risperidone or paliperidone. Due to 
safety concerns and the potential for rapid emergence of adverse events including akathisia, 
dystonia and EPS, oral aripiprazole dosing for 21 days after t he initia l dose of aripiprazole 
lauroxil is not recommended. C ross-tapering patients from long acting injectable risperidone or 
paliperidone palmitate to aripiprazole lauroxil is facilitated by the gradual disappearance of 
plasma risperidone/paliperidone w hile aripiprazole is concomitantly released from the in itial IM 
aripiprazole lauroxil injection.  
Administer aripiprazole lauroxil either in the deltoid muscle (441 mg dose only) or gluteal 
muscle (441 mg, 662 mg or 882 mg). See  Table 3. 
Table 3: A ripiprazole L auroxil Dosing Frequency and Site of Injection 
Dose  Dosing Frequency  Site of Intramuscular Injection  
441 mg Monthly Deltoid or Gluteal  
662 mg Monthly Gluteal  
882 mg Mont hly or every 6 weeks  Gluteal  
During the course of the study, the PI may adjust the dose of aripiprazole lauroxil. Stepwise dose decreases will be allowed for tolerability, accounting for the slow and prolonged release of 
aripiprazole lauroxil. Increased dose or frequency (e.g. to monthly from every 6 weeks) may be 
considered for inadequate efficacy. To allow for the gradual stepwise increase in aripiprazole levels with initial injections, dose increases may be performed after the second injection. 
Schedule changes, from monthly to every 6 weeks (or the reverse) will also be allowed after the 
second injection. Dose changes due to the medical need to initiate concomitant CYP modulators may be performed at any time if the concomitant medication is n ecessary fo r more than 2 weeks. 
After the first change, further dose or schedule changes should be made in consultation with the 
 Medical Monitor and must account for the gradual increase in plasma aripiprazole levels 
following the initial monthly doses.  
PPD
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 34 Table 4 outlines the recommended starting dose for subjects who have been historically 
stabilized  on oral aripiprazole: 
Table 4: Aripiprazole Lauroxil  Doses Based on Oral Aripiprazole T otal Daily Dose  
Oral Aripiprazole Dose  Intramuscular Aripiprazole Lauroxil  Dose  
10 mg 441 mg 
15 mg 662 mg 
20 mg or higher 882 mg 
8.2. Missed Doses 
When a dose is missed, administer the next injection of aripiprazole lauroxil as soon as possible. 
If the time  elapsed since the last aripiprazole lauroxil injection exceeds the length of time noted 
in Table 5, use oral aripiprazole supplementation with the next aripiprazole lauroxil injection as  
recommended  below . 
Table 5: Recommendation for Concomitant Oral Aripiprazole Supplementation 
Following Missed Dosesa 
Dose of Patient’s Last 
Aripiprazole Lauroxil 
Injection  Length of Time Since Last Injection  
No Oral  
Supplementation 
Required  Supplement with 
7 Days Oral 
Aripiprazole  Supplement with 
21 Days Oral  
Aripiprazole  
Monthly 441 mg ≤ 6 weeks > 6 and ≤ 7 weeks  > 7 weeks  
Monthly 662 mg ≤ 8 weeks > 8 and ≤ 12 weeks > 12 weeks 
Monthly 882 mg ≤ 8 weeks > 8 and ≤ 12 weeks > 12 weeks 
882 mg every 6 weeks  ≤ 8 weeks > 8 and ≤ 12 weeks > 12 weeks 
a Oral aripiprazole supplementation  dosage may be per  Table  4. 
8.3. Early Dosing  
The aripiprazole lauroxil injection should not be given earlier than 14 days after the previous 
injection.  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 35 8.4. Dose Adjustments for CYP450 Considerations  
In subjects taking strong CYP2D6 or CYP3A4 modulators t he initial and subsequent dose of 
aripiprazole lauroxil should be selected based upon the recommendations of Table 6 below. 
Once stabilized on aripiprazole lauroxil, refer to the dosing recommendations below for patients 
taking CYP2D6 inhibitors, CYP3A4 inhibitors, or CYP3A4 inducers: 
• No dosage changes recommended for aripiprazole lauroxil , if CYP 450 modulators are 
added for less than 2 weeks . 
• Make dose changes to aripiprazole lauroxil if CYP45 0 modulators are added for greater 
than 2 weeks (see Table 6).  
Table 6: Aripiprazole Lauroxil Dose Adjustments with Concomitant CYP450 
Modulator Use 
Concomitant Medicine  Dose C hange for ARIPIPRAZOLE LAUROXILa 
Strong CYP3A4 Inhibitor Reduce the dose of ARIPIPRAZOLE LAUROXIL  to the next lower 
strength. No dosage adjustment is necessary in patients taking 441 mg 
ARIPIPRAZOLE LAUROXIL , if tolerated.  
For patients known to be poor metabolizers of CYP2D6: Reduce dose to 
441 mg from both higher doses. No dosage adjustment is necessary in patients taking 441 mg ARIPIPRAZOLE LAUROXIL , if tolerated.  
Strong CYP2D6 Inhibitor Reduce the dose of ARIP IPRAZOLE LAUROXIL  to the next lower 
strength. No dosage adjustment is necessary in patients taking 441 mg 
ARIPIPRAZOLE LAUROXIL , if tolerated.  
For patients known to be poor metabolizers  of CYP2D6 : No dose 
adjustment required. 
Both Strong CYP3A4 Inhibitor and Strong 
CYP2D6 Inhibitor  Avoid use for patients at 662 mg or 882 mg dose. No dosage adjustment is 
necessary in patients taking 441 mg ARIPIPRAZOLE LAUROXIL , if 
tolerated. 
For patients known to be poor metabolizers of CYP2D6: Same as for 
extensive metabolizers.  
CYP3A4 Inducers  No dose adjustment for 662 mg and 882 mg dose, increase the 441 mg dose to 662 mg. 
For patients known to be poor metabolizers of CYP2D6: Same as for 
extensive metabolizers.  
a For the 882 mg dose administered every 6 weeks, the nex t lower strength should  be 441 mg administered every 
4 weeks.  
Augmentation with oral antipsychotics is permitted per clinical judgment and should be recorded 
as a concomitant medication  separately from other concomitant medications . 
Sites must have written  procedures in place detailing the healthcare personnel required to be on 
site during subject dosing, the availability of equipment and medications necessary to treat an emergency (should it occur), and the process for transferring a subject to a medical f acility if 
necessary.  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 36 8.5. Oral Aripiprazole Test Doses  
Oral aripiprazole for use as test doses during screening is an approved antipsychotic marketed 
under the trade name Abilify® (Bristol-Myers Squibb 2016). The first test dose will b e 
administered in the clinic.  
Oral test doses of aripiprazole are in 5 mg tablet form.  Oral aripiprazole tablets must be kept in a 
locked storage area before dosing and must be stored in accordance with the full prescribing 
information for Abilify.  
Aripipr azole for use as oral aripiprazole test doses will be commercially available Abilify® 5 mg 
tablets (Bristol-Myers Squibb 2016) or aripiprazole obtained from a local commercial source, 
provided in commercial packaging provided to th e site by Alkermes . 
8.6. Treatment Adherence  
All study drug injections will be directly administered by clinical study staff.  Study staff will 
address non- adherence with the subject as needed.  
8.7. Blinding  
Not applicable. The study is open- label.  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 37 9. STUDY DRUG MATERIALS AND MANAGEMENT  
9.1. Study Drugs  
The product in this study is aripiprazole lauroxil, a covalently bonded modification of 
aripiprazole to form N -lauroyloxymethyl aripiprazole . 
Detailed information about aripiprazole lauroxil can be found in the Aripiprazole Lauroxil 
Investigator’s Brochure  (IB).  
9.2. Accountability  
The clinical site is required to maintain current drug dispensation and accountability logs 
throughout the study. All unused supplies will be checked against the drug movement records 
during the study and/or at the end of the study. 
9.3. Handling and Disposal  
Following completion and verification of accountability logs, all unused and used packages must 
be destroyed. Packages may be destroyed on site according to Good Clinical Practice (GCP) and 
site practice. Alternatively, the sponsor may arrange for destruction with a third party vendor 
operating in accordance with GCP and/or Good Manufacturing Practice (GMP), as applicable.  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 38 10. ASSESSMENT OF EFFICACY  
Efficacy will be evaluated based on Clinical Global Impression s-Severity (CGI -S) and Brief 
Psychiatric Rating Scale (BPRS) responses.  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 39 11. QUALITY OF LIFE, DAILY AND SOCIAL FUNCTI ONING  
The following assessments will be collected to characterize any change in quality of life, 
including daily and social functioning, after t reatment with aripiprazole lauroxil:  
− Heinrichs -Carpenter Quality of Life Scale (QLS)  
− Negative Symptom Assessment -16 (NSA -16) 
− Sexual functioning subscale from UKU Side Effect Rating Scale and CSFQ 
scores  
− Personal and Social Performance scale (PSP)  
− Total and  individual items scores of the Modified MSQ  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 40 12. OTHER ASSESSMENTS 
The following assessments will be collected to explore potential changes in healthcare burden, 
cognition, insight, and psychosocial care needs following a transition to aripiprazole lauroxil: 
• Health economics  
− Total healthcare costs as measured by TSR -6-Modified  for Mental Health  
• Functional Assessment 
− BIS 
• Family Measures  
− CarerQOL –7D and VAS 
− Burden Assessment Scale 
• Investigator- and Caregiver -Rated Cognition  
− Respective NY -AACENT subscales  
• Substanc e Use  
− M.I.N.I. Module I (alcohol use disorder) 
− M.I.N.I. Module J (substance use disorder) 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 41 13. ASSESSMENT OF SAFETY AND TOLERABILITY  
The following safety and tolerability measures will be assessed throughout the study and 
summarized: 
• AEs 
• Injection site reaction s 
• Vital signs (blood pressure, heart rate, respiratory rate, and body temperature), and waist circumference and weight  
• Clinical laboratory parameters (chemistry [including prolactin ], hematology, and 
urinalysis) (Tab le 2) 
• C-SSRS responses 
• ESRS -A scores  
13.1. Definition of Adverse Event  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product. The occurrence, which may or may not have a causal relationship  with the treatment, may include any clinical or laboratory change that does not 
commonly occur in that subject and is considered clinically significant. 
Illnesses present prior to the subject signing the informed consent form (ICF) are considered to 
be pre-existing conditions and are documented on the medical history eCRF. Pre- existing 
conditions that worsen during the study are entered on the AE eCRF. 
All out-of- range laboratory values will be deemed as clinically significant or not clinically 
significant by the investigator. Clinically significant values will be considered AEs and recorded 
as such on the eCRFs. 
Pregnancy alone is not considered an AE, although a female subject will be withdrawn from 
study drug treatment if a pregnancy occurs.  If a pregnancy occurs in the partner of a male 
subject, it is not required that the male be withdrawn from study drug; however, contraceptive requirements should be revisited. As described in Section  7.4.2, the pregnancy must be reported 
to Alkermes and additional follow-up may be required. 
13.2. Definition of Serious Adverse Event  
An SAE is any AE, occurring at any dose and regardless of causality that:  
• Results in death  
• Is life -threatening. The subject is at immediate risk of death from the reaction as it 
occurs. This does not include reaction that, had it occurred in a more severe form, 
might have caused death.  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 42 • Requires inpatient hospitalization or prolongation of existing hospitalization. Hospital 
admission for elective surgery s cheduled prior to study entry is not considered an 
SAE.  
• Results in disability/incapacity (eg, a substantial disruption of a person’s ability to 
conduct normal life functions) 
• Is a congenital anomaly/birth defect  
Important medical events that may not result in death, be immediately life threatening, or require 
hospitalization may be considered to be SAEs when, based upon appropriate medical judgment, 
they may jeopardize the patient or subject and may require intervention to prevent one of the 
other outcomes listed above.  
13.3. Relationship to Study Drug  
The assessment of study drug relationship to each AE will be reported on the appropriate source 
document (and SAE form, in the event of an SAE) by the investigator (or designated 
sub-investigator) according to his/her best clinical judgment. The criteria listed in  Table 7 should 
be used to guide this assessment. Please note that not all criteria must be present to be indicative 
of a particular drug relationship. All study drugs are considered “test drugs” for the purposes of 
the definitions listed in the table.  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 43 Table 7: Adverse Event Causality Guidelines  
Relationship  Criteria for assessment  
Definitely related  There is evidence of exposure to the test drug.  
AND  
The temporal sequence of the AE onset relative to administration of the test drug is 
reasonable. 
The AE is more likely explained by the test drug than by another cause.  
Dechallenge (if performed) is positive.  
Rechallenge (if feasible) is positive.  
The AE shows a pattern consistent with previous knowledge of the test drug or test drug 
class.  
Probably related  There is evidence of exposure to the test drug.  
AND  
The temporal sequence of the AE onset relative to administration of the test drug is 
reasonable. 
The AE is more likely explained by the test drug than by another cause.  
Dechallenge (if performed) is positive.  
Possibly related  There is evidence of exposure to the test drug.  
AND  
The temporal sequence of the AE onset relative to adm inistration of the test drug is 
reasonable. 
The AE could have been due to another equally likely cause.  
Dechallenge (if performed) is positive.  
Probably not 
related  There is evidence of exposure to the test drug.  
AND  
There is another more likely cause of the AE.  
Dechallenge (if performed) is negative or ambiguous.  
Rechallenge (if performed) is negative or ambiguous.  
Definitely not 
related  The subject did not receive the test drug.  
OR 
Temporal sequence of the AE onset relative to administration of the test drug is not 
reasonable. 
OR 
There is another obvious cause of the AE.  
13.4. Monitoring and Recording of Adverse Events  
AE data collection will begin after a subject signs the ICF and will continue until completion of 
the End of Treatment/Early Termination visit (Day 169). Any AE or SAE having an onset after the End of Treatment/Early Termination visit will not be collected or reported unless the 
investigator feels that the event may be related to the study drug.  
Subjects will be instructed by the investigator or  designee to report the occurrence of any AE. 
All volunteered, elicited, and observed AEs are to be recorded on the AE eCRFs. 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 44 The investigator will assess all AEs regarding any causal relationship to the study drug 
(see Section  13.3) , the intensity (severity) of the event, action taken, and subject outcome. 
The following criteria should be used to guide the assessment of intensity (severity): 
• Mild:  Causes awareness of sign or symptom, but is easily tolerated; does not interfere 
with usual activities  
• Moderate:  Causes discomfort enough to interfere with usual activities  
• Severe:  Is incapacitating; results in inability to work or perform usual activities  
All AEs will be followed until resolution, until deemed stable by  the investigator, or until the 
subject is deemed by the investigator  to be lost to follow-up. 
For clinical study safety reporting purposes, the most recent version of the Investigator’s Brochure will be used as the reference document to designate event expectedness.  
Withdrawal from the study as a result of an AE and any therapeutic measures that are taken shall be at the discretion of the investigator . If a subject withdraws from the study for any reason , any 
ongoing AEs will be followed until resolution, until deemed stable by the investigator, or until 
the subject is deemed by the investigator  to be lost to follow -up. 
13.5. Reporting of Serious Adverse Events  
All SAEs must be reported to Alkermes, via  within 1 business day of 
discovery, by faxing the report to the following: 
Attention:  Drug Safety  
PHONE Number:  
FAX Number :  
FAX Number:   
 
The written report should be submitted on the SAE form provided for this purpose. The report 
must include the investigator’s opinion as to whether the event is study drug- related. If this 
relationship is determined to be possibly, probably, or definitely related to study drug, evidence 
to support this assessment must also be provided. 
PPD
PPD
PPD
PPD
PPD
PPD
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 45 14. STATISTICS  
14.1. Sample Size Considerations  
No formal sample size calculations have been performed. The sample size is based on clinical 
considerations. 
14.2. General Statistical Methodology  
In general, summary statistics (n, mean, standard deviation, median, minimum and maximum 
values for continuous variables, and number and percentage of subjects in each category for categorical variables) will be provided for evaluated variables. All individual subject level data 
will be presented as data listings.  
14.2.1. Study Populatio n 
The safety population will include all subjects who received at least one dose of aripiprazole 
lauroxil injection. All analyses will be carried out using the safety population. 
14.3. Demographics and Baseline Data  
Demographics and baseline characteristics such  as gender, age, race, weight, height, and BMI 
will be summarized using descriptive statistics. Medical history will be summarized using the 
number of observations and percentage of subjects reporting each category. 
14.4. Efficacy Analyses  
The change from baseli ne in CGI-S and BPRS scores at each post- baseline visit will be 
summarized.  
14.5. Safety and Tolerability Analysis  
The safety analysis will be carried out using the safety population. Reported AE terms will be coded using the Medical Dictionary for Regulatory Ac tivities (MedDRA).  
The number and percentage of TEAEs will be summarized by treatment group and overall by system organ class, and preferred terms within each system organ class. Serious adverse events (SAEs) and AEs resulting in treatment discontinuation will also be summarized.  
Observed values and change from baseline in vital signs, clinical laboratory data, and ESRS scores will be summarized  
Shift tables and potential clinical significance tables, along with supporting listings, will be 
provided for sel ected parameters.  
Prior and concomitant medication use will be summarized by World Health Organization Drug 
Dictionary Anatomical Therapeutic Class code and treatment group.  
Listings will be provided for all safety endpoints. 
Additional details on the safe ty analysis will be provided in the Statistical Analysis Plan.  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 46 14.6. Analyses of Other Assessments 
Data on quality of life, social functioning, functional assessment, and family measures will be 
summarized using the safety population. 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 47 15. DIRECT ACCESS TO SOURCE DAT A/DOCUMENTS  
15.1. Study Monitoring  
Monitoring of the study site (including, but not limited to, reviewing eCRFs for accuracy and 
completeness) will be performed by an Alkermes monitor or designee. 
15.2. Audits and Inspections  
By signing the protocol, the investigator agrees that, within local regulatory restrictions and 
institutional and ethical considerations, authorized representatives of Alkermes, a regulatory authority, and/or an institutional review board (IRB)/independent ethics committee (IEC) may 
visit the site  to perform audits or inspections, including the drug storage area, study drug stocks, 
drug accountability records, subject charts and source documents, and other records relative to 
study conduct. The purpose of an Alkermes audit or inspection is to syste matically and 
independently examine all study-related activities and documents (eg, laboratory reports, x- rays, 
workbooks, subjects’ medical records) to determine whether these activities were conducted, and data recorded, analyzed, and accurately reported  according to the protocol, GCP guidelines of the 
International Conference on Harmonisation (ICH), and any applicable regulatory requirements. 
The investigator should contact Alkermes immediately if contacted by a regulatory agency 
regarding an inspection. 
15.3. Institutional Review Board/ Independent Ethics Committee  
The investigator must obtain IRB/IEC approval for the investigation. Initial IRB/IEC approval as well as all materials approved by the IRB/IEC for this study, including the subject consent form and recruitment materials, must be maintained by the investigator and made available for 
inspection. 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 48 16. QUALITY CONTROL AND QUALITY ASSURANCE  
This study will be conducted under GCP and all applicable regulatory requirements. To ensure 
data accuracy, completeness and compliance, the study site should have processes in place for 
data review and quality control. Alkermes may also conduct a quality assurance audit. Please see 
Section  15.2 for details regarding the audit proc ess. 
16.1. Case Report Forms  
This study will use eCRFs. All eCRF data must be based on source documents or approved to be the original data (ie, data directly reported on the eCRF). All eCRFs will be completed by the clinic staff prior to review by the Alkermes monitor or designated representative. 
The Alkermes monitor or designated representative will review all source records on -site and 
compare them to the data collected on the eCRF.  
16.2. Confidentiality of Data  
By signing this protocol, the investigator affirms to  Alkermes that he or she will maintain in 
confidence information furnished to him or her by Alkermes and will divulge such information 
to his or her respective IRB or IEC under an appropriate understanding of confidentiality with 
such board. All data will be considered the sole property of Alkermes. Please refer to the Clinical Study Agreement (CSA) for details.  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 49 17. ETHICAL CONSIDERATIONS  
17.1. Ethics Review  
The clinical site’s IRB/IEC must meet all relevant regulatory requirements. The study protocol 
and ICF will be reviewed by the IRB/IEC prior to enrolling subjects into the study; written 
approval from the committee must be received by Alkermes before drug will be released to the investigator. The protocol must be re-approved by the IRB/IEC upon receipt of amendments 
and annually, as local regulatory requirements require. 
The investigator is responsible for submitting all protocol changes and SAE reports to the 
IRB/IEC according to local procedures. At a minimum, all SAEs requiring a drug safety report 
must be immed iately reported. For this study, submissions to the central IRB will be completed 
on behalf of the sites by  as outlined in the study- specific regulatory and safety 
management plans.  
All relevant correspondence from the IRB/IEC will be filed at  the site and collected by the 
Alkermes monitor or designated representative for inclusion in the Trial Master File (TMF) in a 
timely fashion.  
17.2. Ethical Conduct of the Study  
This study will be conducted in accordance with the protocol, the ICH Guideline E6, and all 
applicable local regulatory requirements. GCP is an international ethical and scientific quality 
standard used for designing, conducting, recording, and reporting studies involving the participation of human subjects. Alkermes is committed to compl ying with this standard to 
provide assurance that the rights, safety, and well -being of study subjects will be protected, 
consistent with the principles having their origin in the Declaration of Helsinki. 
17.3. Written Informed Consent  
The investigator (or authorized designee) at each center will ensure that the subject (or the 
subject’s legal representative) and reliable informant is given full and adequate oral and written 
information about the nature, purpose, potential and possible risks and benefits of the study. Each prospective subject and informant will receive an IRB-approved informed consent form 
(ICF) that summarizes the pertinent study information and will be given ample time to read the form and ask questions about the study. All information is to be provided in a language 
understandable to the subject and informant and must not include any language that waives the 
subject’s/informant’s legal rights. Prospective subjects/informants must also be informed of their 
right to withdraw consent without prejudice at any time during the study. If the subject/informant 
chooses to participate, he/she must sign the ICF before any study- specific procedures are 
conducted. 
All subjects/informants will be informed of their rights to privacy and will be made aware that 
the study data will be submitted to Alkermes, the IRB, the contract research organization (CRO) 
if applicable, and to regulatory authorities for review and evaluation for the duration of the study 
and until the project has been approved for marketing, or is withdrawn from investigation. They 
PPD
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 50 will also be informed that the study monitor may inspect their medical records to verify the 
accuracy and completeness of the study records and results.  
Significant changes to the protocol or product safety information may require a revision of the 
ICF, which must be reviewed and approved by the IRB, and then signed by all applicable study 
participants.  
The time that informed consent is obtained must be documented. The investigator must maintain 
the original, signed ICF in the subject’s source documents. A copy of the signed ICF must be 
given to the subject/informant. 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 51 18. DATA HANDLING AND RE CORDKEEPING  
An overview of study data handling and recordkeeping procedures and restrictions is provided in 
the subsequent sections; ple ase refer to the CSA for further details.  
18.1. Data Capture  
As stated in Section  16.1,  this study will use eCRFs for capturing data. All entries, corrections, 
and alterations will be made by the investigator or other authorized study personnel. All data entries will be verified for accuracy and correctness by independent monitors. The electronic 
data capture system maintains a full audit trail.  
A paper copy of all laboratory reports will remain with the source document s at the study site. 
All out of range laboratory values will be deemed as clinically significant or not clinically significant by the investigator. Clinically significant values will be considered AEs and recorded as such on the eCRFs. 
AEs will be coded using MedDRA. Concomitant medications will be categorized using the 
WHO- ATC classification system.  
18.2. Inspection of Records  
Alkermes or its representative will be allowed to conduct site visits to the investigational facilities for the purpose of monitoring any aspect of the study. The investigator agrees to allow 
the monitor to inspect the drug storage area, study drug stocks, drug accountability records, 
subject charts and source documents, and other records relative to study conduct. 
18.3. Retention of Records 
Retention and storage of essential clinical study documents (eg, worksheets, drug accountability 
forms, and other administrative documentation) shall be governed by the terms and conditions of 
the site’s CSA. If the CSA does not state specific document retenti on terms, then the site shall 
keep essential clinical study documentation for the longer of: 
• Ten years after discontinuation of the study, or 
• Two years following the date a marketing application is approved for the study drug 
for the indication for which it is being investigated pursuant to the study, or 
• If no application is to be filed or if the application is not approved for such indication, 
until 2 years after the date the study is terminated.  
Subjects’ medical files should be retained in accordance wit h the applicable legislation and in 
accordance with the maximum period of time permitted by the hospital, institution, or private practice.  
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 52 18.4. Use of Information and Publication Policy  
Data generated in this study are proprietary information that is the sole property of Alkermes. 
Results of the study are to be held in confidence by both the investigators and the sponsor. 
Please refer to the CSA for details on the procedures for publishing and presenting data. 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 53 19. REFERENCES  
American Psychiatric Association (2013). Diagnostic and Statistical Manual o f Mental Disorders 
(DSM -5). Washington, DC. 
Axelrod, B. N., R. S. Goldman and L. D. Alphs (1993). "Validation of the 16- item Negative 
Symptom Assessment." J Psychiatr. Res  27(3): 253 -258. 
Birchwood, M., J. Smith, V. Drury, J. Healy, F. Macmillan and M. Slade (1994). "A self-report 
Insight Scale for psychosis: reliability, validity and sensitivity to change." Acta Psychiatr Scand  
89(1): 62 -67. 
Bristol-Myers Squibb, O. P. C. (2016, 2016). "Prescribing Information: Abilify (aripiprazole), 2016-08." 
Brouwer, W. B., N. J. van Exel, G. B. van and W. K. Redekop (2006). "The CarerQol instrument: a new instrument to measure care -related quality of life of informal caregivers for 
use in economic evaluations." Qual Life Res  15(6): 1005-1021. 
Chouinard, G. and H. C. Mar golese (2005). "Manual for the Extrapyramidal Symptom Rating 
Scale (ESRS)." Schizophr Res 76(2 -3): 247-265. 
Guy, W. (2000). Clinical Global Impressions (CGI) Scale. Handbook of Psychiatric Measures. J. 
Rush, H. A. Pincus, M. B. First et al. Washington, DC, APA: 100-102. 
Heinrichs, D. W., T. E. Hanlon and W. T. Carpenter, Jr. (1984). "The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome." Schizophr Bull  10(3): 388-398. 
Keller, A., E. L. McGarvey and A. H. Clayton (2006). "Re liability and construct validity of the 
Changes in Sexual Functioning Questionnaire short- form (CSFQ -14)." J Sex Marital Ther  32(1): 
43-52. 
Lindstrom, E., T. Lewander, U. Malm, U. F. Malt, H. Lublin and U. G. Ahlfors (2001). "Patient-rated versus clinician -rated side effects of drug treatment in schizophrenia. Clinical validation of 
a self -rating version of the UKU Side Effect Rating Scale (UKU -SERS -Pat)." Nord J Psychiatry  
55 Suppl 44: 5 -69. 
Lingjaerde, O., U. G. Ahlfors, P. Bech, S. J. Dencker and K. Elgen (1987). "The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross -sectional 
study of side effects in neuroleptic- treated patients." Acta Psychiatr Scand Suppl  334: 1 -100. 
Opler, M., D. Antonius and C. Correll (2015). New York Assessment of Adverse Cognitive Effects of Neuropsychiatric Treatment - Revised (NY -AACENT -R), Unpublished Rating 
Instrument. 
Patrick, D. L., T. Burns, P. Morosini, M. Rothman, D. D. Gagnon, D. Wild and I. Adriaenssen 
(2009). "Reliability, validity and ability to detect change of the clinician -rated Personal and 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 54 Social Performance scale in patients with acute symptoms of schizophrenia." Curr. Med. Res. 
Opin  25(2): 325-338. 
Posner, K., D. Brent, C. Lucas, M. Gould, B. Stanley, G. Brown, P. Fisher, J. Zelazny, A. Burke, 
M. Oquendo and J. Mann (2009). Columbia- Suicide Severity Rating Scale (C -SSRS): 
Baseline/Screening Version. New York, NY, New York State Psychiatric Institute.  
Posner, K., D. Brent, C. Lucas, M. Gould, B. Stanley, G. Brown, P. Fisher, J. Zelazny, A. Burke, M. Oquendo and J. Mann (2009). Columbia- Suicide Severity Rating Scale (C -SSRS): Since last 
visit. New York, NY, New York State Psychiatric Institute.  
Reinhard, S. C., G. D. Gubman, A. V. Horwitz and S. Minsky (1994). "Burden a ssessment scale 
for families of the seriously mentally ill." Evaluation and Program Planning 17(3): 261 -269. 
 
 Alkermes, Inc.  
Protocol ALK9072-A401 1.0 (Amendment 1.0) CONFIDENTIAL  
 
Page 55 APPENDICES  
Appendix A. Columbia Suicide Severity Rating Scale (Sample)  
Appendix B. Extrapyramidal Symptom Rating Scale – Abbreviated (ESRS -A) (Sample)  
Appendix C. Clinical Global Impressions -Severity (CGI -S) (Sample)  
Appendix D. Brief Psychiatric Rating Scale (BPRS) (Sample)  
Appendix E. Sexual Functioning Subscale from Udvalg for Kliniske Undersøgelser (UKU) Side Effect  
Rating Scale  (Sample)  
Appendix F. Changes in Sexual Functioning Questionnaire (Sample)  
Appendix G. Personal and Social Performance Scale (PSP) (Sample)  
Appendix H. Heinrichs- Carpenter Quality of Life Scale (QLS) (Sample)  
Appendix I. Negative Symptom Assessment -16 (NSA-16) ( Sample)  
Appendix J.  Modified Medication Satisfaction Questionnaire (Modified MSQ) (Sample)  
Appendix K. Sixth Edition of the Treatment Services Review (TSR -6) (Sample)  
Appendix L. Caregiver Quality of Life (CarerQOL) – Burden Dimensions (7D) [Brouwer WBF, 2006]  
and Visual Analog Scale (VAS) (Sample)  
Appendix M. Burden Assessment Scale (Sample)  
Appendix N. Birchwood Insight Scale (BIS) (Sample)  
Appendix O. New York Assessment of Adverse Cognitive Effects of Neuropsychiatric Treatment  
(NY- AACENT) Subscal es (Sample)  
Appendix P. Mini International Neuropsychiatric Interview (M.I.N.I.) – Modules I and J (Sample)  
Appendix Q. List of Potent Cytochrome P450 3A4 (CYP3A4) Inducers and Moderate- to-Strong  
Inhibitors of 3A4 or 2D6 
 
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX A. COLUMBIA SUICIDE SEVERITY RATING SCALE 
(SAMPLE)  
Page 56
For Review OnlyCOLUMBIA-SUICIDE SEVERITY
RATING SCALE
(C-SSRS) 
Baseline 
Version 1/14/09 
Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, J.; 
Burke, A.; Oquendo, M.; Mann, J.
 
Disclaimer: 
This scale is intended to be used by individuals who have received training in its administration. The questions contained 
in the Columbia-Suicide Severity Rating Scale are suggested probes. Ultimately, the determination of the presence of 
suicidal ideation or behavior depends on the j udgment of the individual administering the scale. 
Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History 
Form , developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders 
(CCNMD), New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032. (Oquendo M. A., 
Halberstam B. & Mann J. J., Risk factors for suicidal behavior: ut ility and limitations of resear ch instruments. In M.B. First 
[Ed.] Standardized Evaluation in Clinical Practice , pp. 103 -130, 2003.) 
 
For reprints of the C-SSRS contact  New York State Psychiatric Institute, 1051 Riverside Drive, New 
York, New York, 10032; inquiries and training requirements contact 
© 2008 The Research Foundation for Mental Hygiene, Inc.  
Page 57
PPD
PPD
For Review OnlySUICIDAL IDEATION  
Ask questions 1 and 2.  If both are negati ve, proceed to “Suicidal  Behavior” section. If the an swer to question 2 is “yes”, 
ask questions 3, 4 and 5.  If the answer to question 1 and/ or 2 is “yes”, complete “Intensity of Ideation” section below.Lifetime:  
Time He/She 
Felt Most 
Suicidal
1.  Wish to be Dead
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up.  
Have you wished you were dead or wished you could go to sleep and not wake up?  
   
If yes, describe: 
 Yes       No 
 /g401    /g401 
2.  Non-Specific Active Suicidal Thoughts
General, non-specific thoughts of wanting to end one’s life/commit suicide (e.g., “I’ve thought about killing myself”) without thoughts of ways to kill 
oneself/associated methods, intent, or plan.  
Have you actually had any thoughts of killing yourself? 
If yes, describe:   Yes      No 
 /g401    Κ
3.  Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act 
Subject endorses thoughts of suicide and has thought of at least one method during the assessment peri od. This is different tha n a specific plan with time, 
place or method details worked out (e.g., thought of method to kill self but not a specific plan).  Includes person who would s ay,“I thought about taking an 
overdose but I never made a specific plan as to when, where or how I would actually do it…and I would never go through with it. ”
Have you been thinking about how you might do this? If yes, describe: 
  Yes      No 
 /g401    Κ
4.  Active Suicidal Ideation with Some Intent to Act, without Specific Plan 
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts , as opposed to “I have the thoughts but I 
definitely will not do anything about them.” 
Have you had these thoughts and had some intention of acting on them?
If yes, describe: 
 Yes       No 
 /g401    Κ
5.  Active Suicidal Ideation with Specific Plan and Intent 
Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it out. Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? 
If yes, describe:  Yes      No 
 /g401    Κ
INTENSITY OF IDEATION  
The following features should be rated with respect to the most severe type of ideation (i.e., 1-5 from above, with 1 being the least severe 
and 5 being the most severe). Ask about time he/she was feeling the most suicidal.  
                                             
Most Severe Ideation:                                                          _____                      _________________________________________________ 
                                                                                                    Type # (1-5)                                         Description of  IdeationMost 
Severe 
Frequency 
How many times have you had these thoughts?  
(1) Less than once a week    (2) Once a week   (3)  2-5 times in week    (4) Daily or almost daily    (5) Many times each day____
Duration 
When you have the thoughts , how long do they last? 
(1) Fleeting - few seconds or minutes                                                 (4) 4-8 hours/most of day 
(2) Less than 1 hour/some of the time                                                 (5) More than 8 hours/persistent or conti nuous
(3) 1-4 hours/a lot of time ____
Controllability 
Could/can you stop thinking about killing yourself or wanting to die if you want to? 
(1) Easily able to control thoughts                                                      (4) Can control thoughts with a lot of  difficulty 
(2) Can control thoughts with little difficulty                                     (5) Unable to control thoughts 
(3) Can control thoughts with some difficulty                                    (0) Does not attempt to control thoughts____
Deterrents 
Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you from wanting to die or acting on
thoughts of committing suicide? 
(1) Deterrents definitely stopped you from attempting suicide            (4) Deterrents most likely did not stop you  
(2) Deterrents probably stopped you                                                    (5) Deterrents definitely did not stop y ou
(3) Uncertain that deterrents stopped you                                             (0) Does not apply ____
Reasons for Ideation 
What sort of reasons did you have for thinking about wanting to die or killing yourself?  Was it to end the pain or stop the wa y
you were feeling (in other words you couldn’t go on living with this pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or both? 
(1) Completely to get attention, revenge or a reaction from others       (4) Mostly to end or stop the pain (you couldn’t go on
(2) Mostly to get attention, revenge or a reaction from others                     living with the pain or how you were feeling )
(3) Equally to get attention, revenge or a reaction from others               (5) Completely to end or stop the pain (you could n’t go on  
       and to end/stop the pain.                                                                        living with the pain or   how you were feeling) 
                                                                                                                 (0)  Does not apply ____
Version 1/14/09 
Page 58
For Review OnlySUICIDAL BEHAVIOR
(Check all that apply, so long as these are separate events; must ask about all types)  
Lifetime  
Actual Attempt:
A potentially self-injurious act committed with at least some wish to die, as a result of act.  Behavior was in part thought of as method to kill oneself. Intent 
does not have to be 100%.  If there is any intent/desire to die associated with the act, then it can be considered an actual suicide attempt. There does not 
have to be any injury or harm , just the potential for injury or harm. If person pulls trigge r while gun is in mouth but gun is broken so no injury results, 
this is considered an attempt.   
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circumsta nces. For example, a highly lethal 
act that is clearly not an accident so no other intent but suicide can be inferred (e.g., gunshot to head, jumping from window of a high floor/story). Also, if 
someone denies intent to die, but they thought that what they did could be lethal, intent may be inferred.  
Have you made a suicide attempt? 
Have you done anything to harm yourself? 
Have you done anything dangerous where you could have died? 
What did you do? Did you______ as a way to end your life?  Did you want to die (even a little) when you_____?  Were you trying to end your life when you _____? Or did you think it was possible you could have died from_____? 
Or did you do it purely for other reasons / without ANY intention of killing yourself (like to relieve stress, 
feel better, get sympath y,
or get something else to happen)? (Self-Injurious Behavior without suicidal intent)
If yes, describe: 
 
 
Has subject engaged in Non-Suicidal Self-Injurious Behavior?   
Yes      No 
/g401   Κ
Total # of 
Attempts 
______
 
  
 
  
Yes    No 
/g401   Κ
Interrupted Attempt:
When the person is interrupted (by an outside circumstance) from starting the potentially self-injurious act (if not for that, actual attempt would have 
occurred).
Overdose: Person has pills in hand but is stopped from ingesting.  Once they ingest any pills, this becomes an attempt rather t han an interrupted attempt. 
Shooting: Person has gun pointed toward self, gun is taken away by someone else, or is somehow prevented from pulling trigger. Once they pull the trigger, 
even if the gun fails to fire, it is an attempt. Jumping: Person is poised to jump, is grabbed and taken down from ledge. Hanging: Person has noose around neck 
but has not yet started to hang - is stopped from doing so. 
Has there been a time when you started to do something to end your life but someone or something stopped you before you 
actually did anything? 
If yes, describe:  
Yes      No 
/g401   /g401 
 
 
Total # of 
interrupted
______
Aborted Attempt:   
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in any  self-destructive behavior. 
Examples are similar to interrupted attempts, except that the individual stops him/herself, instead of being stopped by something else. 
Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually didanything?
If yes, describe:  
Yes      No 
/g401   /g401 
 
Total # of 
aborted 
______
Preparatory Acts or Behavior: 
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or thought, s uch as assembling a specific 
method (e.g., buying pills, purchasing a gun) or preparing for one’s death by suicide (e.g., giving things away, writing a suic ide note).  
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gu n,
giving valuables away or writing a suicide note )?
If yes, describe:  
Yes      No 
/g401   Κ
Suicidal Behavior:
Suicidal behavior was present during the assessment period? Yes      No 
/g401   Κ
Answer for Actual Attempts OnlyMost Recent
Attempt 
Date:Most Lethal         
Attempt 
Date:Initial/First
Attempt 
Date:
Actual Lethality/Medical Damage:   
0.  No physical damage or very minor physical damage (e.g., surface scratches). 
1.  Minor physical damage (e.g., lethargic speech; first-degree burns; mild bleeding; sprains). 
2.  Moderate physical damage; medical attention needed (e.g., conscious but sleepy, somewhat responsive; second-degree 
burns; bleeding of major vessel). 
3.  Moderately severe physical damage; medical  hospitalization and likely intensive care required (e.g., comatose with 
reflexes intact; third-degree burns less than 20% of body; extensive blood loss but can recover; major fractures). 
4.  Severe physical damage; medical  hospitalization with intensive care required (e.g., comatose without reflexes; third-
degree burns over 20% of body; extensive blood loss with unstable vital signs; major damage to a vital area). 
5.  Death Enter Code 
______Enter Code 
______Enter Code 
______
Potential Lethality: Only Answer if Actual Lethality=0 
Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medical damage, had potential for very serious lethality: put gun in mouth and pulled the trigger but gun fails to fire so no medical damage; 
laying on train tracks with oncoming train but pulled away before run over). 
0 = Behavior not likely to result in injury 
1 = Behavior likely to result in injury but not likely to cause death 
2 = Behavior likely to result in death despite available medical care  Enter Code 
______Enter Code 
______Enter Code 
______
Page 59
For Review OnlyCOLUMBIA-SUICIDE SEVERITY
RATING SCALE
(C-SSRS) 
Since Last Visit 
Version 1/14/09 
Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, J.; 
Burke, A.; Oquendo, M.; Mann, J.
 
Disclaimer: 
This scale is intended to be  used by individuals who have  received training in its administrat ion. The questions contained in 
the Columbia-Suicide Severity Rating Scale  are suggested probes. Ultimately, the determination of the presence of suicidal 
ideation or behavior depends on the judgment of the individual administering the scale. 
Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History Form , 
developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders 
(CCNMD), New York State Psychiatr ic Institute, 1051 Riverside Drive, New York, NY, 10032. (Oquendo M. A., 
Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First 
[Ed.] Standardized Evaluation in Clinical Practice , pp. 103 -130, 2003.) 
 
For reprints of the C-SSRS contact  New York State Psychiatric Institute, 1051 Riverside Drive, New 
York, New York, 10032; inquiries and training re quirements contact 
 
© 2008 The Research Foundation for Mental Hygiene, Inc.  
Page 60
PPD
PPD
For Review OnlySUICIDAL IDEATION
Ask questions 1 and 2.  If both are negative, proceed to “ Suicidal Behavior” section. If the answer to question 2 is “yes” ,
ask questions 3, 4 and 5.  If the answer to question 1 and/or 2 is “yes”, complete “Intensity of  Ideation” section below.Since Last 
Visit
1.  Wish to be Dead
Subject endorses thoughts about a wish to be dead or not alive anymore, or  wish to fall asleep and not wake up. 
Have you wi shed you were dead or wished you co uld go to sleep and not wake up? 
If yes, describe:Yes No
□  □
2.  Non-Specific Active Suicidal Thoughts
General , non- specific thoughts of wanting to end one’s life/commit suicide (e.g. ,“I’ve thought about killing myself” ) without thoughts of ways to kill 
oneself/associated methods, intent, or plan du ring the assessment period. 
Have you actually had any tho ughts of killing yourself?
If yes, describe:Yes     No
□    □
3.  Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act
Subject endorses thoughts of suicide and has thought of at least one method during the assessment period. This is different than a specific plan with time, 
place or method details worked out (e.g. , thought of method to kill self but not a specific plan).  Inclu des person who would say, “I thought about taking a n
overdose but I never made a specific plan as to when, where or how I would actually do it… and I would never go through with it. ”
Have you been thinking ab out how you might do this?
If yes, describe:Yes      No
□  □
4.  Active Suicidal Ideation with Some In tent to Act, without Specific Plan
Active suicidal thoughts of killing on eself and subject reports having some intent to act on such thoughts, as opposed to “I have the thoughts but I 
definitely will not do anything about them .”
Have you had these thoughts and had  some intention of acting on them ?
If yes, describe:Yes    No
□   □
5.  Active Suicidal Ideation with Specific Plan and Intent
Thoughts of killing oneself with d etails of plan fully or pa rtially worked out and subject has some intent to carry it out.
Have you started to work out or worked out the details of ho w to kill yourself? Do you intend to carry out this plan?
   
Ifyes, describe:Yes     No
□  □
INTENSITY OF IDEATION
The following features should be rated with respect to the most severe type of  ideation (i.e., 1-5 from above, with 1 being the  least severe 
and 5 being the most severe ). 
                                            
Most Sev ere Ideation:             _____                      _________ ________________________________________                                             
                                                                                                          Type # (1-5)                                         Description of  IdeationMost
Severe
Frequency
How many times have you had these thoughts?
(1) Less than once a week    (2) Once a week   (3)  2-5 times in week    (4) Daily or almost daily    (5) Many times each day____
Duration
When you have the thoughts , how long do they last?
(1) Fleeting - few seconds or minutes                                             (4) 4-8 hours/most of day
(2) Less than 1 hour/some of the time                                                 (5) More than 8 hours/persistent or conti nuous
(3) 1-4 hours/a lot of time                                                                   ____
Controllability
Could /can you stop thinking about killing yourself or wanting to die if you want to?
(1) Easily able to control thoughts                                                      (4) Can control t houghts with a lot of  difficulty
(2) Can control thoughts with little difficulty                                   (5) Unable to control thoughts
(3) Can control thoughts with some difficulty                                    (0) Does not attempt to control thoughts____
Deterrents
Are there things - anyone or anything (e.g., family, religion, pain of death) - that stopped you fro m wanting to die or acting on 
thoughts of committing suicide?
(1) Deterrents definitely stopped you from attempting suicide            (4) Deterren ts most likely did not stop you 
(2) Deterrents probably stopped you                                                (5) Deterrents definitely did not stop you 
(3) Uncertain that deterrents stopped you                                            (0) Does not apply____
Reasons for Ideation
What sort of reasons did you have for thinking about wanting to die or killing yourself?  Was it to end the pain or stop the wa y 
you were feeling (in other words you couldn’t go on living with this pain or how you were feeling) or was it to get attention ,
revenge or a reaction from others? Or both?
(1) Completely to get attention, revenge or a reaction from others       (4) Mostly to end or stop the pain (you couldn’t go on
(2) Mostly to get attention, revenge or a reaction from  others                     living with the pain or how you were feeling )
(3) Equally to get atten tion, revenge or a reaction from others               (5) Completely to end or stop the pain (you couldn’t go on 
       and to end/stop the pain                                                                         living with the pain or   how you were feeling)
                                                                                                                 (0) Does not ap ply____
© 2008 Research Foundation for Mental Hygiene, Inc. C-SSRS—Since Last Visit (Version 1/14/09)   
Page 61
For Review OnlySUICIDAL BEHAVIOR
(Check all that apply, so long as these are separate events; must ask about all types)Since Last 
Visit
Actual Attempt:
A potentially self -injurious act committed with at least some wish to die, as a result of act. Behavior was in part thought of  as method to kill oneself. Intent 
does not have to be 100%.  If there is any intent/desire to die associated with  the act, then it can be con sidered an actual suicide attempt. There does not 
have to be any injury or harm , just the potential for in jury or harm. If person pulls trigg er while gun is in mouth but gun is broken so no injury results,
this is considered an attempt.  
Inferring Intent: Even if an individual denies intent/wish to die, it ma y be inferred clinically from the behavior or circums tances. For example, a highly 
lethal act that is clearly not an accident  so no other intent but su icide can be inferred (e.g., gunshot to head, ju mping from window of a high floor/story). 
Also, if someone denies inten t to die, but they thought that what they did  could be lethal, inten t may be inferred. 
Have you made a suicide attempt?
Have you done an ything to harm yourself?
Have you done anything dangerous where you could have died?
What did you do?
Did you______ as a way to end your life? Did you want to die (even a little) when you_____? 
Were you trying to end your life when you _____?
Or did you think it was possible you could have died from_____?
Or did you do it purely for other reasons / without ANY intention of killing yourself (like to relieve stress, feel better, g et
sympathy, or get something else to happen)? (Self-Injurious Behavior without suicidal intent)
If yes, describe:
Has subject engaged in Non-Suicidal Self-Injurious Behavior?Yes      No
□   □
Total # of
Attempts
____ __
Yes No
□   □
Interrupted Attempt:
When the person is interrupted (by an outside circum stance) from starting the po tentially self-injurious act (if not for that, act ual attempt would have 
occurred).
Overdose: Person has pills in hand but is stopped from ingesting.  Once they ing est any pills, this becomes an attempt rather than an interrupted attempt. 
Shooting: Person has gun pointed toward self, gun is taken away by someone else, or is so mehow prevented from pulling trigger. Once they pull the trigger, 
even if the gun fails to fire, it is an attem pt. Jumping: Person is poised to jump, is gra bbed and taken down from ledge. Hanging: Person has noose around 
neck but has not yet started to hang - is stopped from doing so.
Has there been a time when you started to do something to end your life but someone or something stopped you before you 
actual ly did anything?
If yes, describe:Yes      No
□   □
Total # of 
interrupted
______
Aborted Attempt:  
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in a ny self- destructive behavior. 
Examples are similar to interrupted attemp ts, except that the individual stops him/herself, instead of being stopped by something else.
Has there been a time when you started to  do something to try to end your life but you stopped yourself before you 
actually did anything?
If yes, describe:Yes     No
□   □
Total # of
aborted
____ __
Preparatory Acts or Behavior:
Acts or preparation towards imminently making a suicide atte mpt. This can include anything beyond a verbalization or thought, such as assembling a 
specific method (e.g. , buying pills, purchas ing a gun) or preparing fo r one’s death by suicide (e.g. , giving things away, writing  a suicide note). 
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gu n, 
giving valuables away or writing a suicide note )?
If yes, describe:Yes      No
□   □
Suicidal Behavior:
Suicidal behavior was present during the assessment period?Yes      No
□   □
Suicide: Yes    No
□   □
Answer for Actual Attempts OnlyMost Lethal
Attempt
Date:
Actual Lethality/Medical Damage:  
0.  No physical damage or ve ry minor physical damage (e.g. , surface scratches).
1.  Minor physical damage (e.g. , lethargic speech; first-d egree burns; mild bleeding; sprains).
2.  Moderate physical damage; medical attention needed (e.g., conscious but sleep y, somewhat responsive; second- degree burns; bleeding of major vessel).
3.  Moderately severe physical damage; medical hospitalization and likely intensive care required (e.g., comatose with re flexes intact; third-degree bu rns 
less than 20% of body; extensive blood loss but can recover; major fractures).
4.  Severe physical damage; medical hospitalization with intensive care required (e.g., comatose without reflex es; third-degree burns over 20% of body; 
extensive blood loss with unstable vital signs; major damage to a vital area).
5.  DeathEnter Code
______
Potential Lethality: Only Answer if Actual Lethality=0
Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medica l damage, had potential for very serious 
lethality: put gun in mouth and pu lled the trigger but gun fails to f ire so no medical damage; laying on train tracks with on coming train but pulled away 
before run over).
0 = Behavior not likely to result in injur y
1 = Behavior likely to result in injury but no t likely to cause death
2 = Behavior likely to result in death desp ite available medical care Enter Code
______
© 2008 Research Foundation fo r Mental Hygiene, Inc.  C-SSRS —Since Last Visit (Version 1/14/09)        
Page 62
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX B.  EXTRAPYRAMIDAL SYMPTOM RATING SCALE – 
ABBREVIATED (ESRS-A) (SAMPLE)  
Page 63
For Review OnlyExtrapyramidal Symptom Rating Scale-Abbreviated 
Scoring Sheet-Long Form (NOT FOR COMPLETION) 
Parkinsonism 
Rigidity 
Upper limbs
0No rigidity
1Minimal Very mild, barely perceptible
2Mild Some resistance to passive movements
3Moderate  Definite resistance to passive movements, still easy to move limb, full range motion achieved
4Severe  Marked resistance to passive movements, difficulty to  move limb with full range of motion
5Extreme  Lead pipe rigidity, limb nearly frozen; motion achieved with difficulty
Lower limbs
0No rigidity
1Minimal Very mild, barely perceptible
2Mild Some resistance to passive movements
3Moderate  Definite resistance to passive movements, still easy to move limb, full range motion achieved
4Severe  Marked resistance to passive movements, difficulty to move limb with full range of motion
5Extreme  Lead pipe rigidity, limb nearly frozen; motion achieved with difficulty
Neck 
0No rigidity
1Minimal Very mild, barely perceptible
2Mild Some resistance to passive movements
3Moderate  Definite resistance to passive mo vements, still easy to move n eck, full range motion achieved
4Severe  Marked resistance to passive move ments, difficulty to move neck wi thin full range of motion
5Extreme  Lead pipe rigidity, neck nearly frozen; motion achieved with difficulty
Tremor
Face, jaw/chin, lips, head
0No tremor Absent at rest and during action/posture
1Minimal Tremor with action/posture. Absent at rest; rare (<10% of the time)
2Mild Small amplitude tremor with action/posture; occasional (<50% of the time). Absent at rest
3Moderate  Moderate amplitude tremor with action/posture; noticeable (>50% of the time). May be absent at 
rest
4Severe  Large amplitude tremor at rest or during action/posture; occasional (<50% of the time)
5Extreme  Large amplitude tremor at rest and during ac tion/posture; noticeable (>50% of the time)
Upper limbs/hands
0No tremor Absent at rest and during action/posture
1Minimal Tremor with action/posture. Absent at rest; rare (<10% of the time)
2Mild Small amplitude tremor with acti on/posture; occasional (<50%  of the time) Absent at rest
3Moderate  Moderate amplitude tremor with action/posture; noti ceable (>50% of the time). May be absent at 
rest
4Severe  Large amplitude tremor at rest or during action/posture; occasional (<50% of the time)
5Extreme  Large amplitude tremor at rest and during ac tion/posture; noticeable (>50% of the time)
Lower limbs/feet
0No tremor Absent at rest and during action/posture
1Minimal Tremor with action/posture. Absent at rest; rare (<10% of the time)
2Mild Small amplitude tremor with ac tion/posture (<50% of  the time); absent at rest
3Moderate  Moderate amplitude tremor with action/posture; noticeable (>50% of the time); may be absent at 
rest
4Severe  Large amplitude tremor at rest or during action/posture; occasional (<50% of the time)
5Extreme  Large amplitude tremor at rest and during ac tion/posture; noticeable (>50% of the time)
Page 64
For Review OnlyParkinsonism (continued)  
Reduced facial expression/speech 
0Normal
1Minimal Very mild decrease in facial expressiveness
2Mild Mild decrease in facial expressiveness; hypomania
3Moderate  Rare spontaneous smile, decreased blinking, voice monotonous
4Severe  Difficulty to frown, slurred  speech, staring gaze
5Extreme  Unable to frown, unintelligible sp eech, fixed facial expression, lips parted
Impaired Gait/Posture 
0Normal
1Minimal Very mild decreased pendular arm movement , not quite erect normally: stooped posture
2Mild Mild decrease of pendular arm mo vement, mildly stooped posture
3Moderate  No pendular arm movement, head flexed, can be leaning to one side
4Severe  Small step (shuffling gait), stiff post ure (neck, back), moderate leaning to one side
5Extreme  Festination/freezing on turning, barely able to walk, triple fl exion: posture extreme abnormal
Postural Instability 
0No postural instability
1Minimal Hesitation when suddenly pushed or pulled  but no latero, antero nor retropulsion
2Mild Latero, antero or retr opulsion but recovers unaided
3Moderate  Absence of postural response, wo uld fall if not caught
4Severe  Unstable while standing, even without pushing
5Extreme  Unable to stand without assistance
Bradykinesia/ Hypokinesia
0No slowness of movement
1Minimal Minimally/questionably slowed movements, hesitancy
2Mild Mildly slowed movements, mild poverty of movements
3Moderate  Moderate difficulty in init iating or stopping movements
4Severe  Rare voluntary movements, small amplitude movements
5Extreme  Almost completely immobile
Page 65
For Review Only
  Dystonia 
Tongue
0None No contraction at rest or during action
1Minimal Very mild contraction partial tongue protr usion; rare (<10% of the time)
2Mild Mild contraction partial tongue protrusion; occasio nal (<50% of the time) 
3Moderate  Sustained min effort contraction partial tongue protrusion; noticeable (>50% of the time) 
4Severe  Forceful effort contraction near c omplete tongue protrusion; occasio nal (<50% of the time) 
5Extreme  Forceful effort near complete tongue protrusion; noticeable (>5 0% of the time) 
Jaw
0None No contractions at rest or during action
1Minimal Very mild contraction partial jaw opening or clenching; rare (<10% of the time) 
2Mild Mild contraction partial jaw opening or cl enching; occasional (<50% of the time) 
3Moderate  Sustained min effort partial jaw op ening or clenching; noticeable  (>50% of the time) 
4Severe  Forceful effort complete jaw opening or clenching/bruxism; occasional (<50% of the time) 
5Extreme  Forceful effort complete jaw opening or clenching/bruxism; noticeable (>50% of the time) 
Eyes, upper face, lower face, larynx
0None No contractions at rest or during action
1Minimal Very mild blepharospasm, oculogyration, choked voice or grimacing; rare (<10% of the time) 
2Mild Mild blepharospasm, oculogyration, choked voice or grimacing; occa sional (<50% of the time) 
3Moderate  Sustained min effort blepharospasm, oculogyration, c hoked voice or grimacing; predominant (>50% 
of the time) 
4Severe  Forceful effort blepharospasm, oculogyr ation, choked voice or grim acing; occasional (<50% of the 
time) 
5Extreme  Forceful effort blepharospasm, oculogyr ation, choked voice or grimacin g; noticeable (>50% of the 
time) 
Shoulders, upper limbs, hands
0None No contraction at rest or during action
1Minimal Very mild contraction of shoulder, upper limb  or hand; rare (<10% of the time) 
2Mild Mild contraction of shoulder, upper limb or hand; occasional (<50% of the time) 
3Moderate  Sustained min effort contraction of should er, upper limb or hand; noti ceable (>50% of the time) 
4Severe  Forceful effort contraction of shoulder,  upper limb or hand; occa sional (<50% of the time) 
5Extreme  Forceful effort contraction of shoulder,  upper limb or hand; noti ceable (>50% of the time) 
Hips, lower limbs, feet
0None No contraction at rest or during action 
1Minimal Very mild contraction of hip, lower limb or foot; rare (<10% of the time) 
2Mild Mild contraction of hip, lower limb or foot; occasional (<50% of the time) 
3Moderate  Sustained min effort contraction of hip, lower limb or foot; noticeable (>50% of the time) 
4Severe  Forceful effort contraction of hip, lower limb  or foot; occasional (<50% of the time) 
5Extreme  Forceful effort contraction of hip, lower limb or foot; noticeable (>50% of the time) 
Trunk, neck 
0None No contraction at rest or during action 
1Minimal Very mild contraction trunk bending or head  turning; rare (<10% of the time) 
2Mild Mild contraction trunk bending or head turning; occasional (<50% of the time) 
3Moderate  Sustained min effort trunk bending or head turnin g; noticeable (>50% of the time) 
4Severe  Forceful effort contraction trunk bending or head turning; occasional (<50% of the time) 
5Extreme  Forceful effort contraction trunk ben ding or head turning; noticeable (>50% of the time) 
Page 66
For Review OnlyDyskinesia 
Tongue
0Absent No dyskinesia at rest or during action
1Minimal Very mild dyskinetic lateral or torsion movement of tongue; rare (< 10% of the time)
2Mild Lateral or torsion tongue dyskinesia within oral cavity; occasional (<50 % of the time)
3Moderate Lateral or torsion tongue dys kinesia within oral cavity; noticeable (>50%  of the time)
4Severe Near complete tongue protrusion dyskinesia (fly catching); occasional (<50% of the time)
5Extreme Near complete tongue protrusion dyskinesia (fly catching); noticeable (>50% of the time)
Jaw
0Absent No dyskinesia at rest or during action
1Minimal Very mild dyskinetic lateral, chewing or biting jaw  movement; rare (<10% of the time)
2Mild Lateral, chewing or biting dyskinesia with out jaw opening; occasional (<50% of the time)
3Moderate Lateral, chewing or biting dyskinesia without jaw opening; noticeable (>50% of the time)
4Severe Near complete jaw op ening dyskinesia; occasional (<50% of the time)
5Extreme Near complete jaw ope ning dyskinesia; noticeab le (>50% of the time)
Eyes, upper face, lower face
0Absent No dyskinesia at rest or during action
1Minimal Very mild dyskinetic blinking, or pouti ng; rare (<10% of the time)
2Mild Blinking, or pouting dyskinesia; occasi onal (<50% of the time)
3Moderate Blinking, or pouting dyskinesia; noticea ble (>50% of the time)
4Severe Marked blinking, or pouting dyskinesia; occasional (<50% of the time)
5Extreme Marked blinking, or p outing dyskinesia noticeable (>50% of the time)
Shoulders, upper limbs, hands
0Absent No dyskinesia at rest or during action
1Minimal Very mild dyskinetic shoulder, limb or hand mo vement; rare (<10% of the time)
2Mild Unilateral dyskinesia of shoulder, limb  or hand; occasional (<50% of the time)
3Moderate Unilateral dyskinesia of shoulder, limb or hand; noticeable ( >50% of the time)
4Severe Bilateral dyskinesia of shoulde r, limb or hand; occasional (<50% of the time)
5Extreme Bilateral dyskinesia of shoulder, limb or hand; noticeable (>50% of the time)
Hips, lower limbs, feet
0Absent No dyskinesia at rest or during action
1Minimal Very mild dyskinetic hip, limb or foot movement; rare (<10% of the time)
2Mild Unilateral dyskinesia of hip, li mb or foot; occasional (<50% of the time)
3Moderate Unilateral dyskinesia of hip, li mb or foot; noticeable (>50% of the time)
4Severe Bilateral dyskinesia of hip, limb or fo ot; occasional (<50% of the time)
5Extreme Bilateral dyskinesia of hip, limb or foot; noticeable (>50% of the time)
Trunk, neck
0Absent No dyskinesia at rest or during action
1Minimal Very mild dyskinetic trunk bending or head turning; rare (<10% of the time)
2Mild Mild trunk bending or head turning dyskinesia; occasional (<50% of the time)
3Moderate Moderate trunk bending or head turning dy skinesia; noticeable (>50% of the time)
4Severe Marked trunk bending or head turning d yskinesia; occasional (< 50% of the time)
5Extreme Marked trunk bending or head turning d yskinesia; noticeable (>50% of the time)
Page 67
For Review Only
  Akathisia 
Subjective (reported by the patient)
0None
No feelings of restlessness/urge to move, nor dist ress reported.
1Minimal
Slight vague feelings of restlessness/urge  to move, minimally aware or distressed.
Rare (<10% of the time)
2Mild
Clearly identifiable feelings of  restlessness/urge to move that are manageable, do not require treatment, 
mildly aware or distressed. No impact on daily ac tivities. Occasional ( <50% of the time)
3Moderate
Feelings of restlessness/urge to move require effort to manage, interfe re with some dail y activities, 
moderately aware or distressed. Patient may seek treatment. Noticeable (>50% of the time)
4Severe
Feelings of restlessness/urge to move with significant impact on daily activities, intensely aware or 
distressed. Medications may not completely control symptoms. Occasional (<50% of the time)
5Extreme
Feelings of restlessness/urge to move  with severe impact on all dail y activities, extremel y aware or 
distressed. Medications have minimal effect s. Noticeable (>50% of the time)
Objective (observed during patient examination)
0None
No overt signs of restlessne ss or fidgeting.
1Minimal
Slight restless movements, fidgeting or crossing-uncrossing of leg. Rare (<10% of the time)
2Mild
Mild restless movements. Need to move at least one extremity, fidget s in his/her chair, rocks or crosses 
and uncrosses his/her legs. Occas ional (<50% of the time)
3Moderate
Noticeable restless movements, but can remain seated. Need to move one extremity or to change 
position, fidgets in his/her cha ir, may rock back and forth, m ay need to stand up and walk. Noticeable 
(>50% of the time)
4Severe
Evident restless movements, unable to  sit down for more than a short period of time.
Rocking, need to get up and leave his/her seat, or to pace back and forth, or shift from foot to foot when 
standing. Occasional (<50% of the time)
5Extreme
Unremitting severe restless moveme nts, moves or walks constantly with no apparent control. Rocks 
uncontrollably, cannot sit still , paces back and forth, marches in place.  Noticeable (>50% of the time) 
Page 68
For Review OnlyClinical Global Impression of Movement Severity (CGI-S)
Parkinsonism
0Absent 
1Minimal
2Mild
3Moderate 
4Severe 
5Extreme
Dystonia
0Absent 
1Minimal
2Mild
3Moderate 
4Severe 
5Extreme
Dyskinesia
0Absent 
1Minimal
2Mild
3Moderate 
4Severe 
5Extreme
Akathisia
0Absent 
1Minimal
2Mild
3Moderate 
4Severe 
5Extreme
Page 69
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX C. CLINICAL GLOBAL IMPRESSIONS -SEVERITY (CGI -S) 
(SAMPLE)  
Page 70
For Review Only
Page 1 of2Clinical Global Impression – Severity (CGI-S) Scale 
Considering your total clinical  experience with this particular popul ation, how mentally ill is the 
patient at this time? 
□ 1 = Normal, not at all ill 
□ 2 = Borderline mentally ill 
□ 3 = Mildly ill 
□ 4 = Moderately ill 
□ 5 = Markedly ill 
□ 6 = Severely ill 
□ 7 = Among the most extremely ill patients 
Rater Signature: ________________________    
Busner, J., Targum, S. (2007), as adapted from Kay, Stanley R., Positive and Negative Symptoms in 
Schizophrenia:Assessment and Research.  Clinical and Experimental Psychi atry, Monograph No. 5.  Brunner/Mazel, 1991.
Modified from Guy W. Cl inical Global Impressions: In EC DEU Assessment Manual for Psychopharmacology. 197 6; 218-222.  
Revised DHEW Pub. (ADM) Ro ckville, MD: National Institute for Mental Health 
Page 71
For Review Only
Page 2 of2CGI-S Scoring Guidelines  
1 Normal, not at all ill Symptoms of disorder have not been present in the past seven 
days
2 Borderline mentally illSubtle or suspected pathology pr esent within the past seven 
days 
3 Mildly illClearly established symptoms ca using minimal, if any, distress 
for the subject or difficulty in soc ial and occupational function 
4 Moderately illOvert symptoms causing noticeable , but modest, functional 
impairment or distress for the subject; 
Some symptoms may warrant adjustment of medication 
5 Markedly illIntrusive symptoms that distinc tly impair social/occupational 
function or cause intrusive levels  of distress for the subject; 
There is overt behavioral or socia l dysfunction that is obvious 
to others 
6 Severely illDisruptive pathology; behavior an d function are frequently 
influenced by symptoms; 
Extent of overt dysfunction may require intervention from 
others 
7 Among the most 
extremely ill patientsPathology drastically interferes in  many life functions; patient
may be hospitalized
Rater Signature: ________________________    
Busner, J., Targum, S. (2007), as adapted from Kay, Stanley R., Positive and Negative Symptoms in 
Schizophrenia:Assessment and Research.  Clinical and Experimental Psychi atry, Monograph No. 5.  Brunner/Mazel, 1991.
Modified from Guy W. Cl inical Global Impressions: In ECDE U Assessment Manual for Psychoph armacology. 197 6; 218-222.  
Revised DHEW Pub. (ADM) Ro ckville, MD: National Institute for Mental Health 
Page 72
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX D. BRIEF PSYCHIATRIC RATING SCALE (BPRS) 
(SAMPLE)  
Page 73
For Review Only 
Form ID: BPRSA082801  Form Date: 8/28/01             
                   1 of 8  Hillside Hospital Psychiatry Research - Departmental Form                                    
BPRS-A (Brief Psychiatric  Rating Scale - Anchored)                      DIRECTIONS: There  are 18 items to be rated.  
The starred items (Items 3, 4, 6, 7, 13, 14, 16, 17 and 18) should be rated on the ba sis of observations made during the 
interview. For these items, 1 = Not observed.  The remaining items should be rated on the basis of reported (i.e., subjective) 
information pertaining to the past week. For these items, 1 = Not reported. 
1.SOMATIC CONCERN:  Degree of concern over present bodily health. Rate the degree to which ph ysical health is 
perceived as a problem by the patient, whether complaints have a realistic basis or not. Do not rate mere reporting of 
somatic symptoms. Rate onl y concern for (or worrying about) physical problems (real or imagine d). Rate on the basis 
of reported (i.e., subject ive) information pertaining to the past week. 
-7 = Cannot be assessed adequately because of severe formal thought disorder, un cooperativeness, or marked 
evasiveness/guardedness; or Not assessed 
   1 = Not Reported 
   2 = Very Mild: occasionally is somewhat conce rned about body, symptoms  or physical illness 
   3 = Mild: occasionally is moderately concerned, or often is somewhat concerned 
   4 = Moderate: occasionally is very concerned, or often is moderately concerned 
   5 = Moderately Severe: often is very concerned 
   6 = Severe: is very con cerned most of the time 
   7 = Very Severe: is very concerned nearly all of the time 
/g120 During the past week how has your physical health been? 
/g120 Do you feel you are physically ill in any way? (What do you think is wrong?) (How serious is it?) 
/g120 Have you worried about your health recently? 
2. ANXIETY : Worry, fear or overly concerned for present or future. Rate solely on the basis of verbal report of p atient’s 
own subjective experiences. Do n ot infer anxiety from physic al sign or from neurotic defense mechanisms. Do not rate 
if restricted to somatic concern. 
-7 = Cannot be assessed adequately because of sever e formal thought disorder, un cooperativeness, or marked 
evasiveness/guardedness; or Not assessed 
   1 = Not Reported 
 2 = Very Mild: occasionally feels somewhat anxious 
   3 = Mild: occasionally feels moderately anxious, or of ten feels somewhat anxious 
   4 = Moderate: occasionally feels very anxious, or often feels moderately anxious 
   5 = Moderately Severe: often feels very anxious 
   6 = Severe: feels very anxious  most of the time 
   7 = Very Severe: feels very  anxious nearly all of the time 
/g120During the past week have you felt very frightened or anxious? 
/g120Have you worried a lot? (What do you worry about?) 
/g120Have you had the feel ing that something t errible might happen? 
 
Page 74
For Review Only 
Form ID: BPRSA082801  Form Date: 8/28/01             
                 2 of 8  *3. EMOTIONAL WITHDRAWAL : Deficiency in relating to the in terviewer and to the  interview situation. Overt 
manifestations of this deficiency include poor/absence of eye contact, failure to orient oneself  physically toward the 
interviewer, and a general lack of involvement or engagement in the intervi ew. Distinguish from BLUNTED  
AFFECT, in which defici ts in facial expression, body gesture, and voice pattern are scored.  
-7 = Cannot be assessed (e.g., scored from audio tape) 
   1 = Not observed 
   2 = Very Mild: e.g., occa sionally exhibits poor eye contact 
   3 = Mild: e.g., as above, but more frequent 
   4 = Moderate: e.g., exhibits little eye contact, but still seems engage d in the interview and is appropriately 
responsive to all questions 
   5 = Moderately Severe: e.g., stare s at floor or orients self away from interviewer, bu t still seems moderately 
engaged 
   6 = Severe: e.g., as abov e, but more persistent or pervasive 
   7 = Very Severe: e.g., appears “spac ey” or “out of it” (total absence of emotional relatedness), and is 
disproportionately uninvolved or unengaged in the interview 
*4. CONCEPTUAL DISORGANIZATION:  Degree of speech incomprehensibility. Include any type of formal thought 
disorder (e.g., loose associations, incoheren ce, flight of ideas, neologisms). DO NOT include mere ci rcumstantiality or 
pressured speech, eve n if marked. DO NOT rate on the basis of the patient’s  subjective impressions (e.g., “my 
thoughts are racing. I can’t hold a thought,” “m y thinking gets all mixed up.). Rate ONLY  on the basis of observations 
made during the interview. 
-7 = Not assessed 
 1 = Not observed 
   2 = Very Mild: e.g., somewhat vague , but of doubtful clin ical significance 
   3 = Mild: e.g, frequently vague, but the interview is able to progress smoothly 
   4 = Moderate: e.g., occasional irrelevant statements, infre quent use of neologisms, or moderate loosening of 
associations 
   5 = Moderately Severe: as above, but more frequent    6 = Severe: format thought disorder is pre sent for most of the i nterview, and th e interview is severely strained 
   7 = Very Severe: very little  coherent information can be obtained 
Page 75
For Review Only 
Form ID: BPRSA082801  Form Date: 8/28/01             
                 3 of 8  5. GUILT FEELINGS: Overly concerned or remorseful for past behavior. Rate on the basis of the patient’s subjective 
experiences of guilt as evidenced by verbal report. Do not infer guilt feelings from depression, anxiety or neurotic 
defenses. 
 -7 = Cannot be assessed adequately because of sever e formal thought disorder, un cooperativeness, or marked 
evasiveness/guardedness; or Not assessed 
   1 = Not Reported 
   2 = Very Mild: occasionally feels somewhat guilty 
3 = Mild: occasionally fee ls moderately guilty, or ofte n feels somewhat guilty 
   4 = Moderate: occasionally feels very guilty, or ofte n feels moderately guilty 
   5 = Moderately Severe: of ten feels very guilty 
   6 = Severe: feels very guilty most of  the time, or encapsulated delusion of guilt 
   7 = Very Severe: agonizing constant feel ings of guilt, or pervasive delusions of guilt 
/g120During the past week have you been blaming yourself for anything? 
/g120Have you been feeling guilty? (Do you feel that you deserve punis hment?) (Have you been thinking 
about this a lot?) 
*6. TENSION:  Rate motor restlessness (agitatio n) observed during the interview. DO NOT rate on the basis of subjective 
experiences reported by the patie nt. Disregard suspected pathogenesis (e.g., tardive dyskinsia). 
-7 = Cannot be assessed (e.g.,  scored from audiotape) 
   1 = Not observed    2 = Very Mild: e. g., occasionally fidgets 
   3 = Mild: e.g., frequently fidgets    4 = Moderate: e.g., constantly  fidgets, or frequently fidgets, wrings hands and pulls clothing 
   5 = Moderately Severe: e.g., c onstantly fidgets, wrings hands and pulls clothing 
   6 = Severe: e.g., cannot r emain seated (i.e.,  must pace) 
   7 = Very Severe: e.g., paces in a frantic manner 
*7. MANNERISMS AND POSTURING:  Unusual and unnatural motor behavior. Ra te only abnormality of movements; 
do not rate simple heightened motor acti vity here. Consider frequency, duration, an d degree of bizarreness. Disregard 
suspected pathogenesis. 
-7 = Cannot be assessed (e.g., scored from audiotape) 
   1 = Not observed 
   2 = Very Mild: odd behavior but of doubtful clinic al significance, e.g. occasional unprompted smiling, infrequent 
lip movements 
   3 = Mild: strange behavior  but not obviously bizarre , e.g., infrequent head-tilting  (side to side) in a rhythmic 
fashion, intermittent abnor mal finger movements 
   4 = Moderate: e.g., assumes yoga position for a brief period of tim e, infrequent tongue protrusions, rocking 
   5 = Moderately Severe: e.g., assumes and mainta ins yoga positions throughout interview, unusual movements in 
several body areas 
   6 = Severe: as above, but m ore frequent, intense, or pervasive 
   7 = Very Severe: e.g., bizarre posturing throughout most of the interview, cont inuous abnormal movements in 
several body areas 
Page 76
For Review Only 
Form ID: BPRSA082801  Form Date: 8/28/01             
                 4 of 8  8. GRANDIOSITY:  Inflated self-esteem (self- confidence), or inflated appraisal of one’s talents, powers, abilities, 
accomplishments, knowledge, importance, or identity. Do not score mere grandiose quality of claims (e.g., “I’ m the 
worst sinner in the world, . ‘The entire country is try ing to kill me”) unless the guilt/pe rsecution is related to some 
special, exaggerated attributes of the indiv idual. Also, the patient must claim exagger ated attributes: e.g., if patient 
denies talents, powers, etc., even if he or she states that others indicate that he/she  has these attribu tes, this item should 
not be scored. 
-7 = Cannot be assessed adequately because of severe formal thought disorder, un cooperativeness, or marked 
evasiveness/guardedness, or Not assessed 
   1 = Not reported 
   2 = Very Mild: e.g., is m ore confident than most people, but of only possible clinical significance 
   3 = Mild: e.g., definitely  inflated self-esteem or exaggerates ta lents somewhat out of proportion to the 
circumstances 
   4 = Moderate: e.g., inflated self-este em clearly out of proportion to the circumstances, or suspected grandiose 
delusion(s) 
   5 = Moderately Severe: e. g., a single (definite) encapsulat ed grandiose delusion, or multiple (definite) 
fragmentary grandiose delusions 
   6 = Severe: e.g., a single (definite) grandiose delus ion/delusional system, or mult iple (definite) grandiose 
delusions that the patient seems preoccupied with 
   7 = Very Severe: e.g., as above, but nearly all conversation is directed toward the patient’s grandiose  delusion(s)
/g120During the past week have you felt more self-confide nt than usual? 
/g120Do you have any special abilities or talents? 
/g120Do you feel there is a special purpose or mission to your life? (Have you thought you might be 
somebody rich or famous?) 
9. DEPRESSIVE MOOD: Subjective report of feeling depressed, blue, “down in the dumps,” etc. Rate only degree of 
reported depression. Do not rate on the basis of infere nces concerning depression based upon general retardation and 
somatic complaints. 
-7 = Cannot be assessed adequately because of severe formal thought disorder, un cooperativeness, or marked 
evasiveness/guardedness, or Not assessed 
   1 = Not reported    2 = Very Mild: occasionally feels somewhat depressed 
   3 = Mild: occasionally fe els moderately depressed, or  often feels somewhat depressed 
   4 = Moderate: occasionally feels very depressed, or often feels moderately depressed    5 = Moderately Severe: often feels very depressed 
   6 = Severe: feels very d epressed most of the time 
   7 = Very Severe: feels very  depressed nearly all of the time 
/g120In the past week have you had less interest in your usual activities? 
/g120Have you felt sad or depressed? (Have you cried at all?) (How bad is the feeling?) (How long does it 
last?) 
Page 77
For Review Only 
Form ID: BPRSA082801  Form Date: 8/28/01             
                 5 of 8  10. HOSTILITY:  Animosity, contempt, belligerence, disdain for other people outside the interview  situation. Rate solely 
on the basis of the verbal report of fe elings and actions of the patient toward o thers during the week. Do not infer 
hostility from neurotic defenses, anxiety or somatic complaints. 
-7 = Cannot be assessed adequately because of severe formal thought disorder, un cooperativeness, or marked 
evasiveness/guardedness, or Not assessed 
   1 = Not reported 
   2 = Very Mild: occasionally feels somewhat angry 
   3 = Mild: often feels somewhat angry,  or occasionally feels moderately angry 
   4 = Moderate: occasionally feels very angry, or often feels moderately angry or occ asionally yells at others 
   5 = Moderately Severe: often feels very angry; often yells at others or occasionally threatens to harm others 
   6 = Severe: has acted on his anger  by becoming phys ically abusive on one or two occasions or makes frequent 
threats to harm other 
   7 = Very Severe: has been ph ysically aggressive and/or has required int ervention to prevent assaultiveness on 
several occasions; or an y serious assaultive act. 
/g120During the past week have you been feeling irritable? 
/g120How have you been getting along with other peo ple? (Have you gotten in any arguments or fights?) 
/g120Have you been easily annoyed or angered? (How strongly hav e you felt this wa y?) (How much of the 
time?) 
11. SUSPICIOUSNESS: Belief (delusional or otherwise) th at others have now, or have ha d in the past, malicious or 
discriminatory intent toward the patient. On the basis of ve rbal report, rate onl y those suspicions that are currently held 
whether they concern past or present circumstances. 
-7 = Cannot be assessed adequately because of sever e formal thought disorder, un cooperativeness, or marked 
evasiveness/guardedness, or Not assessed 
1 = Not reported 
   2 = Very Mild: rare instances of suspiciousness that may or may not be warranted by the situation 
   3 = Mild: occasional instances of suspiciousness that are definitely  not warranted by the situation 
   4 = Moderate: more fre quent suspiciousness, or transient ideas of reference 
   5 = Moderately Severe: pervasive sus piciousness, or frequent ideas of reference 
   6 = Severe: definite, delusion(s) of reference or persecution that is (a re) not wholly pervasive (e.g., an 
encapsulated delusion)
   7 = Very Severe: as above, but more widespread, frequent or intense 
/g120How did you get along with people in general, during the past week? 
/g120Do you feel that you have to be on guard with people? 
/g120Has anyone been giving you a hard t ime, or accusing you of things? 
/g120Has anyone deliberately tried to annoy you? 
/g120Tried to harm you? 
Page 78
For Review Only 
Form ID: BPRSA082801  Form Date: 8/28/01             
                 6 of 8  12. HALLUCINATORY BEHAVIOR:  Perceptions (in any sensory modality) in the absence of an ident ifiable external 
stimulus. Rate only those experiences tha t have occurred during the las t week. DO NOT rate “voices in my head,” or 
“visions in my mind” unless  the patient can differentiate between these  experiences and his or her thoughts.
-7 = Cannot be assessed adequately because of sever e formal thought disorder, un cooperativeness, or marked 
evasiveness/guardedness, or Not assessed 
   1 = Not reported 
   2 = Very Mild: suspec ted hallucinations only 
 3 = Mild: definite hallucinations, but insignificant, infrequent, or transient (e.g., occasional formless visual 
hallucinations, a voice call ing the patient’s name)
   4 = Moderate: as above, but more frequent or extensive (e.g., frequently sees the devil’s face, two voices carry on 
lengthy conversations)
   5 = Moderately Severe: hallucinations are experienced nearly e very day, or are a source of extreme distress 
   6 = Severe: as above, and has had a moderate impact on the patient’ s behavior (e.g., concentration difficulties 
leading to impaire d work functioning) 
   7 = Very Severe: as above, and has had a severe impact (e.g., attempts suicide in response to command 
hallucinations) 
/g120Have you had any unusual experi ences during the past week? 
/g120Do you seem to hear noises or vo ices when there’s no one around  and nothing else to explain it?
/g120Have you had visions, or seen things that others couldn’t see ? 
/g120Is there anything unusual about the way thi ngs feel, or taste, or smell? 
/g120How often do you [hear voices]? (Do the voices make it hard to conce ntrate?) (Do they tell you to do 
things?)
*13. MOTOR RETARDATION: Reduction in energy level evidenced in slowed movements. Rate on the basis of 
observed behavior of the patient only; do not rate on the basis of the patient’s subject ive impression of his or her own 
energy level. 
-7 = Cannot be assessed (e.g., scored from audiotape) 
1 = Not observed 
   2 = Very Mild and of doubtful clinical significance 
   3 = Mild: e.g. conversation is som ewhat retarded, movements somewhat slowed 
   4 = Moderate: e.g., conve rsation is noticeably retarded, but not strained  
   5 = Moderately Severe: e.g., conver sation is strained, moves very slowly 
   6 = Severe: e.g., conversation is difficult to maintain, hardly moves at all 
   7 = Very Severe: e.g., conversati on is almost impossible, does not move at all throughout the interview 
Page 79
For Review Only 
Form ID: BPRSA082801  Form Date: 8/28/01             
                 7 of 8  *14. UNCOOPERATIVENESS:  Evidence of resistance, unfriendliness, resentment , and lack of read iness to cooperate 
with the interviewer. Rate only on the basis of the patient’s attitude and  responses to the interviewer and the interview 
situation; do not rate on the basis of reported resentment or uncooperative ness outside the interview situation. 
-7 = Not assessed 
   1 = Not observed 
   2 = Very Mild: e.g., does not seem motivated 
   3 = Mild: e.g., seems  evasive in certain areas 
   4 = Moderate: e.g., monosyllabic,  fails to elaborate spontaneously 
   5 = Moderately Severe: e.g., expre sses resentment and is unfriendly throughout the interview 
   6 = Severe: e.g., refuses to answer a number of questions    7 = Very Severe: e.g. , refuses to answer most questions 
15. UNUSUAL THOUGHT CONTENT:  Severity of delusions of any type – consider conviction, and  effect on actions. 
Assume full conviction if  patient has acted on his or her beliefs. Ra te on the basis of reported (i.e., subjective) 
information pertaining to the past week. 
-7 = Cannot be assessed adequately because of severe formal thought disorder, un cooperativeness, or marked 
evasiveness/guardedness, or Not assessed 
   1 = Not reported    2 = Very Mild: delusion(s) suspected or likely 
   3 = Mild: at times,  patient questions his or her belief(s) (partial delusion) 
   4 = Moderate: full delusional conviction, but delusion(s) has little  or no influence on behavior 
   5 = Moderately Severe: full delusional conviction, but delusion(s) has onl y occasional impact on behavior 
   6 = Severe: delusion(s) has significant effect, e.g. neglects responsibilities because  of preoccupations with belief 
the he/she is God 
   7 = Very Severe: delusion(s) has major impact, e.g., stops eatin g because believes food is poisoned 
/g120Have you had any difficulty with your thinking in the past week? 
/g120Do certain things have special meaning for you? (Give me an example.) 
/g120Is there any interference with your thoughts? 
/g120Is there anything controlling  your thoughts or movements? 
/g120Do you see references to yourself  in surprising places, like on TV? 
Page 80
For Review Only 
Form ID: BPRSA082801  Form Date: 8/28/01   
Rater Signature: ____________ __________________    Date: ______________           
                   8 of 8*16. BLUNTED AFFECT: Diminished affected responsivity , as characterized by deficits in facial expression, body 
gesture, and voice pattern. Distin guish from EMOTIONAL WITHDRAWAL, in which the focus is on the 
interpersonal impairment ra ther than affect. Consider degr ee and consistency of impairment. 
-7 = Cannot be assessed (e.g.,  scored from audiotape) 
   1 = Not observed 
   2 = Very Mild: e.g., occasion ally seems indifferent to material that  is usually accompanied by some show of 
emotion 
   3 = Mild: e.g., somewhat diminished facial expression, or somewhat monotonous voice or somewhat restricted 
gestures 
   4 = Moderate: e.g., as above, but more inte nse, prolonged or frequent 
   5 = Moderately Severe: e.g., flatt ening of affect, including at least two of th e three features: severe lack of facial 
expression, monotonous voice, or restricted body gestures 
   6 = Severe: e.g.,  profound flattening of affect 
   7 = Very Severe: e.g., totally  monotonous voice, and total lack of expre ssive gestures throughout the evaluation 
*17. EXCITEMENT:  Heightened emotional tone, including irr itability and exp ansiveness (hypomani c affect). Do not 
infer affect from statement of grandiose delusions. 
-7 = Not assessed 
   1 = Not observed 
   2 = Very Mild and of doubtful clinical significance 
   3 = Mild: e.g., irrit able or expansive at times 
   4 = Moderate: e.g., frequen tly irritable or expansive 
   5 = Moderately Severe: e.g., constantly  irritable or expansive;or, at times, enraged or euphoric 
   6 = Severe: e.g., enraged or  euphoric throughout most of the interview 
   7 = Very Severe: e.g., as above, but to such a degree that the inte rview must be terminated prematurely 
*18. DISORIENTATION: Confusion or lack of proper association for person, place or time. 
-7 = Cannot be assessed adequately because of severe formal thought disorder, un cooperativeness, or marked 
evasiveness/guardedness, or Not assessed 
   1 = Not observed    2 = Very Mild: e.g., seems somewhat confused    3 = Mild: e.g., indicat es 2000 when, in fact, it is 2001
   4 = Moderate: e.g. indicates 1998    5 = Moderately Severe: e.g., is unsure where he/she it 
   6 = Severe: e.g., has no idea where he/she is 
   7 = Very Severe: e.g., does not know who he/she is 
/g120Now I want to ask you some standard questions that w e usually ask at this po int. What is today’s 
date? (What day of the week is it? What month? What day of the m onth? What year?) 
/g120Where are we now? 
Page 81
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX E.  SEXUAL FUNCTIONING SUBSCALE FROM UDVALG 
FOR KLINISKE UNDERSØ GELSER (UKU) SIDE 
EFFECT RATING SCALE  
Page 82
For Review Only
UKU-SERS-Pat, Summ Form + Patient Form Eng 2001-04-22The UKU Side Effect Rating Scale, Self-rating version Modified  
4.9  Have you noticed milk from your nipples? 
/g84Not at all 
/g84Some 
/g84Yes, but not troublesome 
/g84Much, stains my underwear 
4.10 Have you experienced tension or swelling in your breasts? 
/g84Not at all 
/g84Some tension and swelling 
/g84Breasts are tense and larger than normal 
/g84Breasts clearly enlarged 
4.11 Have you experienced increased sexual interest or increased sexual desire? 
/g84Not at all 
/g84Somewhat more than normal 
/g84More than normal 
/g84Much more than normal
4.12 Have you experienced decreased sexu al interest or decreased sexual desire? 
/g84Not at all 
/g84A little less than normal
/g84Less than normal 
/g84Much less than normal 
Page 83
For Review Only
UKU-SERS-Pat, Summ Form + Patient Form Eng 2001-04-22Females only
4.7a Have you noticed more discharge/bleeding when menstruating? 
/g84Not at all 
/g84Somewhat more than normally 
/g84More than normally 
/g84Profuse discharge/bleeding 
4.7b Have you noticed discharge/bleeding between periods? 
/g84Not at all 
/g84Occasional discharge/bleeding 
/g84Substantial discharge/bleeding, occasionally 
/g84Frequent discharge/bleeding between periods 
4.8 Have you noticed less discharge/bleeding when menstruating? 
/g84Not at all 
/g84Slightly less than normal 
/g84Less than normal 
/g84Menstruation has not occurred 
4.15 Have you experienced difficulty in reaching orgasm? 
/g84Not at all 
/g84Some difficulty 
/g84More difficult than normal 
/g84Rarely have orgasm 
4.16 Do you have problems with a dry vagina during intercourse? 
/g84Not at all 
/g84Some dryness
/g84More problems than normal 
/g84Severe problems, must use lubrication 
Page 84
For Review Only
UKU-SERS-Pat, Summ Form + Patient Form Eng 2001-04-22Males only 
4.13 Have you experienced difficulty in reaching erection? 
/g84Not at all 
/g84Slightly more difficult than normal 
/g84More difficult than normal 
/g84Cannot get erection 
4.14a Have you experienced dif ficulties in ejaculation? 
/g84Not at all 
/g84Ejaculation slightly delayed
/g84Ejaculation delayed
/g84Cannot ejaculate 
4.14b Have you experienced early (premature) ejaculation? 
/g84Not at all 
/g84Ejaculation slightly early
/g84Ejaculation early 
/g84Spontaneous ejaculations 
Page 85
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX F. CHANGES IN SEXUAL FUNCTIONING 
QUESTIONNAIRE  
Page 86
For Review Only
Copyright © 1998 (Rev. 11/99) A. Clayton, Dep t. of Psychiatric Medicine,  University of Virginia Hea lth System. All rights reser ved. CHANGES IN SEXUAL FUNCTIONING  QUESTIONNAIRE (CSFQ-F-C)
Patient Name __________________________________          Today’s Date __________________
NOTE: This is a questionnaire about sexual activity and 
sexual function. By sexual activity, we mean sexual intercourse, masturbation, sexual fantasies and other activity. 
1.  Compared with the mo st enjoyable it has ever been, how 
enjoyable or pleasurable is y our sexual life right now? 
 1-No enjoyment or pleasure 
 2-Little enjoyment or pleasure 
 3-Some enjoyment or pleasure 
 4-Much enjoyment or pleasure 
 5-Great enjoyment or pleasure
2.  How frequently do you engage in sexual activity (sexual 
intercourse, masturbation, etc.) now? 
 1-Never
 2-Rarely (once a month or less) 
 3-Sometimes (more than once a month, up to twice a week) 
 4-Often (more than twice a week) 
 5-Every day 
3.  How often do you des ire to engage in sexual activity? 
 1-Never
 2-Rarely (once a month or less) 
 3-Sometimes (more than once a month, up to twice a week) 
 4-Often (more than twice a week) 
 5-Every day 
4. How frequently do you engage in sexual thoughts (thinking 
about sex, sexual fantasies) now? 
 1-Never
 2-Rarely (once a month or less) 
 3-Sometimes (more than once a month, up to twice a week) 
 4-Often (more than twice a week)
 5-Every day 
5.  Do you enjoy books, movies, music or artwork with sexual 
content? 
 1-Never
 2-Rarely (once a month or less) 
 3-Sometimes (more than once a month, up to twice a week) 
 4-Often (more than twice a week) 
 5-Every day 
6.  How much pleasure or enjoyment do you get from thinking 
about and fantasizing about sex? 
 1-No enjoyment or pleasure 
 2-Little enjoyment or pleasure 
 3-Some enjoyment or pleasure 
 4-Much enjoyment or pleasure 
 5-Great enjoyment or pleasure
7.  How often do y ou become sexually aroused? 
 1-Never
 2-Rarely (once a month or less) 
 3-Sometimes (more than once a month, up to twice a week) 
 4-Often (more than twice a week) 
 5-Every day 8.  Are you easily aroused?  1-Never
 2-Rarely (much less than half the time) 
 3-Sometimes (about half the time) 
 4-Often (much more than half the time) 
 5-Always 
9.  Do you have adequate vaginal lubrication during sexual 
activity?  1-Never
 2-Rarely (much less than half the 
time) 
 3-Sometimes (about half the time) 
 4-Often (much more than half the time) 
 5-Always 
10.  How often do you become aroused and then lose interest?  5-Never
 4-Rarely (much less than half the time) 
 3-Sometimes (about half the time) 
 2-Often (much more than half the time) 
 1-Always 
11. How often do you experience an orgasm?  1-Never
 2-Rarely (much less than half the time) 
 3-Sometimes (about half the time) 
 4-Often (much more than half the time) 
 5-Always 
12.  Are you able to have an orgasm when you want to? 
 1-Never
 2-Rarely (much less than half the time) 
 3-Sometimes (about half the time) 
 4-Often (much more than half the time) 
 5-Always 
13.  How much pleasure or enjoym ent do you get from your 
orgasms? 
 1-No enjoyment or pleasure 
 2-Little enjoyment or pleasure 
 3-Some enjoyment or pleasure 
 4-Much enjoyment or pleasure 
 5-Great enjoyment or pleasure
14.  How often do you have painful orgasm?  5-Never
 4-Rarely (once a month or less) 
 3-Sometimes (more than once a month, up to twice a week) 
 2-Often (more than twice a week) 
 1-Every day 
____ = Pleasure (Item 1)
____ = Desire/Frequency (Item 2 + Item 3)
____ = Desire/Interest (Item 4 + Item 5 + Item 6)
____ = Arousal/Excitement (Item 7 + Item 8 + Item 9)
____ = Orgasm/Completion (Item 11 + Item 12 + Item 13)
____ = Total CSFQ Score (Items 1 to 14)
Page 87
For Review Only
Copyright © 1998 A. Clayton, Dept. of Psychiatric Medicine, University of  Virginia Health Sciences Center. All rights reserved.CHANGES IN SEXUAL FUNCTIONING QUESTIONNAIRE (CSFQ-M-C)
Patient Name __________________________________ Today’s Date __________________
NOTE:  This is a questionnaire ab out sexual activity and 
sexual function. By sexual activity, we mean sexual 
intercourse, masturbation, sexual fantasies and other activity. 
1.  Compared with the most  enjoyable it has ever been, how 
enjoyable or pleasurable is your sexual life right now? 
/g134 1-No enjoyment or pleasure 
/g134 2-Little enjoyment or pleasure 
/g134 3-Some enjoyment or pleasure 
/g134 4-Much enjoyment or pleasure 
/g134 5-Great enjoyment or pleasure
2.  How frequently do y ou engage in sexual  activity (sexual 
intercourse, masturbation, etc.) now? /g134 1-Never 
/g134 2-Rarely (once a month or less) 
/g134 3-Sometimes (more than once a month, up to twice a week) 
/g134 4-Often (more than twice a week) 
/g134 5-Every day 
3.  How often do you desire to engage in sexual activity? 
/g134 1-Never 
/g134 2-Rarely (once a month or less) 
/g134 3-Sometimes (more than once a month, up to twice a week) 
/g134 4-Often (more than twice a week) 
/g134 5-Every day 
4. How frequently do you engage in sexual thoughts (thinking 
about sex, sexual fantasies) now? 
/g134 1-Never 
/g134 2-Rarely (once a month or less) 
/g134 3-Sometimes (more than once a month, up to twice a week) 
/g134 4-Often (more than twice a week) 
/g134 5-Every day 
5.  Do you enjoy books, movies, music or artwork with sexual 
content? /g134 1-Never 
/g134 2-Rarely (once a month or less) 
/g134 3-Sometimes (more than once a month, up to twice a week) 
/g134 4-Often (more than twice a week) 
/g134 5-Every day 
6.  How much pleasure or en joyment do you get from thinking 
about and fantasizing about sex? /g134 1-No enjoyment or pleasure 
/g134 2-Little enjoyment or pleasure 
/g134 3-Some enjoyment or pleasure 
/g134 4-Much enjoyment or pleasure 
/g134 5-Great enjoyment or pleasure
7.  How often do you have an erection related or unrelated to 
sexual activity? 
/g134 1-Never 
/g134 2-Rarely (once a month or less) 
/g134 3-Sometimes (more than once a month, up to twice a week) 
/g134 4-Often (more than twice a week) 
/g134 5-Every day 8.  Do you get an erection easily? 
/g134 1-Never 
/g134 2-Rarely (much less than half the time) 
/g134 3-Som etimes (about half t he 
time) 
/g134 4-Often (much more than half the time) 
/g134 5-Always 
9.  Are you able to maintain an erection? 
/g134 1-Never 
/g134 2-Rarely (much less than half the time) 
/g134 3-Sometimes (about half the time) 
/g134 4-Often (much more than half the time) 
/g134 5-Always 
10.  How often do you experience painful, prolonged 
erections? 
/g134 5-Never 
/g134 4-Rarely (once a month or less) 
/g134 3-Sometimes (more than once a month, up to twice a week) 
/g134 2-Often (more than twice a week) 
/g134 1-Every day 
11.  How often do you have an ejaculation? 
/g134 1-Never 
/g134 2-Rarely (once a month or less) 
/g134 3-Sometimes (more than once a month, up to twice a week) 
/g134 4-Often (more than twice a week) 
/g134 5-Every day 
12.  Are you able to ej aculate when you want to? 
/g134 1-Never 
/g134 2-Rarely (much less than half the time) 
/g134 3-Sometimes (about half the time) 
/g134 4-Often (much more than half the time) 
/g134 5-Always 
13.  How much pleasure or enjoyment do you get from your orgasms? 
/g134 1-No enjoyment or pleasure 
/g134 2-Little enjoyment or pleasure 
/g134 3-Some enjoyment or pleasure 
/g134 4-Much enjoyment or pleasure 
/g134 5-Great enjoyment or pleasure
14.  How often do you have painful orgasm? 
/g134 5-Never 
/g134 4-Rarely (once a month or less) 
/g134 3-Sometimes (more than once a month, up to twice a week) 
/g134 2-Often (more than twice a week) 
/g134 1-Every day 
____ = Pleasure (Item 1)
____ = Desire/Frequency (Item 2 + Item 3)
____ = Desire/Interest (Item 4 + Item 5 + Item 6)
____ = Arousal/Erection (Item 7 + Item 8 + Item 9)
____ = Orgasm/Ejaculation (Item 11 + Item 12 + Item 13)
____ = Total CSFQ Score (Items 1 to 14)
Page 88
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX G.  PERSONAL AND SOCIAL PERFORMANCE SCALE 
(PSP) (SAMPLE)  
Page 89
For Review Only
  Page 1 of 2Personal and Social Performan ce Scale (PSP) – Worksheet 
 
The rating is based on four main areas: (a ) socially useful activit ies, including work and study; (b) personal and social 
relationships; (c) self-care; and (d) disturbing and aggressive behaviors. 
Data will be captured in the following format using the PSP descriptions provided below: 
 Absent Mild Manifest Marked Severe Very 
Severe 
a. Socially useful activities, including work and study       
b. Personal and social relationships      
c. Self-care      
d. Disturbing and aggressive behaviors      
The levels of functioning in other areas should be taken i nto account to adjust the rating inside the decimal level (for 
instance, from 31 to 40).  Suicidal risk is not included in the scale.
10-point 
intervalsPSP descriptions
100-91 Excellent functioning in all four main areas*.  He/she is held in high consideration for 
his/her good qualities, copes adequately with life problems, is involved in a wide range 
of interests and activities
90-81 Good functioning in all four main areas, presence of only common problems or 
difficulties
80-71 Mild difficulties in 1 or more of areas a-c
70-61 Manifest, but not marked difficultie s in 1 or more areas a-c, ormild difficulties in d
60-51 Marked difficulties in 1 of areas a-c, ormanifest difficulties in d
50-41 Marked difficulties in 2 or more, orsevere difficulties in 1 of areas a-c, with or 
without manifest difficulties in d
40-31 Severe difficulties in 1 andmarked difficulties in at  least 1of areas a-c, ormarked 
difficulties in d
30-21 Severe difficulties in 2 of areas a-c, or severe difficulties in d, with or without 
impairment in areas a-c
20-11 Severe difficulties in all areas a-d, orvery severe in d with or without impairment in 
general areas a -c.  If the person reacts to external  prompts the suggested scores are 20-
16; if not, the suggested scores are 15-11.
10-1 Lack of autonomy in basic functioning with extreme behaviors but without survival 
risk (ratings 6 -10) or with survival risk, eg, death risk due to malnutrition, dehydration, 
infections, inability to recog nize situation of manifest danger (ratings 5-1).
Overall score  |___|___|___| 
For main areas a-c, the degrees of severity are:
Absent
Mild Not manifest difficulties, known only to someone who is ver y familiar with the 
person
Manifest, but not 
markedDifficulties clearly noticeable by everyone , but not interfering substantially with 
the person’s ability to perform his/her role in that area, given the person’s s ocio-
cultural context, age, sex and educational levels
Marked Difficulties heavily interfering with role performance in that area; however, the 
person is still able to do somethin g without professional or s ocial help, although 
inadequately and/or occasionally; if helped by someone, he/she may be able to 
reach the previous level of functioning
Severe Difficulties that make the person unable to any role performance in that area, if 
not professionally helped, or lead the pe rson to a destructive role; however, there 
are no survival risks.
Very severe Impairments and difficulties of such i ntensity to endanger  person’s survival.
Page 90
For Review Only
Rater Signature: _____________________________  Date: _________________  
      Page 2 of 2For general area d, the de grees of severity are:
Absent
Mild Mild rudeness, unsocia bility or whingeing
Manifest, but not 
markedSpeaking too loudly or speaking to others in a too-familiar manner, or eating in a 
socially unacceptable manner
Marked Insulting other in public, breaking or wrecking objects, acting frequently in a 
socially inappropriate but not dangerous way (eg, stripping in public or urinating 
in public).
Severe Frequent verbal threats or frequent physical assaults, wit hout intention or 
possibility of severe injuries.
Very severe Frequent aggressive acts, aimed at or likely to cause severe injuries.
Occasional is defined as occurring three or more times in the reference period or occurring even less than three times 
but in circumstances and/or wi th such a previous history to convince the rater that there is a risk of recurrence in the 
near future.  If the aggressive behavior has been present occasionally, the rati ng may be decreased by one degree, eg, 
from severe to marked. 
* Main areas: a=socially useful activities, including work and st udy; b=personal and socia l relationships; c=self-care; 
d=disturbing and aggressive behaviors. 
Guidelines for PSP Total Score 
Ratings from 71-100 reflect  only mild difficulties. 
Ratings from 31-70 reflect manifest disabilities of various degrees. 
Ratings from 1-30 reflect fu nctioning so poor that intensive support or super vision is needed. 
Morosini, P.L., Magliano, L., Brambil la, L., Ugolini, S., Pioli, R. (2000). Develop ment, reliability, and acceptability of 
a new version of the DSM-IV Social a nd Occupational Functioning Assessment Scale  (SOFAS) to assess routine social 
functioning. Acta Psychiatrica Scandinavica 101 (4), 323-329.
Page 91
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX H.  HEINRICHS -CARPENTER QUALITY OF LIFE SCALE 
(QLS) (SAMPLE)  
Page 92
For Review OnlyApril 10, 1992 
QUALITY OF LIFE SCALE
This instrument is designed to evaluate the current functioni ng of 
nonhospitalized schizophrenic persons apart from the presence or absence of florid 
psychotic symptomatology or need for hospitalization. It assesses the richness of their personal experience, the quality of their interpersonal relations, and their productivity in occupational roles. 
It is intended to be administered as a semi-stru ctured interview. Each item 
consists of three parts. First, a brief statem ent is provided to help the interviewer 
understand and focus on the parameter to be assessed. Second, a number of suggested questions are provided that  may help the interviewer begin his 
exploration with the subject. Finally, a seven-point scale is provided for each item, with a brief description at four points to help the interviewer make his judgment and unlabeled points. 
The questions provided are just suggestions. They are to be altered or 
supplemented as needed. Each item should be explore d as much as required to 
allow the rater to make a good clinical judgment. The intent of the schedule is to assess limitations due to psychopathology or personality deficits. Adjustments 
should be made by the rater when extraneous factors are clearly and unambiguously involved (e.g., decreased social contact due to serious physical 
illness).
All items should be rated. Circle the appropriate number on each item scale. 
SCORING: Mean scores of the followi ng subsca1es and total (prorate items 1 and 12 for missing data as 
indicated in the manual). 
Subscale Scores: 
I. Interpersonal Relations (1-8): ______      II. Instrumental Role (9-12): ______
III. Intrapsychic Foundations (13-17,20,21): _____ IV. Common Objects and Activities (18,19):___ 
III plus IV (13 thru 20):  ______           Total Score (Items 1-21): ______ 
Page 93
For Review Only1. RATE INTIMATE RELATIONSH IPS WITH HOUSEHOLD MEMBERS 
This item is to rate close relationships with significant mutual caring and shari ng 
with immediate family or members of the subject's current household. 
Suggested questions:
Are you especially close with any of 
the people you currently live with or your immediate family? 
Can you discuss personal matters 
with them? 
How much have you talked with 
them?
What are these relationships like? 
Can they discuss personal matters 
with you? 
What sorts of things have you done 
together?
When at home, have you spent much 
time around your family or were you generally alone? 0 - Virtually no intimacy 
1 - 
2 - Only sparse and intermittent 
intimate interactions 
3 - 
4 - Some consistent intimate 
interactions but reduced in extent 
or intensity; or intimacy only present erratically 
5 - 
6 - Adequate involvement in intimate 
relations with house hold members 
or immediate family 
9 - Score here if lives alone and no 
immediate family nearby 
Note:  (For Factor and Total Scores, 
prorate this item  on the basis of 
Items 2 through 8.) 
Page 94
For Review Only2. RATE INTIMATE RELATIONSHIPS 
This item is to rate close relationships with significant mutual caring and sharing, 
with pe ople other than immediate family or household members. Exclude 
relationships with mental health workers.
Suggested questions:
Do you have friends with w hom you 
are especially close other than your 
immediate family or the people you 
live with? 
Can you discuss personal matters 
with them? 
How many friends do you have? 
How often have you spoken with 
them recently, in person or by phone? 
What have these relationships been 
like?
Can they discuss personal matters 
with you? 0 - Virtually absent 
1 - 
2 - Only sparse intermittent relations 3 - 4 - Some consistent intimate relations 
but reduced in num ber or 
intensity; or intimacy only present 
erratically
5 - 
6 - Adequate involvement with 
intimate relationships with more 
than one other person 
 
 
Page 95
For Review Only3. RATE ACTIVE ACQUIANTANCES 
This item is to rate relationships with people based on liki ng one another and 
sharing common activities or interests but without the intimate emotional 
investment of the above item. Exclude relationships with mental health workers 
and other household members. 
Suggested questions:
Apart from close personal friends, are 
there people you know with whom 
you have e njoyed doing things? 
How many? 
How often have you gotten together 
with them? 
What things have you done together? 
Have you been with people as a part 
of clubs or organize activities? 
Have you had extra social contact 
with co-workers, such as going to 
lunch together or going out after  0 - Virtually absent 
1 - 
2 - Few active acquaintances and 
      only infrequent contact 
3-
4 - Some ongoing active 
acquainta nce but reduced contact 
and limited shared activity 
5 - 
6 - Adequate involvement with active 
acquaintances
work? 
Page 96
For Review Only4. RATE LEVEL OF SOCIAL ACTIVITY 
This item is to rate involvement in activities with ot her people done for enjoyment. 
Exclude social activity that is primarily instrumental for other goals, for example, 
work and school. Exclude psychotherapy. 
Suggested questions:
How often have you done things for 
enjoyment that involve other people? 
What sort of things? 
Have you participated in clubs or 
other or ganized social groups? 0 - Virtually absent 
1 - 
2 - Occasional social activity but lack 
of regular pattern of such activity, 
or limited only to activity with immed iate family or members of 
household
3 - 
4 - Some regular social activity but 
reduced i n frequency or diversity 
5 - 
6 - Adequate level of regular social 
activity
Page 97
For Review Only5. RATE INVOLVED SOCIAL NETWORK 
This item is to rate the extent to w hich other people concern themselves with the 
person, care about his fortunes or know about his activities. Exclude mental health 
workers. 
Suggested questions:
Are there people who have been 
concerne d about your happiness and 
well being? 
How many? 
How did they show it? If some important and exciting thing 
happene d to you, who would you 
contact or inform? 
Are there people who often provided 
you em otional support or help in day-
to-day matters such as food, transportation, and practical advice? 
Are there people you could turn to or 
depe nd on for help if anything 
happened? 0 - Virtually absent 
1 - 
2 - Minimal in number or degree of 
involvement, and/or limited to 
immed iate family 
3 -
4 - Presence of some involved social 
netw ork but reduced in number of 
degree of involvement 
5 - 6 - Adequate involved social network 
in both exte nt and in degree of 
involvement
Page 98
For Review Only6. RATE SOCIAL INITIATIVES 
This item is to rate the degree to w hich the person is active in directing his social 
interactions - what, how much, and with whom. 
Suggested questions:
Have you often asked people to do 
something with you, or have you usually waited for others to ask you? 
When you have had an idea for a 
good time, have you sometimes 
missed out because it's hard to ask 
others to participate? 
Have you contacted people by 
phone?
Have you tended to seek people out? 
Have you usually done things alone 
or with other people? 0 - Social activity almost completely 
dependent on initiatives of others 
1 - 
2 - Occasional social initiative, but 
social life significantly 
impoverished due to his pattern of 
social passivity, or initiative limited to immediate family 
3 - 
4 - Evidence of some reduction of 
social initiative, but with only 
minimal adverse consequences on 
his social activity 
5 - 
6 - Adequate social initiative 
Page 99
For Review Only7. RATE SOCIAL WITHDRAWAL 
This item is to rate the degree to which the person actively avoids social 
interaction due to his discom fort or disinterest. 
Suggested questions:
Have you felt uncomfortable with people?
Have you turned down offers to do 
things with other pe ople? Would you 
if you were asked? 
Have you done this even when you 
have had nothi ng to do? 
Have you avoided answering the 
phone?
How has this interfered with your 
life?
Have you dealt with people only 
when it' s necessary to accomplish 
something you want? 
Have you stayed to yourself at home? 
Have you preferred to be alone? 0 - Active avoidance of virtually all 
social contact 
1 -
2 - Tolerates that social contact 
required f or meeting other needs, 
but very little social contact for its 
own sake, or lack of withdrawal only with immediate family 
3 - 
4 - Some satisfying and enjoyable 
social engagem ent, but reduced 
due to avoidance 
5 - 
6 - No evidence of significant social 
withdra wal 
Page 100
For Review Only8. RATE SOCIOSEXUAL RELATIONS 
This item is to rate the capacity for mature intimate relations wit h members of the 
opposite sex and satisfying sexual activity. The wording assumes a heterosexual 
preference. In clear cases of consistent homosexual preference, reword 
accordingly and rate these same capacities. 
Suggested questions if single:
Have your social activities involved  women (men)? 
Have you avoided them or found it 
too uncomfortable to deal with them? 
Have you dated? 
Did you have one or more 
girlfriends? (boyfriends?) 
Have the relationships been 
satisfying?
Have emotionally involved were 
you?
Were you in love? 
Were you having sexual activity? Was it satisfying? 
Did you show physical signs of 
affection, such as hugging and kissing?0 - No interest in opposite sex, or 
active avoi dance
1 - 
2 - Some limited contact with 
opposite sex but superficial with 
avoidance of intimacy; or sexual 
activity as just physical release 
without emotional involvement; 
or relationships marked by severe and chronic disruption, dissatisfaction or affective chaos 
3 - 
4 - Relationships with some intimacy 
and em otional investment, 
predominantly satisfying, and 
perhaps some sexual expression or physical signs of affection 
5 - 
6 - Usually has satisfying 
relationships, em otionally rich 
and intimate and appropriate 
sexual expression and physical signs of expression 
Page 101
For Review OnlySuggested questions if married or living 
with someone:
Were you happy in your relationship 
with your partner? 
Have you done many things together? 
Did you talk together much? Did you discuss personal thoughts and 
feelings?
Did you fight much? 
Has your sex life been satisfying? Did you show physical signs of 
affection such as hugging and  
kissing?
Did you feel close to her (him)? 0 - No interest in opposite sex, or active 
avoidance
1 - 2 - Some limited contact with opposite 
sex but superficial with avoida nce of 
intimacy; or sexual activity as just 
physical release without emotional 
involvement; or relationships marked by severe and chronic disruption, dissatisfaction or affective chaos 
3 - 
4 - Relationships with some intimacy 
and em otional investment, 
predominantly satisfying, and 
perhaps some sexual expression or physical signs of affection 
5 - 
6 - Usually has satisfying relationships, 
emotionally rich and intimate and 
appropriate sexual expression and 
physical signs of expression 
Page 102
For Review Only9. RATE OF EXTENT OF OCCUPATIONAL ROLE FUNCTIONING 
This item is to rate the amount of role functioning the pe rson is attempting, not 
how well nor how completely he is succeeding. For homemakers, consider 
whether for a person with normal efficiency the responsibilities would represent a 
full-time job seeking activity.  
Suggested questions:
Have you had a job?     0 – Virtually no role functioning 
How many hours a week did you wor k?  1 -  
Were you involved in school in    2 – Less than half-time 
addition to work?        3  -   Suggested questions:
4 – Half-time or more, but less    
       than full time
What sort of education program were 
you pursui ng?   
How many classes were you taking? 
How much time did school take per  
week?
Were you also working, caring for  
children or responsible for housekeeping? 
Suggested questions for homemakers:
How much was involved in taking care 
of your home and family? 
Were you raising children? 
What were your responsibilities in the 
home? 
How much did other people help with  
these responsibilities? 5 –
6 - Full-time or more 
Page 103
For Review Only10. RATE LEVEL OF ACCOMPLISHMENT 
This item is to rate the level of success and achievement in fulfilling the particular 
role the per son has chosen to attempt. 
Question the subject regarding salary and 
raises, the challenge and responsibility of the job, praise or reprim ands from employer, 
adequacy of interaction with co-workers, absenteeism, promotions or demotions. For 
students
, question regarding grades, the 
difficulty of the curriculum, praise or 
criticism from teachers, adequacy of interaction with other classmates, class attendance, completion of assigned work, and extracurricular activities. For 
homemakers
, question regarding the 
adequate performance of required tasks such 
as cooking, shopping, washing dishes, cleaning, dusting, laundry, management of household budget, physical care of children, and meeting the emotional needs of children. Question further regarding praise or criticism by family members about either 
housekeeping or child raising. 0 - Attempting no role function or 
perform ing at level so poor as to 
imminently threaten the ability to 
continue in that role 
1 - 
2 - Functioning just well enough to keep 
position with very low level of 
accom plishment 
3 - 
4 - Generally adequate functioning 
5 - 6 - Very good functioning with evidence of 
new or progressive accom plishments 
and/or very good functioning in some 
areas
Page 104
For Review Only11. RATE DEGREE OF UN DEREMPLOYMENT 
This item is to rate the degree to which the existing extent  of and accomplishment in 
occupational role functioning reflects full utilization of the potentiality and opportunities 
available to the person. Consider innate abilities, physical handicaps, education, economic 
and social culture factors. Obviously, limitations directly reflecting any mental illness or personality disorder should not be considered in estimating the person's potential. 
Suggested questions:
This item requires a complex judgment. Ask any further questions needed to clarify the abilities and opportunities of this individual.0 - Almost complete failure to actualize 
potentials
1 - 
2 - Significant underemployment of abilities 
or unem ployed but looking for work 
actively.
3 - 
4 - Somewhat below the person's capacity 
5 - 
6 - Role functioning commensurate with 
person' s abilities and opportunities 
Page 105
For Review Only12. RATE SATISFACTION WITH OC CUPATIONAL ROLE FUNCTIONING 
This item is to rate the extent to w hich the person is comfortable with his choice of role, the 
performance of it, and the situation in which he performs it. It also is to rate the extent to 
which it provides a sense of satisfaction, pleasure, and fulfillment to him. 
Suggested questions:
Did you like your work or schooling? 
Would you have preferred to be doing 
something else? 
Do you plan a change? Why? 
Did you get good feelings from doing     
your work – pleasure, fulfillment, etc. 
Did your work or school m ake you feel  
good about yourself? 
Are you enthusiastic about your job? Do you look forward to going to work? 0 - Pervasive unhappiness and 
dissatisfaction with occupational role 
1 - 2 - Little or no definite evidence of 
unha ppiness or dissatisfaction, but role 
does not provide any positive pleasure or 
fulfillment. Perhaps boredom is evident. 
3 - 
4 - Little or no discontent and some limited 
pleasure in work 
5 - 
6 - Rather consistent sense of fulfillment and 
satisfaction, perhaps in spite of some 
limited complaints 
9 - Not applicable if patient not involved in 
any occupa tional role functioning 
Note:  (This item should be rated 2 if item 
#9 is rated less than 3. For Factor and Total scores, prorate this item on the basis if items 9 through 11.) 
Page 106
For Review Only13. RATE SENSE OF PURPOSE 
This item is to rate the degree to which the person posits realistic, integrated goals for his 
life. If the person's current life reflects such goals, it is not necessary that he (she) be 
planning a change in order to be j udged to have a good sense of purpose. 
Suggested questions:
What makes life worth living for you? 
Do you think much about the future? 
Have you set any goals for yourself? 
What do you anticipate your living and 
working situation to be a few months from now?
What plans do you have for your life over 
the next year or so – personal as well as job related one s?0 - No plans, or plans are bizarre, delusional, 
or gr ossly unrealistic 
1 - 
2 - Has plans, but they are vague, somewhat 
unrealistic, poorly integrated with one 
another, or of little consequence to the 
person' s life 
3 - 
4 - Realistic and concise plans for next year 
or so but little integration into long-range 
life plan 
5 - 
6 - Realistic, concise, and integrated plans, 
both short- and long-range 
Page 107
For Review Only14. RATE DEGREE OF M OTIVATION 
This item is to rate the extent to which the person is unable to initiate or sustain goal-
directed activity due to inadequate drive. 
Suggested questions:
How have you been going about 
accomplishing your goals? 
What other things have you worked on or 
accomplished recently? 
Have there been tasks in any area that you 
wanted to do but didn' t because you 
somehow didn't get around to it? 
Has this experience of just not getting 
around to it interfered with your regular daily activities? 
How motivated have you been? 
Have you had much enthusiasm, energy,  
and drive? . 
Have you tended to get into a rut? 
Have you tended to put things off? 0 - Lack of motivation significantly 
interferes with basic routine 
1 - 2 - Able to meet basic maintenance demands 
of life, but lack of m otivation 
significantly impairs any progress or new 
accomplishments 
3 - 
4 - Able to meet routine demands of life and 
some new accomplishments, but lack of 
motivation results in significant 
underachievement in some areas 
5 - 
6 - No evidence of significant lack of 
motivation
 
  
 
.
Page 108
For Review Only15. RATE CURIOSITY 
This item is to rate the degree to which the person is interested in his surroundings and 
questions those thi ngs he doesn't understand. Exclude interest in hallucinations or delusions 
or other psychotic products. However, pathological preoccupation with psychotic products 
or other themes may limit curiosity or interest in other things.
Suggested questions:
How often have you seen or heard about 
something that you wanted to know more 
about or understand better? 
What sorts of things? 
Have you done anything to learn more  
about them? Please specify. 
Have you read the newspapers, or listened  
to the news on TV or radio? 
Were you interested in any issues in
current events or sports? 
How curious about things have you been? 0 - Very little curiosity or interest in new 
topics or events 
1 - 2 - Some sporadic curiosity, but not pursued 
in thought or action 
3 - 
4 - Some curiosity and time spent thinking 
about topics or interest and some actual 
effort to learn more about them 
5 - 
6 - Curiosity about a number of topics and 
some effort to learn more about some of 
them  such as reading, asking questions 
and planned observation 
Page 109
For Review Only16. RATE ANHEDONIA 
This item is to rate the person' s capacity to experience pleasure and humor. Do not rate 
anhedonia that presents as the result of a clear and observable depressive syndrome, e.g., 
agitation, crying, marked feelings of wickedness and worthlessness, etc. However, 
anhedonia accompanied by apathy and withdrawal from which depression may be inferred should be rated. Ask any questions necessary to determine the presence of depression and its effect on hedonic capacity. This is to be distinguished from the capacity to display affect, which is not rated here. 
Suggested questions:
Have you been able to enjoy yourself? 
How often have you really enjoyed or
gotten satisfaction from something youwere doing? 
How often did you choose to do something 
that struck you as am using or made you  
feel like laughing? 
Did you have trouble getting e njoyment 
from things that seemed like they should
be fun? Do other people seem to get more 
enjoyment in things than you do? 
Did you often spend the better part of the 
day bore d or disinterested in things? 0 - Nearly complete inability to experience 
pleasure or hum or
1 - 
2 - Some sporadic and limited experiences 
of pleasure or hum or but a predominant 
lacking of these capacities 
3 - 
4 - Some regular experiences of pleasure & 
humor but reduced in extent & intensity 
5 - 6 - No evidence of anhedonia or can be 
explaine d completely by concurrent 
depression or anxiety
Page 110
For Review Only17. RATE TIME UTILIZATION 
This item is to rate the amount of time passed in aim less inactivity -sleeping during the 
day, lying in bed, sitting around doing nothing or in front of the TV or radio when not 
particularly interested. 
Suggested questions:
Did you spend much time doing nothing  
Just sitting around or in bed? 
Did you spend much time watching TV or 
listening to music - were you really interested or just had nothi ng better to do? 
Did you sleep much during the day? 
How much of your days were spent in  
these ways? 
How have you utilized your time? Did you tend to waste time? 0 - Spends the vast majority of his day in 
aimless activity 
1 - 2 - Spends about half of his days in aimless 
activity
3 - 4 - Some excessive aimless inactivity but 
less than half his day 
5 - 
6 - No excessive aimless inactivity beyond 
the norm al amount required for 
relaxation
Page 111
For Review Only18. RATE COMMONPLACE OBJECTS 
This item assumes that basic participation in living in this culture nearly always requires a 
person to possess cer tain objects. 
Suggested questions:
For this question, inquire about each ofthe 12 items listed below. 
Are you wearing or carrying the following? 
(1) a wallet or purse 
(2) keys 
(3) a driver's license (4) a watch (5) a credit card (6) a Social Security or 
Medical Assistance card 
Do you have with you at your place of residence the following? 
(1) a map of the city or area 
(2) your own alarm clock (3) a comb or hair brush (4) an overnight bag 
(5) a library card 
(6) postage stamps 0 - Absence of nearly all commonplace 
objects (0 items) 
1 - 
2 - Major deficit of commonplace 
objects (3-4 items) 
3 - 
4 - Moderate deficit (7-8 items) 
5 - 6 - Little or no deficit (11-12 items) 
Page 112
For Review Only19. RATE COMMONPLACE ACTIVITIES 
This item assumes that basic participation in living in this culture nearly always requires a 
person t o engage in certain activities. 
Suggested questions:
For this item inquire about each of the 
8 items listed below. Which of the following have you done in the past two 
weeks? (1) read a newspaper, (2) paid a 
bill, (3) wrote a letter, (4) gone to a movie or play, (5) driven a car or ridden public transportation alone, (6) shopped for food, (7) shopped for other than food, (8) eaten in a restaurant, (9) taken a book or record out of the 
library, (10) participated in a public 
gathering, (11) attended a sporting event, (12) visited a public park or other recreational facility. 0 - Absence of nearly all activities (0 items) 
1 - 
2 - Major deficit (3-4 items) 3 - 4 - Moderate deficit (7-8 items) 
5 - 
6 - Little or no deficit 
Page 113
For Review Only20. RATE CAPACITY FOR EM PATHY
This item is to rate the person's capacity to regard and appreciate the other person's 
situation as different from his own - to appreciate different perspectives, affective states 
and points of view. It is reflected in the person's description of interactions with other people and how he views such interactions. Specific probing to elicit the person's description and assessment of relevant situations can be done at this time if sufficient data has not emerged thus far in the interview. 
Suggested questions:
Consider someone you are close to or  
spend a lot of time with. What aboutthem irritates or annoys you? What about you irritates or annoys them? What things do they like? What things that you do please them? If 
they appear upset, how do you usually 
react? If you have an argument or difference of opinion with them, how do you handle it? 
Are you usually sensitive to the 
feelings of others? 
Are you affected very much by how 
other people feel? 0 - Shows no capacity to consider the views 
and feelings of others 
1 - 
2 - Shows little capacity to consider the 
views and feelings of others 
3 - 
4 - He can consider other people's views and 
feelings but  tends to be caught up in his 
own world. 
5 - 
6 - He spontaneously considers the other 
person' s situation in most instances, can 
intuit the other person's affective 
responses, and uses this knowledge to adjust his own responses. 
Page 114
For Review Only21. RATE CAPACITY FOR ENGAGEMENT AND EMOT IONAL INTERACTION 
WITH INTERVIEWER 
This item is to rate the person' s ability to engage the interviewer, to make him feel 
affectively in touch and acknowledge him as a participant individual in the encounter, and 
to react in a give and take way. 
This is a global judgment based on the  
entire interview. 0 - Interviewer feels virtually ignored with 
essentially no sense of  engagement, with 
very little reactivity 
1 - 
2 - Very limited engagement 3 - 
4 - Engagement somewhat limited or present 
erratically
5 - 
6 - Consistently good enga gement and 
reactivity
Page 115
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX I. NEGATIVE SYMPTOM ASS ESSMENT -16 (NSA-16) 
(SAMPLE)  
Page 116
June 22, 2015  10 Nega
tive Symptom Assessment-16  (NSA- 16)—Long Form 
 
 
 
1. P
rolonged time to respond.   After asking the subject a question, he/she pauses for 
inappropr
iately long periods before answering.  Rate severity of the frequency of these 
pauses. 
  
1. No abnormal pauses before speaking 
2. Minimal evidence of inappropriate pauses, may be extreme of normal 
3. Occasionally pauses long enough before answering the question to cause you to 
wonder whether he/she heard it 
4. Long pauses occur frequently (20-40% of responses) 
5. Long pauses occur most of the time (40-80% of responses) 
6. Long pauses occur with almost every response (80-100% of responses) 
9.   Not ratable (use only when all efforts to rate this item have failed)  
 
2. Restricted speech quantity.   This item assesses the amount of speech the subject provides 
in the cour
se of the interview.  Ratings on this item suggest that the subject gives brief 
answers to questions and/or provides elaborating details only after the interviewer prods him. 
 
1. Normal speech quantity 
2. Minimal reduction in quantity, may be extreme of normal 
3. Speech seems reduced, but more can be obtained with minimal prodding 
4. Speech is maintained only by regularly prodding the subject  
5. Res ponses are usually limited to a few words and/or details are only obtained by 
prodding or bribing  
6. Responses are usually non-verbal or limited to 1 or 2 word answers (despite one’s 
best efforts to get the subject to elaborate)   
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
3. Impoverished speech content.   The subject may talk a lot or a little but the information 
conveye
d is very limited.  If this symptom is pronounced, you will feel you have little more 
information at the end of the conversation than at the beginning.  For subjects who give 
minimal responses, rate item based on what the interviewer knows after asking probing 
questions. 
 
1. Normal speech content 
2. Minimal reduction in content, may be extreme of normal 
3. Ideas are sometimes vague 
4. Ideas are vague and/or some ideas remain vague even after the interviewer asks for 
clarification 
5. Ideas remain vague even after the interviewer asks for clarification 
6. No ideas can be clarified beyond vague 
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
Page 117
June 22, 2015  11 4. Inarticul
ate speech.   The subject’s speech cannot be understood because enunciation is 
poor.  Do not rat
e psychotic sub-vocalizations if the rest of the subject’s speech is normal and 
these utterances are not addressed to the interviewer.  For subjects with a strong dialect, rate 
on the basis of the subject’s ability to articulate and not on their competence with the 
language.   
 
1. Clear speech, not mumbled  
2. Minimal garbled speech, may be extreme of normal  
3. A few words slurred, but can be understood in context 
4. The subject must occasionally be asked to repeat mumbled words 
5. Many words are difficult to understand; the subject must frequently be asked to 
repeat, but on repeating can usually be understood 
6. Little language can be understood even after repeating 
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
5. Emotion: Reduced range.   Emotion is the feeling content of a person’s inner life.  This item 
assesses th
e range of emotion experienced by the subject during the last week (or other 
specified time period).  Base ratings on the subject’s answers to queries of whether he/she 
has felt happy, sad, etc. during the last week, as well as any reports of having these emotions 
later in the interview.  A full range of emotions would include, but not be limited to happiness, 
sadness, pride, fear, surprise, and anger.  This item should be distinguished from the 
capacity to display affect, which is rated elsewhere.  (If you sense that a subject’s emotional 
life is autistic and not contextually validated, rate his/her emotional range according to your 
interpretations of his/her experience.) 
 
1. Normal range of emotion 
2. Minimal reduction in range, may be extreme of normal 
3. Range seems restricted relative to a normal person, but during the specified time 
frame subject convincingly reports at least 4 emotions.   
4. Subject convincingly identifies 2 or 3 emotional experiences 
5. Subject convincingly identifies only 1 emotional experience  
6. Subject reports little or no emotional range 
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
6. Affect: Reduced modulation of intensity.   This item assesses the subject’s modulations of 
intensity of affect shown during the interview while discussing matters that would be expected 
to elicit significantly different affective intensities in a normal person 
 
1. Normal modulations of affect 
2. Minimal reduction of modulation, may be extreme of normal 
3. Affective intensity is muted relative to normal, but some spontaneous change in 
affective intensity appropriate to the content of conversation is observed 
4. Affective responses are clearly blunted; but by asking more pointed questions, 
appropriate changes in affective intensity can be elicited  
5. Intensity of affect is modulated only slightly, even after prodding 
6. Affective responses are never modulated, even after prodding  
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
Page 118
June 22, 2015  12 7. A
ffect: Reduced display on demand .  Affect is the outward expression of a person’s 
feelings.  This items assesses the subject’s ability to display a range of affect as expressed 
by changes in his/her facial expression and gestures when asked by the interviewer to show 
how his/her face appears when he/she feels happy, sad, proud, scared, surprised, and angry.  
(Although capable, some subjects are reticent about making facial expressions on demand.  
The interviewer may encourage the subject until convinced that he/she is unable, or unwilling 
to assume the expression.  Do not accept correct affective expressions that are half-hearted 
and unconvincing, and do not accept descriptions of affective expressions.)  
 
1. Subject convincingly displays all requested affective expressions 
2. Subject convincingly displays 5 of 6 requested affective expressions   
3. Subject displays any 4 of 6 requested affective expressions 
4. Subject displays any 2 or 3 of 6 requested affective expressions 
5. Subject displays any 1 of 6 requested affective expressions  
6. Subject is unable to display any of the affective expressions 
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
8. Reduced social drive.   This item assesses how much the subject desires to initiate social 
interactions.  Desire may be measured in part by the number of actual or attempted social 
contacts with others.  To rate severity probes the type of social interactions, and their 
frequency.  Remember the reference range is a normal 20 year old.  Many subjects may be 
rated 2 to 3. 
 
1. Normal social drive 
2. Minimal reduction in social drive, may be extreme of normal 
3. Desire for social interactions seems somewhat reduced 
4. Obvious reduction in desire to initiate social contacts, but a number of contacts are 
initiated each week 
5. Marked reduction in the subject’s desire to initiate social contacts, but a few contacts 
are maintained at subject’s initiation (as with family) 
6. No desire to initiate any social interactions 
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
 
9. Poor rapport with interviewer.   This item assesses the interviewer’s subjective sense that 
he/she an
d the subject are actively engaged in communication with one another.  Evaluate 
both verbal and nonverbal aspects of communication.  Do no rate hostility as lack of rapport.   
 
1. Normal rapport 
2. Minimal reduction in rapport, may be extreme of normal 
3. Interviewer sometimes has to carry the conversation because the subject’s interest 
seems reduced 
4. Interchanges are generally dull and uninspiring; interviewer must often lead the 
conversation because subject is detached  
5. Interviewer must prod to engage the subject in the interview 
6. Prodding does not result in engagement with the interviewer 
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
Page 119
June 22, 2015  13 10. Interest in emotional and physical intimacy. This item assesses how much the subject 
retains interest in emotional and/or physical intimate activities.  Do not exclusively rate 
actual performance even though in many instances performance might indicate desire 
and non-performance the absence of it.  Take the subject’s marital and environmental 
situations into account when rating this item.  (Because of his/her illness, he/she may be 
unable to find a suitable partner; if hospitalized, he/she may be discouraged from being 
intimate with others.)  Emotional and physical intimacy interest can be expressed by a 
wide variety of activities.  If the subject claims to be interested in emotional and physical 
intimacy interest but his/her performance is not consistent with his/her claim, the rater 
should ask him/her to account for this discrepancy.   
 
1. Desires to engage in some form of emotional and/or physical intimate activity once a 
day or more 
2. Desires to engage in some form of emotional and/or physical intimate activity 3- 6 
times a week 
3. Desires to engage in some form emotional and/or physical intimate activity once or 
twice a week 
4. Desires to engage in some form of emotional and/or physical intimate activity 1- 3 
time a month 
5. Desires to engage in some form of emotional and/or physical intimate activity several 
times a year 
6. No emotional and/or physical intimate interest is reported 
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
11. Poor grooming and hygiene.   The subject presents with poorly groomed hair, disheveled 
clothing,
 etc.  Do not rate grooming as poor if it is simply done in what a middle-class 
observer might consider poor taste (e.g.; wild hairdo or excessive facial makeup).   
 
1. Normal grooming and hygiene 
2. Minimal reduction of grooming and hygiene, may be extreme of normal 
3. Clean but untidy, or clothes are mismatched 
4. Clothes are unkempt and unbuttoned (looks as if subject just got out of bed) 
5. Clothes are dirty or stained, or has an odor   
6. Clothes are badly soiled and/or subject has a foul odor 
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
12. Reduced sense of purpose.   This item assesses whether the subject posits integrated goals 
for his/her l
ife.  If the subject already has what seems to be a satisfactory and well-integrated 
life, it is not necessary that he/she be planning a change to be judged as having a good 
sense of purpose. 
 
1. Normal sense of purpose 
2. Minimal reduction in purpose, may be extreme of normal 
3. Life goals somewhat vague, but current activities suggest purpose 
4. Subject has difficulty coming up with life goals, but activities are directed toward 
limited goal or goals 
5. Goals are very limited or have to be suggested, and activities are not focused toward 
achieving any of them 
6. No identifiable life goals 
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
13. Reduced hobbies and interest.   This item assesses the range and intensity of the subject’s 
interests.
 
 
Page 120
June 22, 2015  14 1. 
Normal interests  
2. Minimal reduction in interests, may be extreme of normal 
3. Range of interests and/or commitment to them seems diminished 
4. Range of interests is clearly diminished and is not particularly committed to interests 
held 
5. Only 1 or 2 interests reported, and these pursued superficially   
6. No identifiable goals   
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
14. Reduced daily activity.   This item assesses the level of the subject’s daily activity and 
his/her fai
lure to take advantage of the opportunities his/her environment offers.  Get a 
complete account of what the subject does from the time he/she gets up until he goes to bed.  
Compare his/her activities with those of a young person who is not mentally ill.  If the subject 
participates as an outpatient in a mental health program, determine the level of his/her 
participation, i.e. whether he/she is actively involved, or just passes time there.  If the subject 
is hospitalized rate his/her daily activity as you would for a young person who is not 
hospitalized and without regard for the limitations that the hospital routine may place on 
him/her.   
 
1. Normal daily activity 
2. Minimal reduction in activity, may be extreme of normal 
3. Employed, attends school or volunteers, but is underachieving; few hobbies  
4. Not involved in the activities expected of a normal young person (may be 
unemployed, or minimally employed for education, but may be involved in a mental 
health program one or more days a week) 
5. Most of day spent doing activities, things that require minimal mental or physical 
exertion (watches TV, smokes, drinks coffee, walks to store, but may be involved in a 
mental health program one or more days a week)   
6. Most of day is spent sitting in a chair or lying in bed; has little or no regard for what 
goes on in immediate environment 
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
15. Reduced expressive gestures.  Gestures and body movements that normally facilitate 
communication during speech are less than normal, or are not observed at all.  Do not rate 
involuntary movement disorders. 
 
1. Normal expressive gestures 
2. Minimal reduction in gestures, may be extreme of normal 
3. Hand and head gestures normally seen during conversation are reduced 
4. Hand or head gestures are infrequent; gestures may be limited to periods when the 
subject is discussing topics of special interest 
5. Gestures infrequent even during discussion of highly emotional topics 
6. Gestures are never observed 
9.   Not ratable (use only when all efforts to rate this item have failed) 
 
16. Slowed movements.   This item assesses how much the subject’s voluntary movements are 
slowed.  A
t a minimum one should rate movements as gait and those of rising from a chair.  
Rate these movements in comparison to a normal young person 
 
1. Normal speed of movements  
2. Minimal reduction in speed of movements, may be extreme of normal 
3. Voluntary movements are slightly retarded or slowed 
4. Movements are generally sluggish 
5. Most movements are retarded and made with effort 
6. All movements are made with extreme effort; subject must be assisted from chair 
9.   Not ratable (use only when all efforts to rate this item have failed) 
Page 121
June 22, 2015  15  
Page 122
June 22, 2015  16 GLOBAL NEGATIVE SYMPTOMS RATING.  Rate this item on the basis of overall impression of 
negative symptoms in the subject, not on the basis of a single item or total score. 
 
1. No evidence of negative symptoms  
2. Minimal evidence of negative symptoms  
3. Mild evidence of negative symptoms 
4. Moderate evidence of negative symptoms apparent to the casual observer 
5. Marked evidence of negative symptoms readily apparent to the casual observer 
6. Severe evidence of negative symptoms marked and obvious impact on functioning 
7. Extremely severe negative symptoms (incapacitating) 
 
 
Page 123
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX J. PATIENT SATISFACTION WITH MEDICATION 
QUESTIONNAIRE (PSMQ) -MODIFIED (SAMPLE)  
Page 124
 
MODIFIED  MEDICATION SATISFACTION QUESTIONNAIRE (MSQ)  
 
   
Overall, how satisfied are you with your current medication?  
 
Very 
Dissatisfied  Somewhat  
Dissatisfied  Neither  
Dissatisfied  
nor Satisfied  Somewhat  
Satisfied  Very 
Satisfied  
    □      □      □      □      □  
1 2 3 4 5 
 
 
Overall, do you prefer your current LAI medication or your previous LAI medication 
for the treatment of Schizophrenia (prior to your participation in this study)?  
 
 
Much  
Prefer  
Previous LAI  Prefer  
Previous LAI  Neither  
Prefer  
Previous  nor 
Current LAI Prefer  
Current LAI  Much Prefer  
Current LAI  
    □      □      □      □      □  
1 2 3 4 5 
 
 
How would you rate the side effects of your current LAI medication, compared with 
previous LAI  medication for the treatment of Schizophrenia (prior to your participation 
in this current study)?  
 
Much Less  
Side Effects  Less Side  
Effects  The Same  
as Previous  More Side  
Effects  Much More  
Side Effects  
    □      □      □      □      □  
1 2 3 4 5 
 
    
© International Society for CNS Drug Development (ISCDD)  
 
Page 125
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX K.  SIXTH EDITION OF THE TREATMENT SERVICES 
REVIEW (TSR -6) (SAMPLE)  
Page 126
Page 1 of 7 
ALK9072 -A401 TREATMENT SERVICES REVIEW (Version 6) – Modified for Mental Health  
This interview asks about different services you may have received over the past ___ days, since DATE .  It 
includes medical services, emotional or psychological services, family, marital or parenting services, 
financial or housing services, and legal services.  Do you have any questions before we get started?  
 
TIME STARTED:   
 
DEMOGRAPHIC INFORMATION  
    
Patient initials :  Interviewer Name:   
    
Patient Number:   Date of Interview:   
    
Patient Marital Status  
(circle one):  1. Married  
2. Living as married  
3. Widowed  
4. Divorced  5. Separated  
6. Never married  
7. No reply  
 
 
Coverage Period  From:  To: 
 
NUMBER OF DAYS IN RE CALL PERIOD:   
 
G1 Where did you stay for the past ___ days?   # of Days  
 1. Alone (in private house, apartment, hotel, etc.)   __ __ __  
 2. With others (in private house, apartment, hotel, group home, 
assisted living residence, etc.)    
__ __ __  
 3. Institution, e.g. hospital, jail, prison (controlled environment)    
 (a) Hospital/Residential treatment   __ __ __  
 (b) Jail or prison   __ __ __  
 (c) Day treatment or partial hospital program   __ __ __  
 4. Homeless shelter   __ __ __  
 5. Homeless, i.e. on the street, in an abandoned building, in a car   __ __ __  
 
  
 
  
Page 127
Page 2 of 7 
ALK9072 -A401 MEDICAL SERVICES  
Questions about any medical treatment you have received over the past ___ days  
    
M1 How many nights were you an inpatient in a medical hospital, nursing 
home, or medical rehabilitation facility?    
__ __ __  
 1a) Specify:    
 Medical hospital   __ __ __  
 Nursing home or medical rehab   __ __ __  
 If 0, Skip to M2    
 1b) Diagnosis/major problem ________________________  
1c) Major procedures or evaluations __________________    
    
? ON PAST ___ DAYS WHEN NOT  IN A MEDICAL HOSPITAL:    
    
M2 How many times did you visit an emergency room?   __ __ __  
 IF 0, SKIP to M3    
 2a) What was your reason(s ) for visiting the ER?  Check all that apply:    
 Medical   1 – Yes 
2 – No 
 Psychological   1 – Yes 
2 – No 
 Substance Use   1 – Yes 
2 – No 
 2b) Diagnosis/major problem ________________________    
 2c) Major procedures or evaluations __________________    
    
M3 How many times did you visit a medical doctor (physician, psychiatrist) 
for testing, examination, treatment, or care of medical 
concerns/problems?  
Note: we will ask you about visits for psychological or emotional 
concerns later.    
   
__ __ __  
 If 0, SKIP TO M4    
 3a) Diagnosis/major problem ________________________    
 3b) Major procedures or evaluations __________________    
    
M4 How many times did you visit any other medical professional  (e.g. 
dentist, optometrist, nurse, physical therapist, X -ray or lab technician) 
for testing, examination, or treatment of medical concerns/problems?    
 
__ __ __  
 If 0, SKIP TO M5    
 4a) Diagnosis/major problem ________________________    
 4b) Major procedures or evaluations __________________    
 
   
Page 128
Page 3 of 7 
ALK9072 -A401 M5 How many (individual or group) counseling sessions  did you attend 
with non- medical personnel  during which  medical concerns/problems 
were the main focus ( exclude all previously recorded visits )?   
 
__ __ __  
 If 0, SKIP TO M6    
 5a) Number of sessions with:   __ __ __  
 Non -medical doctor (e.g. psychologist – Ph.D./Psy . D)  __ __ __  
 Physician assistant, Nurse prescriber (Practitioner, APNP)   __ __ __  
 Nurse   __ __ __  
 Other clinician (e.g. counselor, social worker, case manager, 
clergy)   __ __ __  
 Group member(s) (i.e. a support group not professionally led)   __ __ __  
 Don’t know   __ __ __  
 5b) On average, how long did a session last? (record # of minutes)   __ __ mins  
 5c) How many of these were group sessions?   __ __ __  
 
PSYCHOLOGICAL SERVICES  
Questions about any emotional or psychological services received over the past ___ days  
P1  How man y night s were you an inpatien t in a psychiatri c hospita l or 
psych treatmen t unit (i.e., staye d overnight)? Where?  ______________    
__ __ __  
 1a) Diagnosis/major problem ________________________    
 1b) Major procedures or evaluations __________________    
    
? On past ___ days NOT  in psychiatric inpatient treatment:    
    
P2 On how many days did you attend any treatment  for mental health, 
emotional or psychological problems?    
__ __ __  
 Where? ________________________    
 2a) How many of these were day hospital or intensive outpatient 
programs?    
__ __ __  
    
P3 How many individual (one -on-one)  sessions did you attend during 
which your mental health, emotional or psychological problems were 
the main purpose of the discussion (not including inpatient or day 
hospital/intensive outpatient programs)?    
  
__ __ __  
 If 0, SKIP TO P4    
 3a) Number of  individual sessions with:    
 Medical doctor (e.g. psychiatrist or physician)   __ __ __  
 Non -medical doctor (e.g. psychologist – Ph.D./Psy. D.)   __ __ __  
 Physician assistant, Nurse prescriber (Practitioner, APNP)   __ __ __  
 Nurse   __ __ __  
 Other clinician (e.g. counselor, social worker, case manager, 
clergy)   __ __ __  
 Group member(s) (i.e. a support group not professionally led)   __ __ __  
 Don’t know   __ __ __  
 3b) On average, how long did each individual session last? (# of 
minutes)    
__ __ mins  
 
 
Page 129
Page 4 of 7 
ALK9072 -A401 P4 How many group sessions  did you attend for mental health, emotional 
or psychological problems?    
__ __ __  
 If 0, SKIP TO FAMILY SERVICES    
 4a) Number of group sessions with:    
 Medical doctor (e.g. psychiatrist or physician)   __ __ __  
 Non -medical doctor (e.g. psychologist – Ph.D./Psy. D.)   __ __ __  
 Physician assistant, Nurse prescriber (Practitioner, APNP)   __ __ __  
 Nurse   __ __ __  
 Other clinician (e.g. counselor, social worker, case manager, 
clergy)   __ __ __  
 Group member(s) (i.e. a support group not professionally led)   __ __ __  
 Don’t know   __ __ __  
 4b) On average, how long did a group session last? (# of minutes)   __ __  mins  
 4c) On average, how many other patients were in a group?   __ __ __  
 4d) On average, how many group leaders were present in each session?   __ __ __  
 
FAMILY SERVICES  
Questions about family or parenting services received over past ___ days.  
    
F1 How many classes or sessions did you attend to help with parenting or 
problems with children ?    __ __ __  
 
 If 0, SKIP TO F3    
 1a) Number of sessions with:    
 Medical doctor (e.g. psychiatrist or physician)   __ __ __  
 Non -medical doctor (e.g. psychologist – Ph.D./Psy. D.)   __ __ __  
 Physician assistant, Nurse prescriber (Practitioner, APNP)   __ __  __ 
 Nurse   __ __ __  
 Other clinician (e.g. counselor, social worker, case manager, 
clergy)   __ __ __  
 Group member(s) (i.e. a support group not professionally led)   __ __ __  
 Don’t know   __ __ __  
 1b) On average, how long did a session last?   __ __ mins  
 1c) In how many of these sessions were members of other families 
present?    
__ __ __  
    
F2 How many treatment sessions did you attend with some member(s) of 
your family or significant other ? (exclude those recorded  in previous 
sections )   
 
__ __ __ 
 2a) Number of those with:    
 Medical doctor (e.g. psychiatrist or physician)   __ __ __  
 Non -medical doctor (e.g. psychologist – Ph.D./Psy. D.)   __ __ __  
 Physician assistant, Nurse prescriber (Practitioner, APNP)   __ __ __  
 Nurse   __ __ __  
 Other  clinician (e.g. counselor, social worker, case manager, 
clergy)   __ __ __  
 Group member(s) (i.e. a support group not professionally led)   __ __ __  
 Don’t know   __ __ __  
Page 130
Page 5 of 7 
ALK9072 -A401  2b) On average, how long did a session last? (# of minutes)   __ __  mins  
 2c) In how many of these sessions were members of other  families 
present?    
__ __ __  
    
F3 How many sessions did you attend to deal with relationship issues (e.g. 
domestic violence, communication issues) where no other family  
member  was present? (exclude any previously recorded)    
 
__ __ __  
 3a) Number of those with:    
 Medical doctor (e.g. psychiatrist or physician)   __ __ __  
 Non -medical doctor (e.g. psychologist – Ph.D./Psy. D.)   __ __ __  
 Physician assistant, Nurse prescriber  (Practitioner, APNP)   __ __ __  
 Nurse   __ __ __  
 Other clinician (e.g. counselor, social worker, case manager, 
clergy)   __ __ __  
 Group member(s) (i.e. a support group not professionally led)   __ __ __  
 Don’t know   __ __ __  
 3b) On average, how long did a session last? (# of minutes)   __ __ mins  
 3c) How many of these were group sessions?   __ __ __  
 
FINANCIAL/EMPLOYMENT/HOUSING SERVICES  
Questions abou t any specialized educational, financial, employment, or housing services received over 
the past ___ days . 
    
E1 How many days did you attend school or formal training  (e.g. 
apprenticeship, internship)?    
__ __ __  
    
E2 How many days did you work in a therapeutic work setting/sheltered 
workshop ?   
__ __ __  
    
E3 How many sessions did you attend where job/education counseling  or 
placement was the main focus?    
__ __ __  
 3a) Number of those with:    
 Job or education counselor   __ __ __  
 Anyone else (i.e. non -specialist)   __ __ __  
    
E4  
 How man y session s did you atten d wher e specifi c housing services 
were the main focus?   __ __ __  
 4a) Numbe r of thos e with:    
 Any housin g specialist   __ __ __  
 Anyon e else (i.e., non-specialist)   __ __ __  
 
   
Page 131
Page 6 of 7 
ALK9072 -A401 E5 How many sessions or classes did you attend where financial/benefits 
issues  were main focus?    
__ __ __  
 5a) Number of those with:    
 Benefits or financial counselor, or any other financial specialist?   __ __ __  
 Anyone else (i.e. non -specialist)   __ __ __  
 
LEGAL SERVICES  
Following questions concern  any legal or correctional involvement over past ___ days.  
 
L1 Have you been arrested, picked up, or transported by police in the 
last ___ days?   YES OR NO   1 – Yes 
2 – No 
 1a) If yes, why? (Check all that apply)    
            Vagrancy (street person/begging/homelessness/transient)   1 – Yes 
2 – No 
            Related to Drug/Alcohol use or possession   1 – Yes 
2 – No 
            Disorderly conduct/disturbing the peace   1 – Yes 
2 – No 
            Public endangerment   1 – Yes 
2 – No 
            Other:  ___________________________________________   1 – Yes 
2 – No 
 1b) If yes, for how many days were you incarcerated?   __ __ __  
 
OTHER SERVICES  
 
O1 Did you receive any other services during past ___ days (e.g. food bank, 
soup kitchen)?   1 – Yes 
2 – No 
 1a) Specify: _______________________    
 1b) Specify: _______________________    
 1c) Specify: _______________________    
 1d) Specify: _______________________    
    
O2 In the past ___ days, did someone help you manage your overall 
condition – including your physical health, mental health, social, 
housing, financial and legal situation – by giving you information about 
the kind of help that is available or by putting you in touch with others 
who could help you? ( e.g. case management) [ not including services 
already recorded]    
1 – Yes 
2 – No 
 2a) On how many days did you meet/speak with him/her?   __ __ __  
 
   
Page 132
Page 7 of 7 
ALK9072 -A401 O3 Throughou t this interview , you’v e told me about different  services  you’ve  received  over  the past  
___ days [give examples of services patient has described] .  I realiz e thing s aren’ t that cut and 
dried – I know , for example , that you don’ t just talk about medical issues ; you can tal k abou t 
socia l or emotiona l or famil y or medica l problem s.  The same is tru e whe n you go to the docto r – 
you don’ t just talk about medica l problems ; you can talk about emotiona l issue s or a lot of othe r 
things .  Wha t I’d like to do now is to get a sense o f that.  Give n all the service s and treatment s and 
contact s you’v e had in the past ___ days , how much  of all of that dealt  with:  
 
3a) Your physical health or medical problems?  
  
 0 1 2 3 4  
 None  A little bit  Some  Quite a bit  A lot   
       
3b) Your mental health or psychological problems and issues?  
       
 0 1 2 3 4  
 None  A little bit  Some  Quite a bit  A lot   
 
3c) Your family problems and issues?  
       
 0 1 2 3 4  
 None  A little bit  Some  Quite a bit  A lot   
       
3d) Your employment, education, finances, or house?  
       
 0 1 2 3 4  
 None  A little bit  Some  Quite a bit  A lot   
       
3e) Your legal or criminal problems and issues?  
       
 0 1 2 3 4  
 None  A little bit  Some  Quite a bit  A lot   
       
 
TIME ENDED:   
 
Page 133
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX L.  CAREGIVER QUALITY OF LIFE (CARERQOL) – 
BURDEN DIMENSIONS (7D) [ BROUWER WBF, 2006 ] 
AND VISUAL ANALOG SCALE (VAS) (SAMPLE)  
Page 134
For Review OnlyCarerQol-7D
Please draw an “X” to indicate which description best fits your current  care giving situationno
some
a lot of
a.I have fulfillment with carrying out my care tasks.
b.I have relational problems with the care receiver (e.g., he/she is very demanding,
he/she behaves differently, we have communication problems) .
c.I have problems with my own mental health (e.g., stress, fear, gloominess, depression,
concern about the future) .
d.I have problems combining my ca re tasks with my daily activities (e.g., household 
activities, work, study, family and leisure activities).
e.I have financial problems because of my care tasks.
f.I have support with carrying out my  care tasks, when I need it (e.g., from family,
friends, neighbors, acquaintances) .
g.I have problems with my own physical health (e.g., more often sick, tiredness,
physical stress) .
CarerQol-VASPlease draw an “X” on the scale belo w to indicate how happy you feel at this moment 
Completely 
unhappyCompletely 
happy
0 1 2 3 4 5 6 7 8 9 10
Derived from Brouwer WB, van Exel NJ, van Gorp B, Re dekop WK. The CarerQol instrument: a new 
instrument to measure care-related qual ity of life of informal caregivers for use in economic evaluations. Qual 
Life Res. 2006 Aug;15(6):1005-21.
Page 135
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX M. BURDEN ASSESSMENT SCALE (SAMPLE) 
Page 136
For Review OnlyBurden Assessment Scale (BAS) 
 
I am going to read a list of thing s which other people have found to  happen to them because of their 
relative’s illness. Would you tell me to what extent you have had any of  the following experiences in the 
past six months.  
Not at all
1A little
2Some
3A lot
4N/A
9
 Because of (name’s) illness, to what extent have you:  
1. Had financial problems  
2. Missed days at work (or school) 
3. Found it difficult to conce ntrate on your own activities  
4. Had to change your personal plans like taki ng a new job, or going on vacation  
5. Cut down on leisure time  6. Found the household routine was upset  
7. Had less time to spend with friends  8. Neglected other family members’ needs  
9. Experienced family frictions and arguments  
10. Experienced frictions with neighbors, friends, or relatives outside the home  
11. Became embarrassed because of (name’s) behavior  
12. Felt guilty because you were not doing enough to help  13. Felt guilty because you felt responsibl e for causing (name’s) problem  
14. Resented (name) because s/he made to o many demands on you  
15. Felt trapped by your caregiving role  16. Were upset about how much (name) had change d from his or her former self  
17. Worried about how your behavior with (name) might make the illness worse  18. Worried about what the future holds for (name)  19. Found the stigma of the illness upsetting 
 
 
 
 Burden Assessment Scale, Reinhard SC, Gubman GD, Horwitz AV, Minsky S. Burden Assessment Scale for 
families of the seriously mentally ill. Eval uation and Program Planning. 1994;17(3):261-269. 
Page 137
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX N. BIRCHWOOD INSIGHT SCALE (BIS) (SAMPLE) 
Page 138
IS–(present)
Please read the following statements  carefully and then tick the box 
which best applies to you.
Agree Disagree Unsure
1. Some of the symptoms were 
made by my mind 
 
2. I am mentally well 
 
 
3. I do not need medication 
 
 
4. My stay in hospital was 
necessary 
 
5. The doctor is right in 
prescribing medication for me 
 
6. I do not need to be seen by a 
doctor or psychiatrist 
 
7. If someone said I had a nervous 
or mental illness then they would 
be right 
8. None of the unusual things I 
experienced are due to an illness 
 
 
 
  For ForFor ew RevieRevieRevieeOnlyOy
Page 139
Insight Scale (IS)  
(Coding Schedule) 
 
 Agree Disagree Unsure 
1. Some of the symptoms were 
made by my mind 
 2 0 1 
2. I am mentally well 
 
 0 2 1 
3. I do not need medication 
 
 0 2 1 
4. My stay in hospital was 
necessary
 2 0 1 
5. The doctor is right in 
prescribing medication for me 
 2 0 1 
6. I do not need to be seen by a 
doctor or psychiatrist 
 0 2 1 
7. If someone said I had a 
nervous or mental illness then 
they would be right 2 0 1 
8. None of the unusual things I 
experienced are due to an illness  
 0 2 1 
 
Maximum Score  = 12   -  Full insight 
Minimum Score   = 0     -  No insight 
(9 and above = good insight) 
 
Subscales 
Items Possible Total
1, 8 Awareness of symptoms 4
(3or 4 = good insight,
1 or 2 = poor insight)
2, 7 Awareness of illness 4
(3or 4 = good insight, 
1 or 2 = poor insight)
3, 4, 5, 6 Need for treatment 
(items need to be added and divided by 2)4
(3or 4 = good insight, 
1 or 2 = poor insight)Fore saidFormental illnessFor be right eview ReReRehen Re22ewOnly00yyyyy
Page 140
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX O.  NEW YORK ASSESSMENT OF ADVERSE COGNITIVE  
EFFECTS OF NEUROPSYCHIATRIC TREATMENT 
(NY-AACENT) SUBSCALES (SAMPLE)  
Page 141
 SMPL/RA Version Sept-2015 
NY-AACENT-R, ©2012, M. Opler, D. Antonius, C. Correll. All Rights Reserved.  
Not to be reproduced or distributed without express written permission of the authors. New York Assessment of Adverse Cognitive Effects of Neuropsychiatric Treatment 
 
Description:  The NY-AACENT is intended to be used to detect changes in cognitive function subsequent to pharmacological or 
similar treatments for neurological or psychiatric problems. It is originally designed to be used in pediatric populations, but can be 
utilized with other age groups as appropriate. Each of the seven items is derived from the seven domains identified by MATRICS1. 
When coupled with similar adverse event assessments (such as the PAERS2) that are intended to be used in drug treatment 
studies, data on select items on the NY-AACENT (e.g. item #2, Attention/Vigilance) may be imputed from other, identical items 
(e.g. item #9 on the PAERS.)  
 
Instructions: It is recommended that the patient and caregiver forms be completed first as a brief interview, conducted 
separately with subjects and parents. After this has been completed, the forms should be reviewed and the clinician form 
completed, summarizing best judgment . If specific symptoms are reported to be present, please determine: 
  
- Whether the symptoms are likely due to a study medication or concomitant medication (if used in the context of a 
research study); 
- The time-frame of the symptoms, i.e. whether or not they have only emerged or changed subsequent to beginning 
treatment; 
- The extent to which the symptom does or does not have an impact on functioning. 
 
After all information has been collected, the clinician or researcher is instructed to complete the Clinician Form, scoring each 
section accordingly.  
 
Conducting the Interviews. Brief, separate interviews with both patients and caregivers are recommended. For certain subjects, it 
is advisable to interview the patient prior to interviewing the caregiver. In cases where the patient is a poor historian or presents 
with other impairments that reduce the validity of side effect reporting, both the patient and caregiver may be interviewed 
together. The interview should cover each domain of cognition and focus on eliciting specific examples, determining the extent to 
which social, academic or role functioning are impaired, and the emergence of symptoms in relation to the administration of a 
specific medication. If etiology is unclear, it is advisable to ask follow-up questions. 
 
Domains:  Seven domains of cognition are covered in the NY-AACENT. These include –  
 
1. Working memory 
2. Attention/Vigilance 
3. Verbal Learning/Memory 
4. Visual Learning/Memory 
5. Reasoning & Problem Solving  
6. Speed of Processing 
7. Social Cognition  
 
It is strongly advised that prior to conducting the interviews, investigators review the domains of cognition carefully and ensure 
that when querying patients or caregivers, that the proper aspects of cognition and functioning are being considered. 
                                                           
1 Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern R S, Kraemer 
H, Stover E, Weinberger DR, Zalcman S, Marder SR. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-
MATRICS conference to select cognitive domains and test criteria.  Biol Psychiatry. 2004; 56(5):301- 7. 
2 March J, Karayal O, Chrisman A. CAPTN: The Pediatric Adverse Event Rating Scale. Paper presented at: Scientific Proceedings of the 2007 
Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October 23-28, 2007, 2007; Boston, MA. 
Page 142
 SMPL/RA Version Sept-2015 
NY-AACENT-R, ©2012, M. Opler, D. Antonius, C. Correll. All Rights Reserved.  
Not to be reproduced or distributed without express written permission of the authors. Patient Form: Please focus on the past week . (If you have experienced one of these problems, but not in the past week, check 
“Not Present.” ) If present in the past week, indicate the extent to which the described symptom bothered you or was a problem 
for you.  
 
1. Do you have trouble remembering things that people ( co-workers, clinicians, caregivers, friends, relatives) have said to 
you, immediately after you hear them? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothers ome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
___________ _______________________________  
Quite likely due to a specific  medicatio n/medications 
(please list:) 
_______________ _______________________________  
 Almost definitely due to a specific  
medication/medications (please list:) 
_____ ________________________________________  
2. Do you have trouble paying attention in different settings (home, work, clinic, day programs etc), watching TV, browsing 
the internet or using computers? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
_______________ _______________________________  
Quite likely due to a specific medication/medications 
(please list:)  
____________ _________________________________  
 Almost definitely due to a specific  
medication/medications (please list:) 
_____ ________________________________________  
3. Is it difficult for you to  learn or remember words to things (books, songs, TV shows)? Are you able to come up with 
words in conversation? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication relat ed 
 Possibly due to a specific medication/medications 
(please list:)  
______________ _______________________________  
Quite likely due to a specific medication/medications 
(please list:)  
______________ _______________________________  
 Almost definitely due to a specific  
medication/medications (please list:) 
_____ ________________________________________  
4. Do you have difficulty recalling how things look, including shapes, colors? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
_______________ _______________________________  
Quite likely due to a specific medication/medications 
(please list:)  
______________ _______________________________  
 Almost definitely due to a specific  
medication/medications (please 
list:)________________________________________  
 
Page 143
 SMPL/RA Version Sept-2015 
NY-AACENT-R, ©2012, M. Opler, D. Antonius, C. Correll. All Rights Reserved.  
Not to be reproduced or distributed without express written permission of the authors. 5. Do you have t rouble managing money, solving problems, doing puzzles, dealing with new challenges? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not a pplicable  
 Not medication related  
 Possibly due to a specific medicat ion/medications 
(please list:)  
_________ ______ _______________________________  
Quite likely due to a specific medication/medications 
(please list:)  
______________ _______________________ ________  
 Almost definitely due to a specific  
medication/medications (please list:) 
_____ ________________________________________  
6. Do you feel “slowed down”, does it take you longer than usual to do things?  
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
______________ _______________________________  
Quite likely due to a specific medication/medications 
(please list:)  
______________ _______________________________  
 Almost definitely due to a specific  
medication/medications (please list:) 
____________________________________ ________  
7. Do you have trouble understanding what other people intend or want from you, participating in social situations, or 
interacting with others? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
______________ _______________________________  
Quite likely due to a specif ic medication/medications 
(please list:)  
______________ _______________________________  
 Almost definitely due to a specific  
medication/medications (please list:) 
_____ ________________________________________  
 
Page 144
 SMPL/RA Version Sept-2015 
NY-AACENT-R, ©2012, M. Opler, D. Antonius, C. Correll. All Rights Reserved.  
Not to be reproduced or distributed without express written permission of the authors. Caregiver Form : Please focus on the past week. If the patient has experienced one of these problems, but not in the past week 
check “Not Present.” If present in the past week, indicate the extent to which the item bothered him/her by checking one of the 
boxes marked 1 through 4.  
 
1. Patient has trouble remembering things that people ( co-workers, clinicians, caregivers, friends, relatives) have just said 
immediately after hearing them? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
______________ _______________________________  
Quite likely due to a specific medication/m edications 
(please list:)  
______________ _______________________________  
 Almost definitely due to a specific  
medication/medications (please list:) 
______ ________________________________________  
2. Patient has trouble paying attention in in different settings (home, work, clinic, day programs etc) or while playing games, 
watching TV, browsing the internet or using computers? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem  Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
______________ _______________________________  
Quite likely due to a specific medication/medications 
(please list:)  
______________ _______________________________  
 Almost definitely due to a specific  
medication/medications (please list:) 
_____ ________________________________________  
3. Is it difficult to for the patient to learn or remember words to things (book, songs, TV shows)? Is the patient able to come 
up with words in conversation? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
_____________ _______________________________  
Quite likely due to a specific medication/medications 
(please list:)  
_____________ ___________________ ____________  
 Almost definitely due to a specific  
medication/medications (please list:) 
____________________________________________  
4. Does the patient have difficulty recalling how things look, such as shapes and colors? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
_____________ _______________________________  
Quite likely due to a specific medication/medications 
(please list:)  
______________ _______________________________  
 Almost definitely due to a specific  
medication/medications (please list:) 
_____ __________________ ______________________  
 
Page 145
 SMPL/RA Version Sept-2015 
NY-AACENT-R, ©2012, M. Opler, D. Antonius, C. Correll. All Rights Reserved.  
Not to be reproduced or distributed without express written permission of the authors. 5. Does the patient have trouble managing money, solving problems, doing puzzles, dealing with new challenges? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
_____________ _______________________________  
Quite likely due to a specific medication/medic ations 
(please list:)  
______________ _______________________________  
 Almost definitely due to a specific  
medication/medications (please list:) 
_____ ________________________________________  
 
6. Does the patient feel “slowed down”, does it take him/her longer than usual to do things? 
 Not 
Present   A little bit  
bothersome/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
______________ _______________________________  
Quite likely due to a specific medication/medications 
(please list:)  
______________ _______________________________  
 Almost definitely due to a specific  
medication/medications (please list:) 
_____ ________________________________________  
 
7. Does the patient have trouble understanding what other people intend, participating in social situations, or interacting 
with others? 
 Not 
Present   A little bit  
bother some/  
a mild 
problem   Somewhat  
bothersome/  
a moderate  
problem   Quite 
bothersome/    
a severe  
problem   Very 
bothersome
/ an 
extreme  
problem   Not applicable  
 Not medication related  
 Possibly due to a specific medication/medications 
(please list:)  
_____________ _______________________________  
Quite likely due to a specific medication/medications 
(please list:)  
_____________ _______________________________  
 Almost definitely due to a specific  
medication/medications (please list:) 
__________________________ __________________  
Page 146
 SMPL/RA Version Sept-2015 
NY-AACENT-R, ©2012, M. Opler, D. Antonius, C. Correll. All Rights Reserved.  
Not to be reproduced or distributed without express written permission of the authors. Clinician Form : Please complete each section below:  
 
1. Working memory: Trouble remembering things that people ( co-workers, clinicians, caregivers, friends, relatives ) have just 
said? 
 Present 
during past 
week 
 Not present 
in past week   Evident During 
Visit 
 Not Evident 
During Visit   Not drug related  
 Due to study drug  
 Other drug  
 Drug/drug interaction  
 Not applicable   Mild 
 Moderate  
 Severe  
 Extreme  
 Not applicable   Functional/ Role 
Impairment  
 No Functional/ 
Role Impa irment  
 Not applicable  
 
2. Attention/Vigilance: Trouble paying attention in in different settings (home, work, clinic, day programs etc) or while 
playing games, watching TV, browsing the internet or using computers? 
 Present 
during past 
week 
 Not present 
in past week   Evident During 
Visit 
 Not Evident 
During Visit   Not drug related  
 Due to study drug  
 Other drug  
 Drug/drug interaction  
 Not applicable   Mild 
 Moderate  
 Severe  
 Extreme  
 Not applicable   Functional/ Role 
Impairment  
 No Functiona l/ 
Role Impairment  
 Not applicable  
 
3. Verbal Learning/Memory: Difficulty remembering or learning words to things (book, songs, TV shows)? Trouble coming 
up with words in conversation? 
 Present 
during past 
week 
 Not present 
in past week   Evident During 
Visit 
 Not Evident 
During Visit   Not drug related  
 Due to study drug  
 Other drug  
 Drug/drug interaction  
 Not applicable   Mild 
 Moderate  
 Severe  
 Extreme  
 Not applicable   Functional/ Role 
Impairment  
 No Functional/ 
Role Impairment  
 Not applic able 
 
4. Visual Learning/Memory: Patient has difficulty recalling how things look, such as shapes and colors? 
 Present 
during past 
week 
 Not present 
in past week   Evident During 
Visit 
 Not Evident 
During Visit   Not drug related  
 Due to study drug  
 Other drug  
 Drug/drug interaction  
 Not applicable   Mild 
 Moderate  
 Severe  
 Extreme  
 Not applicable   Functional/ Role 
Impairment  
 No Functional/ 
Role Impairment  
 Not applicable  
 
5. Reasoning & Problem Solving: Trouble managing money, solving problems, doing puzzles, dealing with new challenges? 
 Present 
during past 
week 
 Not present 
in past week   Evident During 
Visit 
 Not Evident 
During Visit   Not drug related  
 Due to study drug  
 Other drug  
 Drug/drug interaction  
 Not applicable   Mild 
 Moderate  
 Severe  
 Extreme  
 Not applicable   Functional/ Role 
Impairment  
 No Functional/ 
Role Impairment  
 Not applicable  
 
6. Speed of Processing: Feeling “slowed down”, does it take you longer than usual to do things?  
 Present 
during past 
week 
 Not prese nt 
in past week   Evident During 
Visit 
 Not Evident 
During Visit   Not drug related  
 Due to study drug  
 Other drug  
 Drug/drug interaction  
 Not applicable   Mild 
 Moderate  
 Severe  
 Extreme  
 Not applicable   Functional/ Role 
Impairment  
 No Functi onal/ 
Role Impairment  
 Not applicable  
 
7. Social Cognition: Trouble understanding what other people intend, participating in social situations, or interacting with 
others? 
 Present 
during past 
week 
 Not present 
in past week   Evident During 
Visit 
 Not Ev ident 
During Visit   Not drug related  
 Due to study drug  
 Other drug  
 Drug/drug interaction  
 Not applicable   Mild 
 Moderate  
 Severe  
 Extreme  
 Not applicable   Functional/ Role 
Impairment  
 No Functional/ 
Role Impairment  
 Not applicable  
Notes: 
Page 147
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX P. MINI INTERNATIONAL NEUROPSYCHIATRIC 
INTERVIEW (M.I.N. I.) – MODULES I AND J (SAMPLE) 
Page 148
 CONFIDENTIAL  
Clinical Protocol Amendment 1.0 (Amendment 1.0) Alkermes, Inc.  
 APPENDIX Q.  LIST OF POTENT CYTOC HROME P450 3A4 (CYP3 A4) 
INDUCERS AND MODERAT E-TO-STRONG 
INHIBITORS OF 3A4 OR 2D6 
 
3A4 2D6 
Inducers  Inhibitors  Inhibitors  
• Carbamazepine  
• Barbiturates  
(eg, Phenobarbital) 
• Phenytoin 
• Rifampin  
• Modafinil 
• Cyproterone (eg, 
antiandrogen, progestin, 
Diane -35) 
• Non-nucleotide reverse 
transcriptase inhibitors  
(eg, efavirenz, nevirapine, etravirine)  
• Hyperforin; St. John’s 
Wort • Ketoconazole 
• Itraconazole 
• Fluconazole 
• Clarithromycin  
• Erythromycin  
• Telithromycin  
• Nefazod one 
• Fluvoxamine 
• Protease inhibitors (ritonavir, indinavir, nelfinavir) 
• Verapamil  
• Grapefruit juice  
• Bergamottin  
• Quercetin  • Quinidine 
• Selective serotonin reuptake inhibitors (eg, fluoxetine, paroxetine) 
• Duloxetine 
• Bupropion 
• MDMA (3,4- Methylenedioxymeth -
amphetamine; Ecstasy) 
• Terbinafine  
• Goldenseal  (Hydrastis canadensis)  
 
Page 149